10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 30, 2024 or

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number 1-8002

THERMO FISHER SCIENTIFIC INC.

(Exact name of Registrant as specified in its charter)

Delaware	04-2209186
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

168 Third Avenue

Waltham, Massachusetts 02451

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $1.00 par value	TMO	New York Stock Exchange
0.750% Notes due 2024	TMO 24A	New York Stock Exchange
0.125% Notes due 2025	TMO 25B	New York Stock Exchange
2.000% Notes due 2025	TMO 25	New York Stock Exchange
3.200% Notes due 2026	TMO 26B	New York Stock Exchange
1.400% Notes due 2026	TMO 26A	New York Stock Exchange
1.450% Notes due 2027	TMO 27	New York Stock Exchange
1.750% Notes due 2027	TMO 27B	New York Stock Exchange
0.500% Notes due 2028	TMO 28A	New York Stock Exchange
1.375% Notes due 2028	TMO 28	New York Stock Exchange
1.950% Notes due 2029	TMO 29	New York Stock Exchange
0.875% Notes due 2031	TMO 31	New York Stock Exchange
2.375% Notes due 2032	TMO 32	New York Stock Exchange
3.650% Notes due 2034	TMO 34	New York Stock Exchange
2.875% Notes due 2037	TMO 37	New York Stock Exchange
1.500% Notes due 2039	TMO 39	New York Stock Exchange
1.875% Notes due 2049	TMO 49	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒                                              Accelerated filer ☐                                       Non-accelerated filer ☐

Smaller reporting company ☐                                      Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

As of March 30, 2024, the Registrant had 381,716,323 shares of Common Stock outstanding.

THERMO FISHER SCIENTIFIC INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED MARCH 30, 2024

TABLE OF CONTENTS
		Page
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Income	4
	Condensed Consolidated Statements of Comprehensive Income	5
	Condensed Consolidated Statements of Cash Flows	6
	Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Equity	7
	Notes to Condensed Consolidated Financial Statements	8
	Note 1. Nature of Operations and Summary of Significant Accounting Policies	8
	Note 2. Acquisitions	9
	Note 3. Revenues and Contract-related Balances	10
	Note 4. Business Segment and Geographical Information	11
	Note 5. Income Taxes	12
	Note 6. Earnings per Share	13
	Note 7. Debt and Other Financing Arrangements	13
	Note 8. Commitments and Contingencies	15
	Note 9. Comprehensive Income/(Loss) and Shareholders' Equity	16
	Note 10. Fair Value Measurements and Fair Value of Financial Instruments	16
	Note 11. Supplemental Cash Flow Information	19
	Note 12. Restructuring and Other Costs	19
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28
Item 4.	Controls and Procedures	28
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 5.	Other Information	29
Item 6.	Exhibits	29

2

THERMO FISHER SCIENTIFIC INC.

PART I    FINANCIAL INFORMATION

Item 1.    Financial Statements

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	March 30,		December 31,
(In millions except share and per share amounts)	2024		2023
Assets
Current assets:
Cash and cash equivalents	$	5,499	$	8,077
Short-term investments	1,751		3
Accounts receivable, less allowances of $197 and $193	7,931		8,221
Inventories	5,133		5,088
Contract assets, net	1,422		1,443
Other current assets	1,904		1,757
Total current assets	23,640		24,589
Property, plant and equipment, net	9,324		9,448
Acquisition-related intangible assets, net	16,048		16,670
Other assets	4,241		3,999
Goodwill	43,843		44,020
Total assets	$	97,095	$	98,726
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations	$	4,451	$	3,609
Accounts payable	2,555		2,872
Accrued payroll and employee benefits	1,314		1,596
Contract liabilities	2,632		2,689
Other accrued expenses	2,985		3,246
Total current liabilities	13,937		14,012
Deferred income taxes	1,811		1,922
Other long-term liabilities	4,567		4,642
Long-term obligations	31,157		31,308
Redeemable noncontrolling interest	119		118
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued	—		—
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,822,699 and 442,188,634 shares issued	443		442
Capital in excess of par value	17,482		17,286
Retained earnings	48,542		47,364
Treasury stock at cost, 61,106,376 and 55,541,290 shares	(18,186)		(15,133)
Accumulated other comprehensive income/(loss)	(2,764)		(3,224)
Total Thermo Fisher Scientific Inc. shareholders’ equity	45,516		46,735
Noncontrolling interests	(12)		(11)
Total equity	45,504		46,724
Total liabilities, redeemable noncontrolling interest and equity	$	97,095	$	98,726

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

THERMO FISHER SCIENTIFIC INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

	Three months ended
	March 30,		April 1,
(In millions except per share amounts)	2024		2023
Revenues
Product revenues	$	5,955	$	6,404
Service revenues	4,390		4,306
Total revenues	10,345		10,710
Costs and operating expenses:
Cost of product revenues	2,939		3,337
Cost of service revenues	3,201		3,233
Selling, general and administrative expenses	2,183		2,119
Research and development expenses	331		346
Restructuring and other costs	29		112
Total costs and operating expenses	8,682		9,147
Operating income	1,663		1,563
Interest income	279		146
Interest expense	(363)		(300)
Other income/(expense)	10		(46)
Income before income taxes	1,589		1,363
Provision for income taxes	(281)		(46)
Equity in earnings/(losses) of unconsolidated entities	23		(25)
Net income	1,331		1,292
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest	4		3
Net income attributable to Thermo Fisher Scientific Inc.	$	1,328	$	1,289
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic	$	3.47	$	3.34
Diluted	$	3.46	$	3.32
Weighted average shares
Basic	382		386
Diluted	384		388

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

THERMO FISHER SCIENTIFIC INC.

 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Comprehensive income
Net income	$	1,331	$	1,292
Other comprehensive income/(loss):
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $166 and $(36))	456		44
Unrealized gains/(losses) on available-for-sale debt securities
Unrealized holding losses arising during the period (net of tax (provision) benefit of $0 and $0)	(1)		—
Unrealized gains/(losses) on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax (provision) benefit of $0 and $1)	1		3
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax (provision) benefit of $0 and $(1))	1		1
Total other comprehensive income/(loss)	457		48
Comprehensive income	1,788		1,340
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest	1		6
Comprehensive income attributable to Thermo Fisher Scientific Inc.	$	1,787	$	1,334

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

THERMO FISHER SCIENTIFIC INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Operating activities
Net income	$	1,331	$	1,292
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	285		253
Amortization of acquisition-related intangible assets	551		606
Change in deferred income taxes	(253)		(146)
Stock-based compensation	70		76
Other non-cash expenses, net	53		181
Changes in assets and liabilities, excluding the effects of acquisitions	(787)		(1,533)
Net cash provided by operating activities	1,251		729
Investing activities
Purchases of property, plant and equipment	(347)		(458)
Proceeds from sale of property, plant and equipment	4		6
Proceeds from cross-currency interest rate swap interest settlements	64		2
Acquisitions, net of cash acquired	—		(2,704)
Purchases of investments	(1,758)		(2)
Other investing activities, net	7		14
Net cash used in investing activities	(2,030)		(3,142)
Financing activities
Net proceeds from issuance of debt	1,205		—
Proceeds from issuance of commercial paper	—		1,027
Repayments of commercial paper	—		(523)
Purchases of company common stock	(3,000)		(3,000)
Dividends paid	(135)		(117)
Other financing activities, net	110		20
Net cash used in financing activities	(1,821)		(2,593)
Exchange rate effect on cash	22		(31)
Decrease in cash, cash equivalents and restricted cash	(2,578)		(5,037)
Cash, cash equivalents and restricted cash at beginning of period	8,097		8,537
Cash, cash equivalents and restricted cash at end of period	$	5,519	$	3,500

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

THERMO FISHER SCIENTIFIC INC.

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY

(Unaudited)

	Redeemable Noncontrolling Interest		Common Stock			Capital in Excess of Par Value		Retained Earnings		Treasury Stock			Accumulated Other Comprehensive Items		Total Thermo Fisher Scientific Inc. Shareholders’ Equity		Noncontrolling Interests		Total Equity
(In millions)			Shares	Amount						Shares	Amount
			Three months ended March 30, 2024
Balance at December 31, 2023	$	118	442	$	442	$	17,286	$	47,364	56	$	(15,133)	$	(3,224)	$	46,735	$	(11)	$	46,724
Issuance of shares under stock plans	—		1	1		126		—		—	(24)		—		103		—		103
Stock-based compensation	—		—	—		70		—		—	—		—		70		—		70
Purchases of company common stock	—		—	—		—		—		6	(3,000)		—		(3,000)		—		(3,000)
Dividends declared ($0.39 per share)	—		—	—		—		(149)		—	—		—		(149)		—		(149)
Net income/(loss)	4		—	—		—		1,328		—	—		—		1,328		—		1,328
Other comprehensive items	(3)		—	—		—		—		—	—		460		460		—		460
Contributions from (distributions to) noncontrolling interest	—		—	—		—		—		—	—		—		—		(1)		(1)
Excise tax from stock repurchases	—		—	—		—		—		—	(29)		—		(29)		—		(29)
Balance at March 30, 2024	$	119	443	$	443	$	17,482	$	48,542	61	$	(18,186)	$	(2,764)	$	45,516	$	(12)	$	45,504
			Three months ended April 1, 2023
Balance at December 31, 2022	$	116	441	$	441	$	16,743	$	41,910	50	$	(12,017)	$	(3,099)	$	43,978	$	54	$	44,032
Issuance of shares under stock plans	—		—	—		70		—		—	(36)		—		34		—		34
Stock-based compensation	—		—	—		76		—		—	—		—		76		—		76
Purchases of company common stock	—		—	—		—		—		5	(3,000)		—		(3,000)		—		(3,000)
Dividends declared ($0.35 per share)	—		—	—		—		(135)		—	—		—		(135)		—		(135)
Net income/(loss)	4		—	—		—		1,289		—	—		—		1,289		(1)		1,288
Other comprehensive items	3		—	—		—		—		—	—		45		45		—		45
Excise tax from stock repurchases	—		—	—		—		—		—	(30)		—		(30)		—		(30)
Balance at April 1, 2023	$	123	441	$	441	$	16,889	$	43,064	55	$	(15,083)	$	(3,054)	$	42,257	$	53	$	42,310

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1.    Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.

Interim Financial Statements

The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at March 30, 2024, the results of operations for the three-month periods ended March 30, 2024 and April 1, 2023, and the cash flows for the three-month periods ended March 30, 2024 and April 1, 2023. Interim results are not necessarily indicative of results for a full year.

The condensed consolidated balance sheet presented as of December 31, 2023 has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the 2023 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Certain reclassifications of prior year amounts have been made to conform to the current year presentation.

Note 1 to the consolidated financial statements for 2023 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the three months ended March 30, 2024.

Amounts and percentages reported within these condensed consolidated financial statements are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

Inventories

The components of inventories are as follows:

(In millions)	March 30, 2024		December 31, 2023
Raw materials	$	2,038	$	2,057
Work in process	787		705
Finished goods	2,308		2,326
Inventories	$	5,133	$	5,088

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.

Recent Accounting Pronouncements

The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.

8

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Standard	Description	Required adoption timing and approach	Impact of adoption or other significant matters
Standards recently adopted
ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations	New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented.	Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 annual report using a prospective method	Not material
Standards not yet adopted
ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures	Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.	2024 annual report and interim periods thereafter using a retrospective method	Will increase disclosures in Note 4
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures	Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.	2025 annual report and interim periods thereafter using a prospective or retrospective method	Will increase disclosures in Note 5

Note 2.    Acquisitions

The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.

Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

Proposed Acquisition

On October 17, 2023, the company entered into a purchase agreement to acquire all of the issued and outstanding shares of Olink Holding AB (publ) at a price of $26.00 per share, or approximately $3.1 billion. Olink is a leading provider of next-generation proteomics solutions that will expand the company’s capabilities in this field. The company has commenced a tender offer to acquire all of the American Depositary Shares and common shares of Olink. The transaction is expected to close by mid-year 2024, subject to the satisfaction of customary closing conditions including receipt of applicable regulatory approvals, and completion of the tender offer. Upon completion, Olink will become part of the Life Sciences Solutions segment. The company intends to finance the purchase price with cash on hand and the net proceeds from issuances of debt.

2023

On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not tax deductible.

On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a result of this business combination is not tax deductible.

9

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The components of the purchase price and net assets acquired are as follows:

(In millions)	The Binding Site		CorEvitas
Purchase price
Cash paid	$	2,412	$	730
Debt settled	307		184
Cash acquired	(20)		(4)
	$	2,699	$	910
Net assets acquired
Definite-lived intangible assets:
Customer relationships	$	868	$	260
Product technology	162		47
Tradenames	42		—
Backlog	—		46
Goodwill	1,741		627
Net tangible assets	174		(2)
Deferred tax assets (liabilities)	(288)		(68)
	$	2,699	$	910

In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-line measurement.

The weighted-average amortization periods for definite-lived intangible assets acquired in 2023 are 18 years for customer relationships, 14 years for product technology, 15 years for tradenames, and 13 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2023 is 17 years.

Note 3.    Revenues and Contract-related Balances

Disaggregated Revenues

Revenues by type are as follows:

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Revenues
Consumables	$	4,328	$	4,506
Instruments	1,627		1,898
Services	4,390		4,306
Consolidated revenues	$	10,345	$	10,710

Revenues by geographic region based on customer location are as follows:

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Revenues
North America	$	5,519	$	5,778
Europe	2,619		2,601
Asia-Pacific	1,861		1,986
Other regions	346		345
Consolidated revenues	$	10,345	$	10,710

Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data.

10

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Remaining Performance Obligations

The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of March 30, 2024 was $26.37 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 51% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.

Contract-related Balances

Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows:

(In millions)	March 30, 2024		December 31, 2023
Current contract assets, net	$	1,422	$	1,443
Noncurrent contract assets, net	9		4
Current contract liabilities	2,632		2,689
Noncurrent contract liabilities	1,427		1,499

In the three months ended March 30, 2024, the company recognized revenues of $1.32 billion that were included in the contract liabilities balance at December 31, 2023. In the three months ended April 1, 2023, the company recognized revenues of $1.30 billion that were included in the contract liabilities balance at December 31, 2022.

Note 4.    Business Segment and Geographical Information

Business Segment Information

	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Revenues
Life Sciences Solutions	$	2,285	$	2,612
Analytical Instruments	1,687		1,723
Specialty Diagnostics	1,109		1,108
Laboratory Products and Biopharma Services	5,723		5,763
Eliminations	(460)		(496)
Consolidated revenues	10,345		10,710
Segment Income
Life Sciences Solutions	840		836
Analytical Instruments	400		421
Specialty Diagnostics	294		280
Laboratory Products and Biopharma Services	744		793
Subtotal reportable segments	2,278		2,330
Cost of revenues adjustments	(15)		(41)
Selling, general and administrative expenses adjustments	(19)		(8)
Restructuring and other costs	(29)		(112)
Amortization of acquisition-related intangible assets	(551)		(606)
Consolidated operating income	1,663		1,563
Interest income	279		146
Interest expense	(363)		(300)
Other income/(expense)	10		(46)
Consolidated income before taxes	$	1,589	$	1,363

Cost of revenues adjustments included in the above table consist of charges for the sale of inventories revalued at the date of acquisition and inventory write-downs associated with large-scale abandonment of product lines. Selling, general and administrative expenses adjustments included in the above table consist of third-party transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration.

11

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Geographical Information

Revenues by country based on customer location are as follows:

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Revenues
United States	$	5,322	$	5,587
Other	5,023		5,123
Consolidated revenues	$	10,345	$	10,710

Note 5.    Income Taxes

The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following:

	Three months ended
(In millions)	March 30, 2024			April 1, 2023
Statutory federal income tax rate	21		%	21		%
Provision for income taxes at statutory rate	$	334		$	286
Increases (decreases) resulting from:
Foreign rate differential	(38)			(52)
Income tax credits	(89)			(83)
Global intangible low-taxed income	12			12
Foreign-derived intangible income	(22)			(23)
Excess tax benefits from stock options and restricted stock units	(33)			(27)
Provision for (reversal of) tax reserves, net	185			9
Intra-entity transfers	(102)			(144)
Provision for (reversal of) valuation allowances, net	47			67
Withholding taxes	4			5
Tax return reassessments and settlements	(29)			(3)
State income taxes, net of federal tax	19			24
Other, net	(6)			(25)
Provision for income taxes	$	281		$	46

During the first quarter of 2024, the company recorded a tax reserve and associated interest of $240 million related to the potential settlement of international tax audits for tax years 2009 through 2016.

The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate.

Unrecognized Tax Benefits

As of March 30, 2024 the company had $0.69 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:

(In millions)	2024
Balance at beginning of year	$	540
Additions for tax positions of prior years	195
Reductions for tax positions of prior years	(42)
Balance at end of period	$	693

12

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 6.    Earnings per Share

	Three months ended
	March 30,		April 1,
(In millions except per share amounts)	2024		2023
Net income attributable to Thermo Fisher Scientific Inc.	$	1,328	$	1,289
Basic weighted average shares	382		386
Plus effect of: stock options and restricted stock units	2		2
Diluted weighted average shares	384		388
Basic earnings per share	$	3.47	$	3.34
Diluted earnings per share	$	3.46	$	3.32
Antidilutive stock options excluded from diluted weighted average shares	2		2

Note 7.    Debt and Other Financing Arrangements

	Effective interest rate at March 30,		March 30,	December 31,
(Dollars in millions)	2024		2024	2023
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)	0.93	%	1,079	1,104
1.215% 3-Year Senior Notes, Due 10/18/2024	1.42	%	2,500	2,500
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)	0.40	%	863	883
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)	2.10	%	691	706
0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated)	1.05	%	147	158
0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated)	0.15	%	593	607
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)	3.38	%	540	552
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)	1.52	%	755	773
4.953% 3-Year Senior Notes, Due 8/10/2026	5.19	%	600	600
5.000% 3-Year Senior Notes, Due 12/5/2026	5.25	%	1,000	1,000
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)	1.65	%	540	552
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)	1.96	%	647	662
1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated)	1.18	%	191	205
4.80% 5-Year Senior Notes, Due 11/21/2027	5.00	%	600	600
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)	0.77	%	863	883
1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated)	1.77	%	366	—
0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated)	0.90	%	192	206
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)	1.46	%	647	662
1.75% 7-Year Senior Notes, Due 10/15/2028	1.89	%	700	700
5.000% 5-Year Senior Notes, Due 1/31/2029	5.24	%	1,000	1,000
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)	2.07	%	755	773
2.60% 10-Year Senior Notes, Due 10/1/2029	2.74	%	900	900
1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated)	1.44	%	31	33
4.977% 7-Year Senior Notes, Due 8/10/2030	5.12	%	750	750
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)	0.88	%	1,888	1,932
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)	1.13	%	971	993
2.00% 10-Year Senior Notes, Due 10/15/2031	2.23	%	1,200	1,200
1.840% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated)	1.91	%	460	—
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)	2.54	%	647	662
1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated)	1.60	%	42	45

13

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

	Effective interest rate at March 30,		March 30,		December 31,
(Dollars in millions)	2024		2024		2023
4.95% 10-Year Senior Notes, Due 11/21/2032	5.09	%	600		600
5.086% 10-Year Senior Notes, Due 8/10/2033	5.20	%	1,000		1,000
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)	1.20	%	1,619		1,656
5.200% 10-Year Senior Notes, Due 1/31/2034	5.34	%	500		500
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)	3.76	%	809		828
1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated)	1.58	%	142		152
2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated)	2.09	%	361		—
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)	2.94	%	755		773
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)	1.73	%	971		993
2.80% 20-Year Senior Notes, Due 10/15/2041	2.90	%	1,200		1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)	1.77	%	1,349		1,380
2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated)	2.13	%	97		104
5.404% 20-Year Senior Notes, Due 8/10/2043	5.50	%	600		600
2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated)	2.06	%	192		206
5.30% 30-Year Senior Notes, Due 2/1/2044	5.37	%	400		400
4.10% 30-Year Senior Notes, Due 8/15/2047	4.23	%	750		750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)	1.98	%	1,079		1,104
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)	2.07	%	809		828
2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated)	2.43	%	220		236
Other			75		77
Total borrowings at par value			35,687		35,028
Unamortized discount			(108)		(113)
Unamortized debt issuance costs			(186)		(188)
Total borrowings at carrying value			35,393		34,727
Finance lease liabilities			215		190
Less: Short-term obligations and current maturities			4,451		3,609
Long-term obligations			$	31,157	$	31,308

The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs.

See Note 10 for fair value information pertaining to the company’s long-term borrowings.

Credit Facilities

The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), a Euro Interbank Offered Rate (EURIBOR)-based rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of March 30, 2024, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.

14

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Commercial Paper Programs

The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis.

Senior Notes

Interest is payable annually on the euro and Swiss franc-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S. dollar and euro-denominated fixed rate senior notes and Japanese yen-denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of Japanese yen-denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants related to its senior notes at March 30, 2024.

Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes outstanding as of March 30, 2024, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.

Note 8.    Commitments and Contingencies

Environmental Matters

The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. At March 30, 2024, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2023 financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.

Litigation and Related Contingencies

The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in the company’s 2023 financial statements and notes included in the company’s Annual Report on Form 10-K, nor are material losses deemed probable for such matters. It is reasonably possible, however, that

15

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more such matters could have a material adverse effect on the company’s results of operations, financial position and cash flows.

Product Liability, Workers Compensation and Other Personal Injury Matters

The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. At March 30, 2024, there have been no material changes to the accruals for pending product liability, workers compensation, and other personal injury matters disclosed in the company’s 2023 financial statements and notes included in the company’s Annual Report on Form 10-K. Although the company believes that the amounts accrued and estimated insurance recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.

Note 9.    Comprehensive Income/(Loss) and Shareholders' Equity

Comprehensive Income/(Loss)

Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows:

(In millions)	Currency translation adjustment		Unrealized gains/(losses) on available-for-sale debt securities		Unrealized gains/(losses) on hedging instruments		Pension and other postretirement benefit liability adjustment		Total
Balance at December 31, 2023	$	(2,941)	$	—	$	(28)	$	(255)	$	(3,224)
Other comprehensive income/(loss) before reclassifications	456		(1)		—		1		456
Amounts reclassified from accumulated other comprehensive income/(loss)	3		—		1		—		4
Net other comprehensive income/(loss)	459		(1)		1		1		460
Balance at March 30, 2024	$	(2,482)	$	(1)	$	(27)	$	(254)	$	(2,764)

Note 10.    Fair Value Measurements and Fair Value of Financial Instruments

Fair Value Measurements

The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:

	March 30,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
(In millions)	2024		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	2,692	$	2,692	$	—	$	—
Bank time deposits	1,751		1,751		—		—
Investments	21		21		—		—
Insurance contracts	221		—		221		—
Derivative contracts	220		—		220		—
Total assets	$	4,904	$	4,464	$	440	$	—
Liabilities
Derivative contracts	$	57	$	—	$	57	$	—
Contingent consideration	83		—		—		83
Total liabilities	$	141	$	—	$	57	$	83

16

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

	December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
(In millions)	2023		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	5,021	$	5,021	$	—	$	—
Bank time deposits	3		3		—		—
Investments	20		20		—		—
Insurance contracts	210		—		210		—
Derivative contracts	8		—		8		—
Total assets	$	5,262	$	5,044	$	218	$	—
Liabilities
Derivative contracts	$	290	$	—	$	290	$	—
Contingent consideration	87		—		—		87
Total liabilities	$	377	$	—	$	290	$	87

The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense.

In the three months ended March 30, 2024 and April 1, 2023, the company recorded $10 million and $(44) million, respectively, of net gains/(losses) on investments, which are included in other income/(expense) in the accompanying statements of income.

The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.

	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Contingent consideration
Beginning balance	$	87	$	174
Payments	(2)		(15)
Changes in fair value included in earnings	(2)		(23)
Ending balance	$	83	$	136

Derivative Contracts

The following table provides the aggregate notional value of outstanding derivative contracts.

(In millions)	March 30, 2024		December 31, 2023
Cross-currency interest rate swaps designated as net investment hedge - euro	$	1,000	$	1,000
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen	4,650		4,650
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc	2,500		2,500
Currency exchange contracts	1,381		1,567

While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.

17

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

	Fair value – assets				Fair value – liabilities
	March 30,		December 31,		March 30,		December 31,
(In millions)	2024		2023		2024		2023
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a)	$	219	$	5	$	56	$	287
Derivatives not designated as hedging instruments
Currency exchange contracts (b)	1		3		1		3
Total derivatives	$	220	$	8	$	57	$	290

(a)    The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.

(b)    The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.

	Gain (loss) recognized
	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to interest expense	$	(1)	$	—
Amount reclassified from accumulated other comprehensive items to other income/(expense)	—		(4)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items	275		(144)
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items	444		(9)
Included in interest expense	66		17
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues	3		(3)
Included in other income/(expense)	(6)		23

Gains and losses recognized on currency exchange contracts are included in the accompanying statements of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.

The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.

See Note 1 to the consolidated financial statements for 2023 included in the company’s Annual Report on Form 10-K for additional information on the company’s risk management objectives and strategies.

18

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Fair Value of Other Financial Instruments

The carrying value and fair value of the company’s debt instruments are as follows:

	March 30, 2024				December 31, 2023
	Carrying		Fair		Carrying		Fair
(In millions)	value		value		value		value
Senior notes	$	35,318	$	32,587	$	34,650	$	32,191
Other	75		75		77		77
	$	35,393	$	32,662	$	34,727	$	32,268

The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.

Note 11.    Supplemental Cash Flow Information

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment	$	165	$	242
Declared but unpaid dividends	150		137
Issuance of stock upon vesting of restricted stock units	63		91
Excise tax from stock repurchases	29		30

Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:

(In millions)	March 30, 2024		December 31, 2023
Cash and cash equivalents	$	5,499	$	8,077
Restricted cash included in other current assets	7		6
Restricted cash included in other assets	14		14
Cash, cash equivalents and restricted cash	$	5,519	$	8,097

Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

Note 12.    Restructuring and Other Costs

In the first three months of 2024, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2024, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.

As of May 3, 2024, the company has identified restructuring actions that will result in additional charges of approximately $75 million, primarily in 2024, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred.

Restructuring and other costs by segment are as follows:

	Three months ended
(In millions)	March 30, 2024
Life Sciences Solutions	$	2
Analytical Instruments	7
Specialty Diagnostics	5
Laboratory Products and Biopharma Services	14
Corporate	1
	$	29

19

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheet. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.

(In millions)	Total (a)
Balance at December 31, 2023	$	60
Net restructuring charges incurred in 2024 (b)	25
Payments	(32)
Currency translation	(2)
Balance at March 30, 2024	$	51

(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.

(b)Excludes $4 million of net non-cash charges.

The company expects to pay accrued restructuring costs primarily through 2024.

20

THERMO FISHER SCIENTIFIC INC.

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), are made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, and our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; the COVID-19 pandemic; and any other statements that address events or developments that Thermo Fisher intends or believes will or may occur in the future. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this report.

A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 (which is on file with the SEC). Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, including our proposed acquisition of Olink, may not materialize as expected.

The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP Measures” later in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Certain amounts and percentages reported within this Quarterly Report on Form 10-Q are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

Overview

Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 4): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.

Consolidated Results

	Three months ended
	March 30,			April 1,
(Dollars in millions except per share amounts)	2024			2023			Change
Revenues	$	10,345		$	10,710		(3)	%
GAAP operating income	1,663			1,563			6	%
GAAP operating income margin	16.1		%	14.6		%	1.5	pt
Adjusted operating income (non-GAAP measure)	2,278			2,330			(2)	%
Adjusted operating income margin (non-GAAP measure)	22.0		%	21.8		%	0.2	pt
GAAP diluted earnings per share attributable to Thermo Fisher Scientific Inc.	3.46			3.32			4	%
Adjusted earnings per share (non-GAAP measure)	5.11			5.03			2	%

21

THERMO FISHER SCIENTIFIC INC.

Organic Revenue Growth

	Three months ended
	March 30, 2024
Revenue growth	(3)	%
Impact of acquisitions	0	%
Impact of currency translation	0	%
Organic revenue growth (non-GAAP measure)	(4)	%

Since 2020, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business have supported COVID-19 diagnostic testing. Additionally, our pharma services business has provided our pharma and biotech customers with the services they needed to develop and produce vaccines and therapies globally. Since the company’s acquisition of PPD in December 2021, the clinical research business has continued to play a leading role in supporting the clinical trials for COVID-19 vaccines and therapies. These positive impacts are expected to continue at much lower levels in 2024 as customer testing as well as therapy and vaccine demand declines. Sales of products related to COVID-19 testing were $0.03 billion and $0.14 billion in the first quarter of 2024 and 2023, respectively.

During the first quarter of 2024, revenues from pharma and biotech customers declined due to reduced demand for our products and services that support COVID-19 vaccines and therapies as well as a challenging macroeconomic environment and low economic activity in China, partially offset through strong commercial execution. Revenues in the academic and government as well as the industrial and applied markets declined due to strong shipments of analytical instruments to customers in these markets in the first quarter of 2023 as we fulfilled backlog that had been caused by pandemic-related supply chain disruptions. The diagnostics and healthcare market declined due to decreased demand for COVID-19 testing products. During the first quarter of 2024, sales growth in all major regions declined due to decreased demand for COVID-19 related products, as well as a challenging macroeconomic environment and low economic activity in China. Contributions to organic revenue during the first quarter of 2024 from the Specialty Diagnostics segment was more than offset by declines in the Life Sciences Solutions, Laboratory Products and Biopharma Services and Analytical Instruments segments.

The company continues to execute its proven growth strategy which consists of three pillars:

•High-impact innovation,

•Our trusted partner status with customers, and

•Our unparalleled commercial engine.

GAAP operating income margin and adjusted operating income margin increased in the first quarter of 2024 due primarily to exceptionally strong productivity improvements, partially offset by unfavorable business mix and strategic investments. GAAP operating income margin in the first quarter of 2023 was also impacted by restructuring and other charges incurred for headcount reductions and facility consolidations in an effort to streamline operations.

The company’s references to strategic investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references throughout this discussion to productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system including reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following restructuring actions including headcount reductions and consolidation of facilities, and low cost region manufacturing.

Notable Recent Acquisitions

On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma.

On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development.

22

THERMO FISHER SCIENTIFIC INC.

Segment Results

The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 4 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2023. Accordingly, the following segment data are reported on this basis.

	Three months ended
	March 30,		April 1,
(Dollars in millions)	2024		2023
Revenues
Life Sciences Solutions	$	2,285	$	2,612
Analytical Instruments	1,687		1,723
Specialty Diagnostics	1,109		1,108
Laboratory Products and Biopharma Services	5,723		5,763
Eliminations	(460)		(496)
Consolidated revenues	$	10,345	$	10,710

Life Sciences Solutions

	Three months ended												Organic (non-GAAP measure)
(Dollars in millions)	March 30, 2024			April 1, 2023			Total Change		Currency Translation		Acquisitions/ Divestitures
Revenues	$	2,285		$	2,612		(13)	%	0	%	0	%	(12)	%
Segment income	840			836			1	%
Segment income margin	36.8		%	32.0		%	4.8	pt

The decrease in organic revenues in the first quarter of 2024 was primarily due to moderation in COVID-19 related revenue, as well as lower levels of activity in the bioproduction business. The increase in segment income margin resulted primarily from exceptionally strong productivity improvements and strong pricing realization, partially offset by unfavorable volume pull-through.

Analytical Instruments

	Three months ended												Organic (non-GAAP measure)
(Dollars in millions)	March 30, 2024			April 1, 2023			Total Change		Currency Translation		Acquisitions/ Divestitures
Revenues	$	1,687		$	1,723		(2)	%	(1)	%	0	%	(1)	%
Segment income	400			421			(5)	%
Segment income margin	23.7		%	24.4		%	(0.7)	pt

The decrease in organic revenues in the first quarter of 2024 was primarily due to the impact of strong instrument shipments in the first quarter of 2023, largely offset by very strong growth in the electron microscopy business. The decrease in segment income margin resulted primarily from unfavorable business mix and strategic investments, partially offset by strong productivity improvements.

Specialty Diagnostics

	Three months ended												Organic (non-GAAP measure)
(Dollars in millions)	March 30, 2024			April 1, 2023			Total Change		Currency Translation		Acquisitions/ Divestitures
Revenues	$	1,109		$	1,108		0	%	0	%	0	%	0	%
Segment income	294			280			5	%
Segment income margin	26.5		%	25.3		%	1.2	pt

Organic revenues in the first quarter of 2024 were flat when compared to the first quarter of 2023, with strong underlying growth in the transplant diagnostics, immunodiagnostics, and healthcare market channel businesses, offset by decreased demand for products addressing diagnosis of COVID-19. The increase in segment income margin was due to favorable business mix and good productivity improvements, partially offset by strategic investments.

23

THERMO FISHER SCIENTIFIC INC.

Laboratory Products and Biopharma Services

	Three months ended												Organic (non-GAAP measure)
(Dollars in millions)	March 30, 2024			April 1, 2023			Total Change		Currency Translation		Acquisitions/ Divestitures
Revenues	$	5,723		$	5,763		(1)	%	0	%	0	%	(1)	%
Segment income	744			793			(6)	%
Segment income margin	13.0		%	13.8		%	(0.8)	pt

The decrease in organic revenues in the first quarter of 2024 was primarily due to decreased demand in COVID-19 vaccines and therapies, partially offset by strong growth in the clinical research business. The decrease in segment income margin was primarily due to unfavorable business mix and strategic investments, partially offset by strong productivity improvements.

Non-operating Items

	Three months ended
	March 30,			April 1,
(Dollars and shares in millions)	2024			2023
Net interest expense	$	84		$	154
GAAP other income/(expense)	10			(46)
Adjusted other income/(expense) (non-GAAP measure)	(1)			—
GAAP tax rate	17.7		%	3.4		%
Adjusted tax rate (non-GAAP measure)	10.5		%	10.0		%
Weighted average diluted shares	384			388

Net interest expense (interest expense less interest income) decreased due primarily to higher cash, and cash equivalents and short-term investments balances, as well as higher interest rates on these balances when compared to the first quarter of 2023. In the first quarter of 2024 and 2023, the company’s net interest expense was reduced by approximately $65 million and $17 million, respectively, as a result of its interest rate swap and cross-currency interest rate swap arrangements (Note 10).

GAAP other income/(expense) and adjusted other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities, and net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in the first quarter of 2024 and 2023 also includes $10 million and $(43) million, respectively, of net gains/(losses) on investments.

The company’s GAAP tax rate increased in the first quarter of 2024 compared to 2023 due to $176 million of expense, net, primarily for a provision associated with a tax audit recorded in the first quarter of 2024. The company’s 2024 and 2023 GAAP and adjusted tax rates were also impacted by $102 million and $144 million, respectively, of tax benefits resulting from capital losses generated as part of intra-entity transactions (Note 5).

The effective tax rates in both 2024 and 2023 were also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting purposes and are expected to total approximately $1.60 billion in 2024.

The company expects its GAAP effective tax rate in 2024 will be between 9% and 11% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits. The effective tax rate can vary significantly from period to period as a result of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 10.5% in 2024.

The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income, aside from any resulting one-time adjustment to the company’s deferred tax balances to reflect a new rate.

Weighted average diluted shares decreased in 2024 compared to 2023 due to share repurchases, net of option dilution.

Liquidity and Capital Resources

The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital primarily via mergers and acquisitions and secondarily via share buybacks and dividends.

24

THERMO FISHER SCIENTIFIC INC.

(In millions)	March 30, 2024		December 31, 2023
Cash and cash equivalents	$	5,499	$	8,077
Short-term investments	1,751		3
Total debt	35,608		34,917

Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S. including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also transfers cash to the U.S. using non-taxable intercompany transactions, including loans and returns of capital, as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.

The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.

As of March 30, 2024, the company’s short-term obligations and current maturities of long-term obligations totaled $4.45 billion. The company has a revolving credit facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit (Note 7). If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of March 30, 2024, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by immaterial outstanding letters of credit.

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Net cash provided by operating activities	$	1,251	$	729
Net cash used in investing activities	(2,030)		(3,142)
Net cash used in financing activities	(1,821)		(2,593)
Free cash flow (non-GAAP measure)	908		277

Operating Activities

During the first three months of 2024, cash provided by income was offset in part by investments in working capital. Changes in other assets and other liabilities used cash of $0.57 billion primarily due to the timing of payments for compensation and income taxes. Cash payments for income taxes were $0.65 billion during the first three months of 2024.

During the first three months of 2023, cash provided by income was offset in part by investments in working capital. Changes in other assets and other liabilities used cash of $1.31 billion primarily due to the timing of payments for compensation and income taxes. Cash payments for income taxes were $0.57 billion during the first three months of 2023.

Investing Activities

During the first three months of 2024, purchases of short-term investments used cash of $1.76 billion. The company’s investing activities also included purchases of $0.35 billion of property, plant and equipment for capacity and capability investments.

During the first three months of 2023, the acquisition of The Binding Site Group used cash of $2.70 billion. The company’s investing activities also included purchases of $0.46 billion of property, plant and equipment for capacity and capability investments.

The company expects that for all of 2024, expenditures for property, plant and equipment, net of disposals, will be between $1.3 billion and $1.5 billion.

Financing Activities

During the first three months of 2024, issuance of debt provided $1.20 billion of cash. The company’s financing activities also included the repurchase of $3.00 billion of the company’s common stock (5.5 million shares) and the payment of $0.14 billion in cash dividends. On November 14, 2023, the Board of Directors announced that it replaced the existing authorization to repurchase the company’s common stock, of which $1.00 billion was remaining, with a new authorization to repurchase up to $4.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during the first quarter of 2024 were under this program. At May 3, 2024, authorization remained for $1.00 billion of future repurchases of the company’s common stock.

25

THERMO FISHER SCIENTIFIC INC.

During the first three months of 2023, net commercial paper activity used cash of $0.50 billion. The company’s financing activities also included the repurchase of $3.00 billion of the company’s common stock (5.2 million shares) and the payment of $0.12 billion in cash dividends.

The company’s commitments for purchases of property, plant and equipment, contractual obligations and other commercial commitments, including the agreement to acquire Olink (Note 2), did not change materially subsequent to March 30, 2024.

Non-GAAP Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on revenues. Thermo Fisher management uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.

We report adjusted operating income, adjusted operating margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:

•Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.

•Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not indicative of our normal operating costs.

•Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

•The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

•The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.

We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.

The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-Q are not meant to be considered superior to or a substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth within the “Consolidated Results” and “Segment Results” sections and below.

26

THERMO FISHER SCIENTIFIC INC.

	Three months ended
	March 30,			April 1,
(Dollars in millions except per share amounts)	2024			2023
Reconciliation of adjusted operating income
GAAP operating income	$	1,663		$	1,563
Cost of revenues adjustments (a)	15			41
Selling, general and administrative expenses adjustments (b)	19			8
Restructuring and other costs (c)	29			112
Amortization of acquisition-related intangible assets	551			606
Adjusted operating income (non-GAAP measure)	$	2,278		$	2,330
Reconciliation of adjusted operating income margin
GAAP operating income margin	16.1		%	14.6		%
Cost of revenues adjustments (a)	0.1		%	0.4		%
Selling, general and administrative expenses adjustments (b)	0.2		%	0.1		%
Restructuring and other costs (c)	0.3		%	1.0		%
Amortization of acquisition-related intangible assets	5.3		%	5.7		%
Adjusted operating income margin (non-GAAP measure)	22.0		%	21.8		%
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense)	$	10		$	(46)
Adjustments (d)	(11)			46
Adjusted other income/(expense) (non-GAAP measure)	$	(1)		$	—
Reconciliation of adjusted tax rate
GAAP tax rate	17.7		%	3.4		%
Adjustments (e)	(7.2)		%	6.6		%
Adjusted tax rate (non-GAAP measure)	10.5		%	10.0		%
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc.	$	3.46		$	3.32
Cost of revenues adjustments (a)	0.04			0.10
Selling, general and administrative expenses adjustments (b)	0.05			0.02
Restructuring and other costs (c)	0.08			0.29
Amortization of acquisition-related intangible assets	1.44			1.56
Other income/expense adjustments (d)	(0.03)			0.12
Provision for income taxes adjustments (e)	0.13			(0.44)
Equity in earnings/losses of unconsolidated entities	(0.06)			0.06
Adjusted EPS (non-GAAP measure)	$	5.11		$	5.03
Reconciliation of free cash flow
GAAP net cash provided by operating activities	$	1,251		$	729
Purchases of property, plant and equipment	(347)			(458)
Proceeds from sale of property, plant and equipment	4			6
Free cash flow (non-GAAP measure)	$	908		$	277

(a) Adjusted results in 2024 and 2023 exclude charges for inventory write-downs associated with large-scale abandonment of product lines. Adjusted results in 2023 exclude $10 million of charges for the sale of inventory revalued at the date of acquisition.

(b) Adjusted results in 2024 and 2023 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration.

(c) Adjusted results in 2024 and 2023 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, abandoned facilities, and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude $18 million of net charges for pre-acquisition litigation and other matters.

(d) Adjusted results in 2024 and 2023 exclude net gains/losses on investments.

(e) Adjusted results in 2024 and 2023 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax impacts from audit settlements.

27

THERMO FISHER SCIENTIFIC INC.

Critical Accounting Policies and Estimates

Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2023 describe the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no significant changes in the company’s critical accounting policies during the first three months of 2024.

Recent Accounting Pronouncements

A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

The company’s exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Item 4.    Controls and Procedures

Management’s Evaluation of Disclosure Controls and Procedures

The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended March 30, 2024, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.

PART II    OTHER INFORMATION

Item 1.    Legal Proceedings

There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 8 to our Condensed Consolidated Financial Statements under the heading “Commitments and Contingencies.”

Item 1A.    Risk Factors

The risks that we believe are material to our investors are discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 under the caption “Risk Factors,” which is on file with the SEC.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

A summary of the share repurchase activity for the company’s first quarter of 2024 follows:

Period	Total number of shares purchased	Average price paid per share (1)		Total number of shares purchased as part of publicly announced plans or programs (2)	Maximum dollar amount of shares that may yet be purchased under the plans or programs (1)(2) (in millions)
Fiscal January (Jan. 1 - Feb. 3)	5,523,139	$	543.17	5,523,139	$	1,000
Fiscal February (Feb. 4 - Mar. 2)	—	—		—	1,000
Fiscal March (Mar. 3 - Mar. 30)	—	—		—	1,000
Total first quarter	5,523,139	$	543.17	5,523,139	$	1,000

28

THERMO FISHER SCIENTIFIC INC.

(1)    Amounts exclude excise taxes and other transaction costs.

(2)    On November 14, 2023, the Board of Directors announced that it replaced the existing authorization to repurchase the company’s common stock, of which $1.00 billion was remaining, with a new authorization to repurchase up to $4.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during the first quarter of 2024 were under this program.

Item 5.    Other Information

Director and Officer Trading Arrangements

On February 12, 2024, Stephen Williamson, our senior vice president and chief financial officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Williamson’s plan is for the exercise of vested stock options and the associated sale of up to 21,925 shares of company common stock through February 26, 2025. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and February 27, 2025.

On March 14, 2024, Gianluca Pettiti, our executive vice president, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Pettiti’s plan is for the sale of up to 1,200 shares of company common stock through April 28, 2025. The foregoing sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and April 30, 2025.

Item 6.    Exhibits

Exhibit Number	Description of Exhibit
10.1	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement effective as of February 21, 2024.*
10.2	Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement effective as of February 21, 2024.*
10.3	Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement effective as of February 21, 2024.*
10.4	Form of Thermo Fisher Scientific Inc.’s Performance Nonstatutory Stock Option Agreement effective as of February 21, 2024.*
10.5	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 21, 2024.*
10.6	Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 21, 2024.*
10.7	Form of Thermo Fisher Scientific Inc.’s Performance Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 21, 2024.*
31.1	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Definition Linkbase Document.
101.LAB	XBRL Taxonomy Label Linkbase Document.
101.PRE	XBRL Taxonomy Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
	The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries.

 _______________________

*    Indicates management contract or compensatory plan, contract or arrangement.

**    Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.

29

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:	May 3, 2024	THERMO FISHER SCIENTIFIC INC.
		/s/ Stephen Williamson
		Stephen Williamson
		Senior Vice President and Chief Financial Officer
		/s/ Joseph R. Holmes
		Joseph R. Holmes
		Vice President and Chief Accounting Officer

30

EX-10.1

Exhibit 10.1

THERMO FISHER SCIENTIFIC INC.

PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT

This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below.

Notice of Award

Name of participant (the “Participant”):

Award date (“Award Date”):

Number of shares of the Company’s Common Stock subject to this Award (“Shares”):

Vesting Schedule:

Vesting date (“Vesting Date”):	Number of RSUs that vest:
See Schedule A
Except as otherwise provided in this Agreement, all vesting is dependent on the Participant remaining an Eligible Participant (as defined in Exhibit A) through the applicable Vesting Date.

This Agreement includes this Notice of Award and the following Exhibits, which are expressly incorporated by reference in their entirety herein:

Exhibit A – General Terms and Conditions

Schedule A: Vesting Schedule for Performance-based Restricted Stock Units

Exhibit B – Country Addendum (for Participants in all non-U.S. countries)

This Agreement must be accepted on the final page below.

Exhibit 10.1

EXHIBIT A

GENERAL TERMS AND CONDITIONS

1.Award of Restricted Stock Units.

This Agreement (including the Notice of Award and, for Participants that work and/or reside outside of the U.S., the Country Addendum attached hereto as Exhibit B) sets forth the terms and conditions of an award on the Award Date set forth in the Notice of Award, by the Company to the Participant of that number of restricted stock units of the Company set forth in the Notice of Award (individually, an “RSU” and collectively, the “RSUs” or the “Award”). Each RSU represents the right to receive one share of common stock, $1.00 par value, of the Company (“Common Stock”) pursuant to the terms, conditions and restrictions set forth in this Agreement and in the Company’s Amended and Restated 2013 Stock Incentive Plan, as from time to time amended (the “Plan”). The number of RSUs set forth in the Notice of Award is referred to as the “Target Award.” Capitalized terms used in this Agreement and not otherwise defined shall have the same meaning as in the Plan.

2.Vesting Schedule.

Except as otherwise provided in paragraphs (b) through (e) of Section 3 and the Plan, the RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of Award and Schedule A below, provided that on each Vesting Date set forth in the Notice of Award, the Participant is, and has been at all times since the Award Date, providing service as (as applicable) an employee, officer or director of, or consultant or advisor to, the Company (or a Subsidiary or Affiliate) (an “Eligible Participant”). For the avoidance of doubt, “service” shall mean (i) if the Participant is an employee of the Company (or a Subsidiary or Affiliate) on the Award Date, only service as an employee, and (ii) if the Participant is a consultant, advisor or other non-employee service provider of the Company (or a Subsidiary or Affiliate) on the Award Date, service only in such position. Unless otherwise determined by the Administrator, a Participant shall cease to be an Eligible Participant upon a change in the employment or service relationship (e.g. a change from employee to a consultant).

3.Additional Vesting Provisions.

(a)Termination of Relationship with the Company. In the event that the Participant ceases to be an Eligible Participant for any reason other than those set forth in paragraphs (b) through (e) below before the final Vesting Date (as defined in Schedule A), the RSUs that have not previously vested shall be immediately forfeited to the Company.

(b)Death or Disability. In the event that the Participant’s service with the Company (or a Subsidiary or Affiliate) is terminated by reason of death or employment with the Company (or a Subsidiary or Affiliate) is terminated by reason of Disability after the Performance Certification Date (as defined in Schedule A) but prior to the final Vesting Date, then all unvested RSUs (based on the number of RSUs determined on the Performance Certification Date to be eligible to be received) shall vest 100% upon the date of such termination due to death or Disability.

Exhibit 10.1

(c)Change in Control Event. In the event that the Participant’s employment or service is terminated by the Company (or a Subsidiary or Affiliate) due to a Qualifying Termination (as defined in Section 5(e) below) within 18 months after a Change in Control Event that occurs prior to the Performance Certification Date, then all unvested RSUs (based on the number of RSUs determined to be eligible to be received assuming the last day of the performance period was the last day of the fiscal quarter immediately prior to the Change in Control Event) shall vest immediately upon such Qualifying Termination (without regard to performance for any periods following the last day of the fiscal quarter immediately prior to the Change in Control Event), provided that the Compensation Committee of the Board of Directors has certified the achievement of the performance conditions. In the event of such termination on or after the Performance Certification Date but before the final Vesting Date, then all unvested RSUs (based on the number of RSUs determined on the Performance Certification Date to be eligible to be received, as adjusted pursuant to any applicable provisions of Schedule A) shall vest upon the date of such termination.

(d)Retirement. If the Participant Retires from the Company (or a Subsidiary or Affiliate) after the later of (i) the Performance Certification Date or (ii) the second anniversary of the Award Date, then nevertheless the Participant shall become vested in the remaining RSUs to be delivered (calculated based on the units earned as of the Performance Certification Date, as adjusted pursuant to any applicable provisions of Schedule A).

(e)Discharge for Cause. In the event that the Participant is discharged by the Company (or a Subsidiary or Affiliate) for Cause, all unvested RSUs and all vested RSUs that have not been delivered in accordance with Section 4 below shall terminate immediately upon the effective date of such discharge. The Participant shall be considered to have been discharged for Cause if the Company determines, within thirty (30) days after the Participant’s resignation, that discharge for Cause was warranted.

4.Delivery of Shares.

(a)Except as provided in (b) below, the Company shall deliver the Shares that become issuable pursuant to an RSU within the sixty (60) day period following the date the RSUs vest pursuant to Sections 2 or 3 above, but in no event later than the last day of the period specified in Treas. Reg. section 1.409A-1(b)(4)(i)(A).

(b)In the event that the Participant Retires under the conditions of Section 3(d) above, the Company shall deliver the Shares that become issuable pursuant to an RSU, to the extent not previously delivered, within the sixty (60) day period following the date such RSUs would have vested had the Participant remained employed with the Company.

(c)The Company shall not be obligated to deliver Shares to the Participant unless the issuance and delivery of such Shares shall comply with all relevant provisions of law and other legal requirements including, without limitation, any applicable federal, state or foreign securities or exchange control laws and the requirements of any stock exchange upon which shares of Common Stock may then be listed.

5.Meaning and Use of Certain Terms.

For purposes of this Agreement,

Exhibit 10.1

(a)“Cause” means the willful engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company (or a Subsidiary or Affiliate). For purposes of the foregoing, no act or failure to act by the Participant shall be considered “willful” unless it is done or omitted to be done, in bad faith and without reasonable belief that the Participant's action or omission was in the best interests of the Company (or a Subsidiary or Affiliate).

(b)“Change in Control Event” has the meaning ascribed to it in the Plan.

(c)“Disability” or “Disabled.” A Participant shall be deemed to be disabled at such time as the Participant is receiving disability benefits under the Company’s (or a Subsidiary’s or Affiliate’s) long term disability coverage, as then in effect; provided however that the Participant shall not be treated as Disabled unless the disability is described under Section 409A of the Code.

(d)“Good Reason” has the meaning ascribed to it in the Plan.

(e)“Qualifying Termination.” A Participant has a Qualifying Termination if the Participant’s employment or service is terminated by the Company (or a Subsidiary or Affiliate) without Cause or by the Participant for Good Reason and such termination results in a separation from service under Section 409A of the Code.

(f)“Retire” or “Retirement.” For the purposes of this Agreement, the Participant shall be deemed to have “retired” (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company (or a Subsidiary or Affiliate), upon the Participant’s resignation from employment with the Company (or a Subsidiary or Affiliate) either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake of clarity, subject to execution of a release of claims in a form acceptable to the Company, a termination of employment initiated by the Company (or a Subsidiary or Affiliate), that is not a “termination for Cause” may, to the extent permitted by the Company in its sole discretion, be recharacterized as a voluntary termination by reason of Retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company (or a Subsidiary or Affiliate) to the Participant pursuant to any agreement between the Company (or a Subsidiary or Affiliate) and the Participant or any Company policy. Any determination concerning eligibility for Retirement shall be made by the Administrator in its sole discretion.

(g)“Subsidiary” or “Affiliate” has the meaning ascribed to it in the Plan, and shall for the avoidance of doubt include any such entity only so long as the Company maintains a controlling interest in such entity.

6.Restrictions on Transfer.

Exhibit 10.1

The Participant shall not sell, assign, transfer, pledge, hypothecate, or otherwise dispose of, by operation of law or otherwise (collectively “transfer”) any RSUs, or any interest therein, except by will or the laws of descent and distribution.

7.Provisions of the Plan.

This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.

8.Dividends; Other Corporate Transactions.

(a)If at any time during the period between the Performance Certification Date and the date that Shares are delivered after the RSU vests, the Company pays a dividend or other distribution with respect to its Common Stock, including without limitation a distribution of shares of the Company’s stock by reason of a stock dividend, stock split or otherwise, then on the date the Shares issuable upon vesting of the RSU are delivered, the Company shall pay the Participant, at the time of delivery of Shares pursuant to Section 4, the dividend or other distribution that would have been paid on such Shares if the Participant had owned such Shares during the period beginning on the Performance Certification Date and ending on the respective delivery date. No dividend or other distribution shall be paid with respect to RSUs that are forfeited.

(b)In the event of a Reorganization Event, then the rights of the Company under this Agreement and all other terms of this Agreement (including without limitation vesting provisions) shall inure to the benefit of the Company’s successor and shall apply to the cash, securities, or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to the Shares. Such cash, securities, or other property shall be delivered or paid at the time provided in Section 4, except that payments in connection with the liquidation of the Company shall be made only as permitted under Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”).

(c)Except as set forth in Section 8(a) or (b) above and in the Plan, neither the Participant nor any person claiming under or through the Participant shall be, or have any rights or privileges of, a stockholder of the Company in respect of the Shares issuable pursuant to the RSUs granted hereunder until the Shares have been delivered to the Participant.

9.Withholding Taxes; No Section 83(b) Election.

(a)In the case of a Participant that works and/or resides in the U.S., the Participant expressly acknowledges that the delivery of Shares to the Participant will give rise to “wages” subject to withholding and Participant hereby authorizes the Company to hold back from the Shares to be delivered pursuant to Section 4 of this Agreement that number of Shares (which may include fractional shares) calculated to satisfy all such federal, state, local or other applicable taxes required to be withheld in connection with such delivery of Shares; provided, however, that at the Company’s discretion, a Participant who is not subject to Section 16 of the Securities Exchange Act of 1934 may provide notice to the Company prior to the delivery of the Shares that the Participant will make payment to the Company on the date of delivery to satisfy all required withholding taxes in lieu of satisfying such obligation through the withholding of Shares.

Exhibit 10.1

(b)The Participant acknowledges that no election under Section 83(b) of the Code may be filed with respect to this Award.

10.No Right To Employment or Other Status. The grant of an award of RSUs shall not be construed as giving the Participant the right to continued employment or any other relationship with the Company or its Subsidiaries or Affiliates. The Company and its Subsidiaries and Affiliates expressly reserve the right at any time to dismiss or otherwise terminate its relationship with the Participant free from any liability or claim under the Plan or this Agreement, except as expressly provided herein.

11.Conflicts With Other Agreements. In the event of any conflict or inconsistency between the terms of this Agreement and any employment, severance, or other agreement between the Company and the Participant, the terms of this Agreement shall govern.

12.Governing Law. Except as provided in Addendum A, this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to any applicable conflicts of laws and in the event of a dispute related to or arising out of this Agreement, the parties submit to the exclusive jurisdiction and venue of the Delaware federal and Chancery Courts.

13.Unfunded Rights. The right of the Participant to receive Common Stock pursuant to this Agreement is an unfunded and unsecured obligation of the Company. The Participant shall have no rights under this Agreement other than those of an unsecured general creditor of the Company.

14.Compliance with Section 409A of the Code. To the extent the Participant is a U.S. taxpayer, this Agreement is intended to provide for deferred compensation that is exempt from or compliant with Section 409A of the Code and shall be interpreted consistently with such intent. Accordingly, the Participant shall have no right to designate the taxable year of payment. Notwithstanding any other provision of this Agreement, if and to the extent any portion of any payment under this Agreement to the Participant is payable upon the Participant’s separation from service and the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, as determined by the Company in accordance with its procedures, by which determination the Participant (through accepting the Award) agrees thatthe Participant is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six (6) months plus one (1) day after the date of “separation from service”, except as Section 409A of the Code may then permit.

The Company makes no representations or warranties and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under this Agreement are determined to constitute nonqualified deferred compensation subject to Section 409A of the Code but do not satisfy the conditions of that section.

15.Clawback. In accepting this Award, the Participant expressly agrees to be bound by, and subject to, the following clawback policy and any clawback policy that the Company has in effect (as the same may be amended from time to time) or may adopt in the future:

Exhibit 10.1

(a)The Award is intended to align the Participant’s long-term interests with those of the Company. Accordingly, subject to Addendum A and unless otherwise expressly provided in the Plan or any other applicable agreement, plan, or policy, and to the extent permitted by applicable law, the Company may terminate any unsettled RSUs, whether vested or unvested (“Termination”), recapture any Shares acquired pursuant to the RSUs (“Recapture”), or require the Participant to reimburse the Company for any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the RSUs (“Reimbursement”), upon the occurrence of any of the following events (collectively, the “Conditions”):

(i)the Participant has engaged in misuse of the Company’s confidential information and/or conduct in breach of any (A) confidentiality obligation to the Company under any agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to, the Company’s standard form of Information and Invention Agreement applicable to such Participant, or (B) applicable noncompetition or nonsolicitation obligation to the Company under any applicable agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to the Company’s standard form of Noncompetition Agreement applicable to such Participant; or

(ii)the Participant's employment or other service has been terminated for Cause; or

(iii)during the Participant’s employment or other service, the Participant (A) has rendered services to or otherwise directly or indirectly engaged in or assisted, any organization or business that, in the judgment of the Company in its sole and absolute discretion, is against the interest of the Company or one of its affiliates; or (B) has engaged in activities that are materially prejudicial to or in conflict with the interests of the Company, including any breaches of fiduciary duty or the duty of loyalty.

For purposes of this Section 15, “RSU Benefits” shall mean any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the RSUs, including any sales proceeds, dividends and/or dividend equivalents.

(b)Prior to the issuance of any Shares upon settlement of vested RSUs pursuant to this Agreement, the Participant shall, if requested in writing by the Company, certify on a form acceptable to the Company that the Participant is in compliance with the terms and conditions of this Agreement and with the obligations contained in the Plan, or any other relevant agreement, plan, or contract listed in Section 15(a).

(c)Within ten (10) calendar days after receiving notice from the Company of any such activity described in Section 15(a) of this Agreement, the Participant shall either deliver to the Company the applicable Shares or make a cash payment to the Company equal to the RSU Benefits. For purposes of the Company’s exercise of its Recapture and/or Reimbursement rights hereunder, the Participant expressly and explicitly authorizes the Company to issue instructions, on the Participant’s behalf, to any brokerage firm and/or third-party administrator engaged by the Company to hold Shares and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company.

Exhibit 10.1

(d)Notwithstanding the foregoing provisions of this Section 15, the Company may, in its sole and absolute discretion, choose to refrain from exercising its rights of Termination, Recapture and/or Reimbursement with respect to any particular act of the Participant or with respect to any other participant in the Plan, and its determination to refrain from exercising such rights shall not in any way reduce or eliminate the Company’s authority to exercise its rights of Termination, Recapture and/or Reimbursement with respect to any other act of the Participant. Nothing in this Section 15 shall be construed to impose obligations on the Participant to refrain from engaging in lawful competition with the Company after the termination of employment that does not violate the Conditions, other than any obligations that are part of any applicable separate agreement between the Company and the Participant or that arise under applicable law.

(e)Notwithstanding anything to the contrary in the Plan or this Agreement, the Company shall not seek to exercise its rights of Termination, Recapture or Reimbursement relating to any RSUs that were vested and settled more than twelve (12) months prior to the date of the Participant’s act or omission set forth in Section 15(a); provided that, notwithstanding the foregoing, all RSUs shall be subject to the Company’s rights of Termination, Recapture and/or Reimbursement to the extent required by applicable law, including but not limited to Section 10D of the Securities Exchange Act of 1934.

16.Country Addendum. Notwithstanding any provisions in this Agreement, in the case of Participants that work and/or reside outside of the U.S., the RSUs shall be subject to any additional terms and conditions for the Participant’s country of residence (and county of employment or other provision of services, if different)set forth in the “Country Addendum” attached hereto as Exhibit B. Further, if the Participant relocates to one of the countries included in the Country Addendum, the additional terms and conditions for such country will apply to the Participant to the extent that the Company determines, in its discretion, that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Country Addendum constitutes part of this Agreement.

17.Affirmative Acceptance of Award. As a condition to the grant of this Award, the Participant must affirmatively accept this Award and Agreement by logging onto Fidelity’s website at www.netbenefits.fidelity.com and completing the acceptance procedures reflected therein within 120 calendar days of the Award Date (the “Award Acceptance Deadline”). If the Participant fails to accept this Award and Agreement by the Award Acceptance Deadline, this Award automatically will be forfeited and immediately terminate without any further action by the parties.

Exhibit 10.1

Addendum A

1.    Massachusetts.

For Participants domiciled in the State of Massachusetts, the following language shall be added to Section 15(a)(i) of this Agreement:

Notwithstanding Section 12 of this Agreement, for any Termination, Recapture, and/or Reimbursement that is based, in whole or in part, on the Participant’s breach of a noncompete agreement or nonsolicitation obligation, such disputes shall be governed by and interpreted in accordance with the laws of the State of Massachusetts, and any dispute arising out of the Agreement shall be asserted exclusively in the federal or state courts located in or covering the county in which the Participant resides within the State of Massachusetts, and the Parties hereby submit to the personal jurisdiction and venue of those state and federal courts.

2.    California.

For Participants domiciled in the State of California, Section 15(a)(i)(B) of this Agreement shall not apply except to the extent a noncompetition and/or non-solicitation agreement exists and is subject to California Business & Professions Code section 16601 et seq.

*********************************

Exhibit 10.1

As a condition to the grant of this Award, the Participant by signing below acknowledges receipt and affirmatively agrees to the Agreement, including without limitation the provisions of the above General Terms and Conditions.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

		THERMO FISHER SCIENTIFIC INC.
Date:
	By:
	Name:
	Title:
		Participant

EX-10.2

Exhibit 10.2

THERMO FISHER SCIENTIFIC INC.

RESTRICTED STOCK UNIT AGREEMENT

This Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below.

Notice of Award

Name of participant (the “Participant”):

Award date (“Award Date”):

Number of shares of the Company’s Common Stock subject to this Award (“Shares”):

Vesting Schedule:

Vesting date (“Vesting Date”):	Number of RSUs that vest:
Except as otherwise provided in this Agreement, all vesting is dependent on the Participant remaining an Eligible Participant (as defined in Exhibit A) through the applicable Vesting Date.

This Agreement includes this Notice of Award and the following Exhibits, which are expressly incorporated by reference in their entirety herein:

Exhibit A – General Terms and Conditions

Exhibit B – Country Addendum (for Participants in all non-U.S. countries)

This Agreement must be accepted on the final page below.

EXHIBIT A

GENERAL TERMS AND CONDITIONS

1.Award of Restricted Stock Units.

This Agreement (including the Notice of Award and, for Participants that work and/or reside outside of the U.S., the Country Addendum attached hereto as Exhibit B) sets forth the terms and conditions of an award on the Award Date set forth in the Notice of Award, by the Company to the Participant of that number of restricted stock units of the Company set forth in the Notice of Award (individually, an “RSU” and collectively, the “RSUs” or the “Award”). Each RSU represents the right to receive one share of common stock, $1.00 par value, of the Company (“Common Stock”) pursuant to the terms, conditions and restrictions set forth in this Agreement and in the Company’s Amended and Restated 2013 Stock Incentive Plan, as from time to time amended (the “Plan”). Capitalized terms used in this Agreement and not otherwise defined shall have the same meaning as in the Plan.

2.Time-Based Vesting.

Except as otherwise provided in paragraphs (b) through (e) of Section 3 and the Plan, the RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of Award provided that on each Vesting Date set forth in the Notice of Award, the Participant is, and has been at all times since the Award Date, providing service as (as applicable) an employee, officer or director of, or consultant or advisor to, the Company (or a Subsidiary or Affiliate) (an “Eligible Participant”). For the avoidance of doubt, “service” shall mean (i) if the Participant is an employee of the Company (or a Subsidiary or Affiliate) on the Award Date, only service as an employee, and (ii) if the Participant is a consultant, advisor or other non-employee service provider of the Company (or a Subsidiary or Affiliate) on the Award Date, service only in such position. Unless otherwise determined by the Administrator, a Participant shall cease to be an Eligible Participant upon a change in the employment or service relationship (e.g. a change from employee to a consultant).

3.Additional Vesting Provisions.

(a)    Termination of Relationship with the Company. In the event that the Participant ceases to be an Eligible Participant for any reason not described in paragraphs (b) through (e) below, RSUs that have not previously vested shall be immediately forfeited to the Company.

(b)    Death or Disability. In the event that the Participant’s service with the Company (or a Subsidiary or Affiliate) is terminated by reason of death or employment with the Company (or a Subsidiary or Affiliate) is terminated by reason of Disability prior to the final Vesting Date, the RSUs that have not previously vested shall vest 100% upon the date of such termination due to death or Disability.

(c)    Change in Control Event. In the event that the Participant’s employment or service is terminated by the Company (or a Subsidiary or Affiliate) due to a Qualifying

2

Termination (as defined in Section 5(e) below) within 18 months after a Change in Control Event that occurs prior to the final Vesting Date, the RSUs that have not previously vested shall vest 100% upon the date of such termination.

(d)    Retirement. If the Participant Retires from the Company (or a Subsidiary or Affiliate) prior to the final Vesting Date, the RSUs that have not previously vested shall vest 100% upon the effective date of such Retirement, provided that the Retirement date occurs at least two years after the Award Date.

(e)    Discharge for Cause. In the event that the Participant is discharged by the Company (or a Subsidiary or Affiliate) for Cause, all unvested RSUs and all vested RSUs that have not been delivered in accordance with Section 4 below shall terminate immediately upon the effective date of such discharge. The Participant shall be considered to have been discharged for Cause if the Company determines, within thirty (30) days after the Participant’s resignation, that discharge for Cause was warranted.

4.Delivery of Shares

(a)    The Company shall deliver the Shares that become issuable pursuant to an RSU within the sixty (60) day period following the date the RSUs vest pursuant to Sections 2 or 3 above.

(b)    The Company shall not be obligated to deliver Shares to the Participant unless the issuance and delivery of such Shares shall comply with all relevant provisions of law and other legal requirements including, without limitation, any applicable federal, state or foreign securities or exchange control laws and the requirements of any stock exchange upon which shares of Common Stock may then be listed.

5.Meaning and Use of Certain Terms.

For purposes of this Agreement:

(a)    “Cause” means the willful engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company (or a Subsidiary or Affiliate). For purposes of the foregoing, no act or failure to act by the Participant shall be considered “willful” unless it is done or omitted to be done, in bad faith and without reasonable belief that the Participant's action or omission was in the best interests of the Company (or a Subsidiary or Affiliate).

(b)    “Change in Control Event” has the meaning ascribed to it in the Plan.

(c)    “Disability” or “Disabled”. A Participant shall be deemed to be disabled at such time as the Participant is receiving disability benefits under the Company’s (or a Subsidiary’s or Affiliate’s) long term disability coverage, as then in effect; provided however that the Participant shall not be treated as Disabled unless the disability is described under Section 409A of the Code.

3

(d)    “Good Reason” has the meaning ascribed to it in the Plan.

(e)    “Qualifying Termination”. A Participant has a Qualifying Termination if the Participant’s employment or service is terminated by the Company (or a Subsidiary or Affiliate) without Cause or by the Participant for Good Reason and such termination results in a separation from service under Section 409A of the Code.

(f)    “Retire” or “Retirement”. For the purposes of this Agreement, the Participant shall be deemed to have “retired” (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company (or a Subsidiary or Affiliate), upon the Participant’s resignation from employment with the Company (or a Subsidiary or Affiliate) either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake of clarity, subject to execution of a release of claims in a form acceptable to the Company, a termination of employment initiated by the Company (or a Subsidiary or Affiliate), that is not a “termination for Cause” may, to the extent permitted by the Company in its sole discretion, be recharacterized as a voluntary termination by reason of Retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company (or a Subsidiary or Affiliate) to the Participant pursuant to any agreement between the Company (or a Subsidiary or Affiliate) and the Participant or any Company policy. Any determination concerning eligibility for Retirement shall be made by the Administrator in its sole discretion.

(g)    “Subsidiary” or “Affiliate” has the meaning ascribed to it in the Plan, and shall for the avoidance of doubt include any such entity only so long as the Company maintains a controlling interest in such entity.

6.Restrictions on Transfer.

The Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively “transfer”) any RSUs, or any interest therein, except by will or the laws of descent and distribution.

7.Provisions of the Plan.

This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.

8.Dividends; Other Corporate Transactions.

(a)    If at any time during the period between the Award Date and the date that Shares are delivered after the RSU vests, the Company pays a dividend or other distribution with respect to its Common Stock, including without limitation a distribution of shares of the Company’s

4

stock by reason of a stock dividend, stock split or otherwise, then on the date the Shares issuable upon vesting of the RSU are delivered, the Company shall pay the Participant, at the time of delivery of Shares pursuant to Section 4, the dividend or other distribution that would have been paid on such Shares if the Participant had owned such Shares during the period beginning on the Award Date and ending on the respective delivery date. No dividend or other distribution shall be paid with respect to RSUs that are forfeited.

(b)    In the event of a Reorganization Event, then the rights of the Company under this Agreement and all other terms of this Agreement (including without limitation vesting provisions) shall inure to the benefit of the Company’s successor and shall apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to the Shares. Such cash, securities, or other property shall be delivered or paid at the time provided in Section 4, except that payments in connection with the liquidation of the Company shall be made only as permitted under Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”).

(c)    Except as set forth in Section 8(a) or (b) above and in the Plan, neither the Participant nor any person claiming under or through the Participant shall be, or have any rights or privileges of, a stockholder of the Company in respect of the Shares issuable pursuant to the RSUs granted hereunder until the Shares have been delivered to the Participant.

9.Withholding Taxes; No Section 83(b) Election.

(a)    In the case of a Participant that works and/or resides in the U.S., the Participant expressly acknowledges that the delivery of Shares to the Participant will give rise to “wages” subject to withholding and Participant hereby authorizes the Company to hold back from the Shares to be delivered pursuant to Section 4 of this Agreement that number of Shares (which may include fractional shares) calculated to satisfy all such federal, state, local or other applicable taxes required to be withheld in connection with such delivery of Shares; provided, however, that at the Company’s discretion, a Participant who is not subject to Section 16 of the Securities Exchange Act of 1934 may provide notice to the Company prior to the delivery of the Shares that the Participant will make payment to the Company on the date of delivery to satisfy all required withholding taxes in lieu of satisfying such obligation through the withholding of Shares.

(b)    The Participant acknowledges that no election under Section 83(b) of the Code may be filed with respect to this Award.

10.No Right To Employment or Other Status. The grant of an award of RSUs shall not be construed as giving the Participant the right to continued employment or any other relationship with the Company or its Subsidiaries or Affiliates. The Company and its Subsidiaries and Affiliates expressly reserve the right at any time to dismiss or otherwise terminate its relationship with the Participant free from any liability or claim under the Plan or this Agreement, except as expressly provided herein.

5

11.Conflicts With Other Agreements. In the event of any conflict or inconsistency between the terms of this Agreement and any employment, severance or other agreement between the Company and the Participant, the terms of this Agreement shall govern.

12.Governing Law. Except as provided in Addendum A, this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to any applicable conflicts of laws and in the event of a dispute related to or arising out of this Agreement, the parties submit to the exclusive jurisdiction and venue of the Delaware federal and Chancery Courts.

13.Unfunded Rights. The right of the Participant to receive Common Stock pursuant to this Agreement is an unfunded and unsecured obligation of the Company. The Participant shall have no rights under this Agreement other than those of an unsecured general creditor of the Company.

14.Compliance with Section 409A of the Code. To the extent the Participant is a U.S. taxpayer, this Agreement is intended to provide for deferred compensation that is exempt from or compliant with Section 409A of the Code and shall be interpreted consistently with such intent. Accordingly, the Participant shall have no right to designate the taxable year of payment. Notwithstanding any other provision of this Agreement, if and to the extent any portion of any payment under this Agreement to the Participant is payable upon the Participant’s separation from service and the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, as determined by the Company in accordance with its procedures, by which determination the Participant (through accepting the Award) agrees thatthe Participant is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six (6) months plus one (1) day after the date of “separation from service”, except as Section 409A of the Code may then permit.

The Company makes no representations or warranties and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under this Agreement are determined to constitute nonqualified deferred compensation subject to Section 409A of the Code but do not satisfy the conditions of that section.

15.Clawback. In accepting this Award, the Participant expressly agrees to be bound by, and subject to, the following clawback policy and any clawback policy that the Company has in effect (as the same may be amended from time to time) or may adopt in the future:

(a)    The Award is intended to align the Participant’s long-term interests with those of the Company. Accordingly, subject to Addendum A and unless otherwise expressly provided in the Plan or any other applicable agreement, plan, or policy, and to the extent permitted by applicable law, the Company may terminate any unsettled RSUs, whether vested or unvested (“Termination”), recapture any Shares acquired pursuant to the RSUs (“Recapture”), or require the Participant to reimburse the Company for any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the RSUs (“Reimbursement”), upon the occurrence of any of the following events (collectively, the “Conditions”):

(i)    the Participant has engaged in misuse of the Company’s confidential information and/or conduct in breach of any (A) confidentiality obligation to the Company under

6

any agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to, the Company’s standard form of Information and Invention Agreement applicable to such Participant, or (B) applicable noncompetition or nonsolicitation obligation to the Company under any applicable agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to the Company’s standard form of Noncompetition Agreement applicable to such Participant;

(ii)    the Participant's employment or other service has been terminated for Cause; or

(iii)    during the Participant’s employment or other service, the Participant (A) has rendered services to or otherwise directly or indirectly engaged in or assisted, any organization or business that, in the judgment of the Company in its sole and absolute discretion, is against the interest of the Company or one of its affiliates; or (B) has engaged in activities that are materially prejudicial to or in conflict with the interests of the Company, including any breaches of fiduciary duty or the duty of loyalty.

For purposes of this Section 15, “RSU Benefits” shall mean any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the RSUs, including any sales proceeds, dividends and/or dividend equivalents.

(b)    Prior to the issuance of any Shares upon settlement of vested RSUs pursuant to this Agreement, the Participant shall, if requested in writing by the Company, certify on a form acceptable to the Company that the Participant is in compliance with the terms and conditions of this Agreement and with the obligations contained in the Plan, or any other relevant agreement, plan, or contract listed in Section 15(a).

(c)    Within ten (10) calendar days after receiving notice from the Company of any such activity described in Section 15(a) of this Agreement, the Participant shall either deliver to the Company the applicable Shares or make a cash payment to the Company equal to the RSU Benefits. For purposes of the Company’s exercise of its Recapture and/or Reimbursement rights hereunder, the Participant expressly and explicitly authorizes the Company to issue instructions, on the Participant’s behalf, to any brokerage firm and/or third-party administrator engaged by the Company to hold Shares and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company.

(d)    Notwithstanding the foregoing provisions of this Section 15, the Company may, in its sole and absolute discretion, choose to refrain from exercising its rights of Termination, Recapture and/or Reimbursement with respect to any particular act of the Participant or with respect to any other participant in the Plan, and its determination to refrain from exercising such rights shall not in any way reduce or eliminate the Company’s authority to exercise its rights of Termination, Recapture and/or Reimbursement with respect to any other act of the Participant. Nothing in this Section 15 shall be construed to impose obligations on the Participant to refrain from engaging in lawful competition with the Company after the termination of employment that does not violate the Conditions, other than any obligations that are part of any applicable separate agreement between the Company and the Participant or that arise under applicable law.

7

(e)    Notwithstanding anything to the contrary in the Plan or this Agreement, the Company shall not seek to exercise its rights of Termination, Recapture or Reimbursement relating to any RSUs that were vested and settled more than twelve (12) months prior to the date of the Participant’s act or omission set forth in Section 15(a); providedthat notwithstanding the foregoing, all RSUs shall be subject to the Company’s rights of Termination, Recapture and/or Reimbursement to the extent required by applicable law, including but not limited to Section 10D of the Securities Exchange Act of 1934.

16.Country Addendum. Notwithstanding any provisions in this Agreement, in the case of Participants that work and/or reside outside of the U.S., the RSUs shall be subject to any additional terms and conditions for the Participant’s country of residence (and county of employment or other provision of services, if different)set forth in the “Country Addendum” attached hereto as Exhibit B. Further, if the Participant relocates to one of the countries included in the Country Addendum, the additional terms and conditions for such country will apply to the Participant to the extent that the Company determines, in its discretion, that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Country Addendum constitutes part of this Agreement.

17.Affirmative Acceptance of Award. As a condition to the grant of this Award, the Participant must affirmatively accept this Award and Agreement by logging onto Fidelity’s website at www.netbenefits.fidelity.com and completing the acceptance procedures reflected therein within 120 calendar days of the Award Date (the “Award Acceptance Deadline”). If the Participant fails to accept this Award and Agreement by the Award Acceptance Deadline, this Award automatically will be forfeited and immediately terminate without any further action by the parties.

8

Addendum A

1.    Massachusetts.

For Participants domiciled in the State of Massachusetts, the following language shall be added to Section 15(a)(i) of this Agreement:

Notwithstanding Section 12 of this Agreement, for any Termination, Recapture, and/or Reimbursement that is based, in whole or in part, on the Participant’s breach of a noncompete agreement or nonsolicitation obligation, such disputes shall be governed by and interpreted in accordance with the laws of the State of Massachusetts, and any dispute arising out of the Agreement shall be asserted exclusively in the federal or state courts located in or covering the county in which the Participant resides within the State of Massachusetts, and the Parties hereby submit to the personal jurisdiction and venue of those state and federal courts.

2.    California.

For Participants domiciled in the State of California, Section 15(a)(i)(B) of this Agreement shall not apply except to the extent a noncompetition and/or non-solicitation agreement exists and is subject to California Business & Professions Code section 16601 et seq.

*****************************

9

As a condition to the grant of this Award, the Participant by signing below acknowledges receipt and affirmatively agrees to the Agreement, including without limitation the provisions of the above General Terms and Conditions.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

		THERMO FISHER SCIENTIFIC INC.
Date:
	By:
	Name:
	Title:
		Participant

10

EX-10.3

Exhibit 10.3

THERMO FISHER SCIENTIFIC INC.

NONSTATUTORY STOCK OPTION AGREEMENT

This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below.

Notice of Grant

Name of participant (the “Participant”):

Grant date (“Grant Date”):

Number of shares of the Company’s Common Stock subject to this Option (“Shares”):

Option exercise price per Share:

Final exercise date (“Final Exercise Date”):

Vesting Schedule:

Vesting date (“Vesting Date”):	Number of Options that vest:
[Enter vesting schedule here]
Except as otherwise provided in this Agreement, all vesting is dependent on the Participant remaining an Eligible Participant (as defined in Exhibit A) through the applicable Vesting Date.

This Agreement includes this Notice of Grant and the following Exhibits, which are expressly incorporated by reference in their entirety herein:

Exhibit A – General Terms and Conditions

Exhibit B - Country Addendum (for Participants in all non-U.S. countries)

This agreement must be accepted on the final page below.

EXHIBIT A

GENERAL TERMS AND CONDITIONS

1.Grant of Option. This Agreement (including the Notice of Grant and, for Participants that work and/or reside outside of the U.S., the Country Addendum attached hereto as Exhibit B) evidences the grant on the Grant Date set forth in the Notice of Grant, by the Company tothe Participant of an option (the “Option”) to purchase, in whole or in part, on the terms provided herein and in the Company’s Amended and Restated 2013 Stock Incentive Plan, as from time to time amended (the “Plan”), the number of Shares set forth in the Notice of Grant, of common stock, $1.00par value per share, of the Company (“Common Stock”), at the exercise price per Share set forth in the Notice of Grant. Unless earlier terminated pursuant to Section 3(b) through (f) below, this Option shall expire at 5:00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant.

It is intended that the Option evidenced by this Agreement shall not be an incentive stock option as defined in Section 422 of the U.S. Internal Revenue Code of 1986, as amended. Except as otherwise indicated by the context, the term “Participant”, as used in this Agreement, shall be deemed to include any person who acquires the right to exercise this Option validly under its terms. Capitalized terms used in this Agreement and not otherwise defined shall have the same meaning as in the Plan.

2.Vesting Schedule. Except as otherwise provided in paragraphs (c) through (f) of Section 3 below and the Plan, this Option will become exercisable (“vest”) in accordance with the Vesting Schedule set forth in the Notice of Grant, providedthat on each such Vesting Date set forth in the Notice of Grant the Participant is, and has been at all times since the Grant Date providing service as (as applicable) an employee, officer or director of, or consultant or advisor to, the Company (or a Subsidiary or Affiliate) (an “Eligible Participant”). For the avoidance of doubt, “service” shall mean (i) if the Participant is an employee of the Company (or a Subsidiary or Affiliate) on the Grant Date, only service as an employee, and (ii) if the Participant is a consultant, advisor or other non-employee service provider of the Company (or a Subsidiary or Affiliate) on the Grant Date, service only in such position. Unless otherwise determined by the Administrator, a Participant shall cease to be an Eligible Participant upon a change in the employment or service relationship (e.g. a change from employee to a consultant). The right of exercise shall be cumulative so that to the extent the Option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this Option under Section 3 hereof or the Plan.

3.Exercise of Option.

(a)Form of Exercise. Each election to exercise this Option shall be in accordance with the instructions provided from time to time by the Company. The Participant may purchase less than the number of shares covered hereby, providedthat no partial exercise of this Option may be for any fractional share.

- 2 -

(b)Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (c)-(f) below, the right to exercise this Option shall terminatethree months after such cessation (but in no event after the Final Exercise Date); providedthat this Option shall be exercisable only to the extent that the Participant was entitled to exercise this Option on the date of such cessation; and, provided further that, if the Participant’s service with the Company (or a Subsidiary or Affiliate) is terminated by the Company without Cause and if the date on which such Participant’s Option would terminate pursuant to this Section 3(b) occurs at a time when trading in the shares of Common Stock by the Participant is prohibited by the Company’s insider trading policy (or during a Company-imposed “blackout period”), then the termination date (or the Final Exercise Date, if earlier) shall be automatically extended until the 30th day following the expiration of such prohibition, but not beyond the day before the tenth anniversary of the Grant Date.

(c)Death or Disability. If the Participant’s service with the Company (or a Subsidiary or Affiliate) is terminated by reason of death or employment with the Company (or a Subsidiary or Affiliate) is terminated by reason of Disability prior to the Final Exercise Date while the Participant is an Eligible Participant, this Option shall vest and become 100% exercisable upon the date of such termination due to death or Disability and the right to exercise this Option shall terminate one year following such date (but in no event after the Final Exercise Date).

(d)Discharge for Cause. If the Participant, prior to the Final Exercise Date, is discharged by the Company (or a Subsidiary or Affiliate) for Cause, the right to exercise this Option shall terminate immediately upon the effective date of such discharge. The Participant shall be considered to have been discharged for Cause if the Company determines, within thirty (30) days after the Participant’s resignation, that discharge for Cause was warranted.

(e)Retirement. If the Participant Retires from the Company (or a Subsidiary or Affiliate) prior to the Final Exercise Date then, subject to Section 3(d) above, the right to exercise this Option shall terminate on the Final Exercise Date and, provided that the Retirement date occurs at least two years after the Grant Date, this Option shall vest and become 100% exercisable upon the date of such Retirement.

(f)Change in Control Event. If the Participant’s employment or service is terminated by the Company or any Subsidiary or Affiliate due to a Qualifying Termination (as defined in Section 5(e) below) within 18 months following a Change in Control Event, this Option shall vest and become 100% exercisable upon the date of such termination of employment or service and the right to exercise this Option shall terminate one year following such date (but in no event after the Final Exercise Date).

4.Withholding. No Shares will be issued pursuant to the exercise of this Option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of any federal, state, local, or other applicable taxes required to be withheld in respect of this Option in accordance with the instructions provided from time to time by the Company; provided, however, where Shares are being used to satisfy such tax obligations for a Participant who is not subject to Section 16 of the Securities Exchange Act of 1934, the Participant hereby authorizes the Company to hold back from the Shares to be delivered pursuant to this Agreement

- 3 -

that number of Shares (which may include fractional shares) calculated to satisfy all such federal, state, local or other applicable taxes required to be withheld in connection with the issuance of such Shares.

5.Meaning and Use of Certain Terms.

For purposes of this Agreement:

(a)    “Cause” means the willful engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company (or a Subsidiary or Affiliate). For purposes of the foregoing, no act or failure to act by the Participant shall be considered “willful” unless it is done or omitted to be done, in bad faith and without reasonable belief that the Participant's action or omission was in the best interests of the Company (or a Subsidiary or Affiliate).

(b)    “Change in Control Event” has the meaning ascribed to it in the Plan.

(c)    “Disability” or “Disabled”. A Participant shall be deemed to be disabled at such time as the Participant is receiving disability benefits under the Company’s (or a Subsidiary’s or Affiliate’s) long term disability coverage, as then in effect; provided however that the Participant shall not be treated as Disabled unless the disability is described under Section 409A of the Code.

(d)    “Good Reason” has the meaning ascribed to it in the Plan.

(e)    “Qualifying Termination”. A Participant has a Qualifying Termination if the Participant’s employment or service is terminated by the Company (or a Subsidiary or Affiliate) without Cause or by the Participant for Good Reason and such termination results in a separation from service under Section 409A of the Code.

(f)    “Retire” or “Retirement”. For the purposes of this Agreement, the Participant shall be deemed to have “retired” (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company (or a Subsidiary or Affiliate), upon the Participant’s resignation from employment with the Company (or a Subsidiary or Affiliate) either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake of clarity, subject to execution of a release of claims in a form acceptable to the Company, a termination of employment initiated by the Company (or a Subsidiary or Affiliate), that is not a “termination for Cause” may, to the extent permitted by the Company in its sole discretion, be recharacterized as a voluntary termination by reason of Retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company (or a Subsidiary or Affiliate) to the Participant pursuant to any agreement between the Company (or a Subsidiary or Affiliate) and the Participant or any

- 4 -

Company policy. Any determination concerning eligibility for Retirement shall be made by the Administrator in its sole discretion.

(g)    “Subsidiary” or “Affiliate” has the meaning ascribed to it in the Plan, and shall for the avoidance of doubt include any such entity only so long as the Company maintains a controlling interest in such entity.

6.Nontransferability of Option. This Option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this Option shall be exercisable only by the Participant.

7.Provisions of the Plan. This Option is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.

8.No Right To Employment or Other Status. The grant of this Option shall not be construed as giving the Participant the right to continued employment or any other relationship with the Company or its Subsidiaries or Affiliates. The Company and its Subsidiaries and Affiliates expressly reserve the right at any time to dismiss or otherwise terminate its relationship with the Participant free from any liability or claim under the Plan or this Agreement, except as expressly provided herein.

9.Clawback. In accepting this Option, the Participant expressly agrees to be bound by, and subject to, the following clawback policy and any clawback policy that the Company has in effect (as the same may be amended from time to time), or may adopt in the future:

(a)The Option is intended to align the Participant’s long-term interests with those of the Company. Accordingly, subject to Addendum A and unless otherwise expressly provided in the Plan or any other applicable agreement, plan, or policy, and to the extent permitted by applicable law, the Company may terminate any unsettled portion of the Option, whether vested, unvested or unexercised (“Termination”), recapture any Shares acquired pursuant to the Option (“Recapture”), or require the Participant to reimburse the Company for any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the Option (“Reimbursement”), upon the occurrence of any of the following events (collectively, the “Conditions”):

(i)the Participant has engaged in misuse of the Company’s confidential information and/or conduct in breach of any (A) confidentiality obligation to the Company under any agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to, the Company’s standard form of Information and Invention Agreement applicable to such Participant, or (B) applicable noncompetition or nonsolicitation obligation to the Company under any applicable agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to the Company’s standard form of Noncompetition Agreement applicable to such Participant;

(ii)the Participant's employment or other service has been terminated for Cause; or

- 5 -

(iii)during the Participant’s employment or other service, the Participant (A) has rendered services to or otherwise directly or indirectly engaged in or assisted, any organization or business that, in the judgment of the Company in its sole and absolute discretion, is against the interest of the Company or one of its affiliates; or (B) has engaged in activities that are materially prejudicial to or in conflict with the interests of the Company, including any breaches of fiduciary duty or the duty of loyalty.

For purposes of this Section 9, “Option Benefits” shall mean any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the Option, including any sales proceeds and/or dividends.

(b)Prior to the issuance of any Shares upon settlement of the Option pursuant to this Agreement, the Participant shall, if requested in writing by the Company, certify on a form acceptable to the Company that the Participant is in compliance with the terms and conditions of this Agreement and with the obligations contained in the Plan, or any other relevant agreement, plan, or contract listed in Section 9(a).

(c)Within ten (10) calendar days after receiving notice from the Company of any such activity described in Section 9(a) of this Agreement, the Participant shall either deliver to the Company the applicable Shares or make a cash payment to the Company equal to the Option Benefits. For purposes of the Company’s exercise of its Recapture and/or Reimbursement rights hereunder, the Participant expressly and explicitly authorizes the Company to issue instructions, on the Participant’s behalf, to any brokerage firm and/or third-party administrator engaged by the Company to hold Shares and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company.

(d)Notwithstanding the foregoing provisions of this Section 9, the Company may, in its sole and absolute discretion, choose to refrain from exercising its rights of Termination, Recapture and/or Reimbursement with respect to any particular act of the Participant or with respect to any other participant in the Plan, and its determination to refrain from exercising such rights shall not in any way reduce or eliminate the Company’s authority to exercise its rights of Termination, Recapture and/or Reimbursement with respect to any other act of the Participant. Nothing in this Section 9 shall be construed to impose obligations on the Participant to refrain from engaging in lawful competition with the Company after the termination of employment that does not violate the Conditions, other than any obligations that are part of any applicable separate agreement between the Company and the Participant or that arise under applicable law.

(e)Notwithstanding anything to the contrary in the Plan or this Agreement, the Company shall not seek to exercise its rights of Termination, Recapture or Reimbursement relating to any Options that were settled more than twelve (12) months prior to the date of the Participant’s act or omission set forth in Section 9(a), providedthat, notwithstanding the foregoing, all Options shall be subject to the Company’s rights of Termination, Recapture and/or Reimbursement to the extent required by applicable law, including but not limited to Section 10D of the Securities Exchange Act of 1934.

10.Governing Law. Except as provided in Addendum A, this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to any

- 6 -

applicable conflicts of laws and in the event of a dispute related to or arising out of this Agreement, the parties submit to the exclusive jurisdiction and venue of the Delaware federal and Chancery Courts.

11.Country Addendum. Notwithstanding any provisions in this Agreement, in the case of Participants that work and/or reside outside of the U.S., this Option shall be subject to any additional terms and conditions for the Participant’s country of residence (and county of employment or other provision of services, if different)set forth in the “Country Addendum” attached hereto as Exhibit B. Further, if the Participant relocates to one of the countries included in the Country Addendum, the additional terms and conditions for such country will apply to the Participant to the extent that the Company determines, in its discretion, that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Country Addendum constitutes part of this Agreement.

12.Affirmative Acceptance of Award. As a condition to the grant of this Option, the Participant must affirmatively accept this Option and Agreement by logging onto Fidelity’s website at www.netbenefits.fidelity.com and completing the acceptance procedures reflected therein within 120 calendar days of the Grant Date (the “Award Acceptance Deadline”). If the Participant fails to accept this Option and Agreement by the Award Acceptance Deadline, this Award automatically will be forfeited and immediately terminate without any further action by the parties.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

- 7 -

Addendum A

1.    Massachusetts.

For Participants domiciled in the State of Massachusetts, the following language shall be added to Section 9(a)(i) of this Agreement:

Notwithstanding Section 10 of this Agreement, for any Termination, Recapture, and/or Reimbursement that is based, in whole or in part, on the Participant’s breach of a noncompete agreement or nonsolicitation obligation, such disputes shall be governed by and interpreted in accordance with the laws of the State of Massachusetts, and any dispute arising out of the Agreement shall be asserted exclusively in the federal or state courts located in or covering the county in which the Participant resides within the State of Massachusetts, and the Parties hereby submit to the personal jurisdiction and venue of those state and federal courts.

2.    California.

For Participants domiciled in the State of California, Section 9(a)(i)(B) of this Agreement shall not apply except to the extent a noncompetition and/or non-solicitation agreement exists and is subject to California Business & Professions Code section 16601 et seq.

*********************************

- 8 -

As a condition to the grant of this Award, the Participant by signing below acknowledges receipt and affirmatively agrees to the Agreement, including without limitation the provisions of the above General Terms and Conditions.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

		THERMO FISHER SCIENTIFIC INC.
Date:
	By:
	Name:
	Title:
		Participant

- 9 -

EX-10.4

Exhibit 10.4

THERMO FISHER SCIENTIFIC INC.

NONSTATUTORY STOCK OPTION AGREEMENT

This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below.

Notice of Grant

Name of participant (the “Participant”):

Grant date (“Grant Date”):

Number of shares of the Company’s Common Stock subject to this Option upon full satisfaction of vesting conditions, including performance at target (“Shares”):

Option exercise price per Share:

Final exercise date (“Final Exercise Date”):

Vesting Schedule:

Vesting date (“Vesting Date”):	Number of Options that vest:
See Schedule A
Except as otherwise provided in this Agreement, all vesting is dependent on the Participant remaining an Eligible Participant (as defined in Exhibit A) through the applicable Vesting Date.

This Agreement includes this Notice of Grant and the following Exhibits, which are expressly incorporated by reference in their entirety herein:

Exhibit A – General Terms and Conditions

This agreement must be accepted on the final page below.

EXHIBIT A

GENERAL TERMS AND CONDITIONS

1.Grant of Option. This Agreement (including the Notice of Grant) evidences the grant on the Grant Date set forth in the Notice of Grant, by the Company tothe Participant of an option (the “Option”) to purchase, in whole or in part, subject to the terms, conditions and restrictions provided herein and in the Company’s Amended and Restated 2013 Stock Incentive Plan, as from time to time amended (the “Plan”), the number of Shares set forth in the Notice of Grant, of common stock, $1.00par value per share, of the Company (“Common Stock”), at the exercise price per Share set forth in the Notice of Grant. The number of shares subject to the Option as set forth in the Notice of Award is referred to as the “Target Award.” Unless earlier terminated pursuant to Section 3(b) through (f) below, this Option shall expire at 5:00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant.

It is intended that the Option evidenced by this Agreement shall not be an incentive stock option as defined in Section 422 of the U.S. Internal Revenue Code of 1986, as amended. Except as otherwise indicated by the context, the term “Participant”, as used in this Agreement, shall be deemed to include any person who acquires the right to exercise this Option validly under its terms. Capitalized terms used in this Agreement and not otherwise defined shall have the same meaning as in the Plan.

2.Vesting Schedule. Except as otherwise provided in paragraphs (c) through (f) of Section 3 below and the Plan, this Option will become exercisable (“vest”) as described on Schedule A hereto, provided that on the Vesting Date (as defined in Schedule A) the Participant is, and has been at all times since the Grant Date providing service as an employee, officer or director of, or consultant or advisor to, the Company (or a Subsidiary or Affiliate) (an “Eligible Participant”). Unless otherwise determined by the Committee, a Participant shall cease to be an Eligible Participant upon a change in the employment or service relationship (e.g. a change from employee to a consultant).

3.Exercise of Option.

(a)Form of Exercise. Each election to exercise this Option shall be in accordance with the instructions provided from time to time by the Company. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this Option may be for any fractional share.

(b)Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (c)-(f) below, the right to exercise this Option shall terminatethree months after such cessation (but in no event after the Final Exercise Date); providedthat this Option shall be exercisable only to the extent that the Participant was entitled to exercise this Option on the date of such cessation; and, provided further that, if the Participant’s service with the Company (or a Subsidiary or Affiliate) is terminated by the Company without Cause and if the date on which such Participant’s Option would terminate pursuant to this Section 3(b) occurs at a time when trading in the shares of

- 2 -

Common Stock by the Participant is prohibited by the Company’s insider trading policy (or during a Company-imposed “blackout period”), then the termination date (or the Final Exercise Date, if earlier) shall be automatically extended until the 30th day following the expiration of such prohibition, but not beyond the day before the tenth anniversary of the Grant Date.

(c)Death or Disability. If the Participant’s service with the Company (or a Subsidiary or Affiliate) is terminated by reason of death, or employment with the Company (or a Subsidiary or Affiliate) is terminated by reason of Disability prior to the Vesting Date (as defined in Schedule A) while the Participant is an Eligible Participant, this Option shall vest and become exercisable to the extent that and upon the date that such Option would have vested had the Participant remained employed with the Company on the Vesting Date and the right to exercise this Option shall terminate one year following such Vesting Date (but in no event after the Final Exercise Date).

(d)Discharge for Cause. If the Participant, prior to the Final Exercise Date, is discharged by the Company (or a Subsidiary or Affiliate) for Cause, the right to exercise this Option shall terminate immediately upon the effective date of such discharge. The Participant shall be considered to have been discharged for Cause if the Company determines, within thirty (30) days after the Participant's resignation, that discharge for Cause was warranted.

(e)Retirement. If the Participant Retires from the Company (or a Subsidiary or Affiliate) prior to the Vesting Date then, subject to Section 3(d) above, this Option shall vest and become exercisable to the extent that and upon the date that such Option would have vested had the Participant remained employed with the Company on the Vesting Date, subject to further adjustment under the “Retirement” provisions of Schedule A, and the right to exercise this Option shall terminate on the Final Exercise Date.

(f)Change in Control Event. If the Participant’s employment or service is terminated by the Company or any Subsidiary or Affiliate due to a Qualifying Termination (as defined in Section 5(e) below) within 18 months following a Change in Control Event, this Option shall vest and become 100% exercisable upon the date of such termination of employment or service and the right to exercise this Option shall terminate one year following such date (but in no event after the Final Exercise Date).

4.Withholding. No Shares will be issued pursuant to the exercise of this Option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of any federal, state, local, or other applicable taxes required to be withheld in respect of this Option in accordance with the instructions provided from time to time by the Company; provided, however, where Shares are being used to satisfy such tax obligations for a Participant who is not subject to Section 16 of the Securities Exchange Act of 1934, the Participant hereby authorizes the Company to hold back from the Shares to be delivered pursuant to this Agreement that number of Shares (which may include fractional shares) calculated to satisfy all such federal, state, local or other applicable taxes required to be withheld in connection with the issuance of such Shares.

5.Meaning and Use of Certain Terms.

- 3 -

For purposes of this Agreement:

(a)    “Cause” means the willful engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company (or a Subsidiary or Affiliate). For purposes of the foregoing, no act or failure to act by the Participant shall be considered “willful” unless it is done or omitted to be done, in bad faith and without reasonable belief that the Participant's action or omission was in the best interests of the Company (or a Subsidiary or Affiliate).

(b)    “Change in Control Event” has the meaning ascribed to it in the Plan.

(c)    “Disability” or “Disabled”. A Participant shall be deemed to be disabled at such time as the Participant is receiving disability benefits under the Company’s (or a Subsidiary’s or Affiliate’s) long term disability coverage, as then in effect; provided however that the Participant shall not be treated as Disabled unless the disability is described under Section 409A of the Code.

(d)    “Good Reason” has the meaning ascribed to it in the Plan.

(e)    “Qualifying Termination”. A Participant has a Qualifying Termination if the Participant’s employment or service is terminated by the Company (or a Subsidiary or Affiliate) without Cause or by the Participant for Good Reason and such termination results in a separation from service under Section 409A of the Code.

(f)    “Retire” or “Retirement”. For the purposes of this Agreement, the Participant shall be deemed to have “retired” (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company (or a Subsidiary or Affiliate), upon the Participant’s resignation from employment with the Company (or a Subsidiary or Affiliate) either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake of clarity, subject to execution of a release of claims in a form acceptable to the Company, a termination of employment initiated by the Company (or a Subsidiary or Affiliate), that is not a “termination for Cause” may, to the extent permitted by the Company in its sole discretion, be recharacterized as a voluntary termination by reason of Retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company (or a Subsidiary or Affiliate) to the Participant pursuant to any agreement between the Company (or a Subsidiary or Affiliate) and the Participant or any Company policy. Any determination concerning eligibility for Retirement shall be made by the Committee in its sole discretion.

(g)    “Subsidiary” or “Affiliate” has the meaning ascribed to it in the Plan, and shall for the avoidance of doubt include any such entity only so long as the Company maintains a controlling interest in such entity.

- 4 -

6.Nontransferability of Option. This Option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this Option shall be exercisable only by the Participant.

7.Provisions of the Plan. This Option is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.

8.No Right To Employment or Other Status. The grant of this Option shall not be construed as giving the Participant the right to continued employment or any other relationship with the Company or its Subsidiaries or Affiliates. The Company and its Subsidiaries and Affiliates expressly reserve the right at any time to dismiss or otherwise terminate its relationship with the Participant free from any liability or claim under the Plan or this Agreement, except as expressly provided herein.

9.Clawback. In accepting this Option, the Participant expressly agrees to be bound by, and subject to, the following clawback policy and any clawback policy that the Company has in effect (as the same may be amended from time to time), or may adopt in the future:

(a)The Option is intended to align the Participant’s long-term interests with those of the Company. Accordingly, subject to Addendum A and unless otherwise expressly provided in the Plan or any other applicable agreement, plan, or policy, and to the extent permitted by applicable law, the Company may terminate any unsettled portion of the Option, whether vested, unvested or unexercised (“Termination”), recapture any Shares acquired pursuant to the Option (“Recapture”), or require the Participant to reimburse the Company for any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the Option (“Reimbursement”), upon the occurrence of any of the following events (collectively, the “Conditions”):

(i)the Participant has engaged in misuse of the Company’s confidential information and/or conduct in breach of any (A) confidentiality obligation to the Company under any agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to, the Company’s standard form of Information and Invention Agreement applicable to such Participant, or (B) applicable noncompetition or nonsolicitation obligation to the Company under any applicable agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to the Company’s standard form of Noncompetition Agreement applicable to such Participant;

(ii)the Participant’s employment or other service has been terminated for Cause; or

(iii)during the Participant’s employment or other service, the Participant (A) has rendered services to or otherwise directly or indirectly engaged in or assisted, any organization or business that, in the judgment of the Company in its sole and absolute discretion, is against the interest of the Company or one of its affiliates; or (B) has engaged in activities that

- 5 -

are materially prejudicial to or in conflict with the interests of the Company, including any breaches of fiduciary duty or the duty of loyalty.

For purposes of this Section 9, “Option Benefits” shall mean any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the Option, including any sales proceeds and/or dividends.

(b)Prior to the issuance of any Shares upon settlement of the Option pursuant to this Agreement, the Participant shall, if requested in writing by the Company, certify on a form acceptable to the Company that the Participant is in compliance with the terms and conditions of this Agreement and with the obligations contained in the Plan, or any other relevant agreement, plan, or contract listed in Section 9(a).

(c)Within ten (10) calendar days after receiving notice from the Company of any such activity described in Section 9(a) of this Agreement, the Participant shall either deliver to the Company the applicable Shares or make a cash payment to the Company equal to the Option Benefits. For purposes of the Company’s exercise of its Recapture and/or Reimbursement rights hereunder, the Participant expressly and explicitly authorizes the Company to issue instructions, on the Participant’s behalf, to any brokerage firm and/or third-party administrator engaged by the Company to hold Shares and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company.

(d)Notwithstanding the foregoing provisions of this Section 9, the Company may, in its sole and absolute discretion, choose to refrain from exercising its rights of Termination, Recapture and/or Reimbursement with respect to any particular act of the Participant or with respect to any other participant in the Plan, and its determination to refrain from exercising such rights shall not in any way reduce or eliminate the Company’s authority to exercise its rights of Termination, Recapture and/or Reimbursement with respect to any other act of the Participant. Nothing in this Section 9 shall be construed to impose obligations on the Participant to refrain from engaging in lawful competition with the Company after the termination of employment that does not violate the Conditions, other than any obligations that are part of any applicable separate agreement between the Company and the Participant or that arise under applicable law.

(e)Notwithstanding anything to the contrary in the Plan or this Agreement, the Company shall not seek to exercise its rights of Termination, Recapture or Reimbursement relating to any Options that were settled more than twelve (12) months prior to the date of the Participant’s act or omission set forth in Section 9(a); providedthat, notwithstanding the foregoing, all Options shall be subject to the Company’s rights of Termination, Recapture and/or Reimbursement to the extent required by applicable law, including but not limited to Section 10D of the Securities Exchange Act of 1934.

10.Governing Law. Except as provided in Addendum A, this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to any applicable conflicts of laws and in the event of a dispute related to or arising out of this Agreement, the parties submit to the exclusive jurisdiction and venue of the Delaware federal and Chancery Courts.

- 6 -

11.Affirmative Acceptance of Award. As a condition to the grant of this Option, the Participant must affirmatively accept this Option and Agreement by logging onto Fidelity’s website at www.netbenefits.fidelity.com and completing the acceptance procedures reflected therein within 120 calendar days of the Grant Date (the “Award Acceptance Deadline”). If the Participant fails to accept this Option and Agreement by the Award Acceptance Deadline, this Award automatically will be forfeited and immediately terminate without any further action by the parties.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

- 7 -

Addendum A

1.    Massachusetts.

For Participants domiciled in the State of Massachusetts, the following language shall be added to Section 9(a)(i) of this Agreement:

Notwithstanding Section 10 of this Agreement, for any Termination, Recapture, and/or Reimbursement that is based, in whole or in part, on the Participant’s breach of a noncompete agreement or nonsolicitation obligation, such disputes shall be governed by and interpreted in accordance with the laws of the State of Massachusetts, and any dispute arising out of the Agreement shall be asserted exclusively in the federal or state courts located in or covering the county in which the Participant resides within the State of Massachusetts, and the Parties hereby submit to the personal jurisdiction and venue of those state and federal courts.

2.    California.

For Participants domiciled in the State of California, Section 9(a)(i)(B) of this Agreement shall not apply except to the extent a noncompetition and/or non-solicitation agreement exists and is subject to California Business & Professions Code section 16601 et seq.

*********************************

- 8 -

As a condition to the grant of this Award, the Participant by signing below acknowledges receipt and affirmatively agrees to the Agreement, including without limitation the provisions of the above General Terms and Conditions.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

		THERMO FISHER SCIENTIFIC INC.
Date:
	By:
	Name:
	Title:
		Participant

- 9 -

EX-10.5

Exhibit 10.5

THERMO FISHER SCIENTIFIC INC.

PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT

This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below.

Notice of Award

Name of participant (the “Participant”):	Marc N. Casper
Award date (“Award Date”):
Number of shares of the Company’s Common Stock subject to this Award (“Shares”):

Vesting Schedule:

Vesting date (“Vesting Date”):	Number of RSUs that vest:
See Schedule A	See Schedule A
Except as otherwise provided in this Agreement, all vesting is dependent on the Participant remaining an Eligible Participant (as defined in Exhibit A) through the applicable Vesting Date.

This Agreement includes this Notice of Award and the following Exhibits, which are expressly incorporated by reference in their entirety herein:

Exhibit A – General Terms and Conditions

Schedule A: Vesting Schedule for Performance-based Restricted Stock Units

This Agreement must be accepted on the final page below.

EXHIBIT A

GENERAL TERMS AND CONDITIONS

1.Award of Restricted Stock Units.

This Agreement (including the Notice of Award) sets forth the terms and conditions of an award on the Award Date set forth in the Notice of Award, by the Company to the Participant of that number of restricted stock units of the Company set forth in the Notice of Award (individually, an “RSU” and collectively, the “RSUs” or the “Award”). Each RSU represents the right to receive one share of common stock, $1.00 par value, of the Company (“Common Stock”) pursuant to the terms, conditions and restrictions set forth in this Agreement and in the Company’s Amended and Restated 2013 Stock Incentive Plan, as from time to time amended (the “Plan”). The number of RSUs set forth in the Notice of Award is referred to as the “Target Award.” Capitalized terms used in this Agreement and not otherwise defined shall have the same meaning as in the Plan.

2.Vesting Schedule.

Except as otherwise provided in paragraphs (b) through (f) of Section 3 and the Plan, the RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of Award and Schedule A below, provided that on each Vesting Date set forth in the Notice of Award, the Participant is, and has been at all times since the Award Date, an employee, officer or director of, or consultant or advisor to, the Company (or a Subsidiary or Affiliate) (an “Eligible Participant”). Unless otherwise determined by the Committee, the Participant shall continue to be an Eligible Participant upon a change in the employment or service relationship (e.g. a change from employee to a director).

3.Additional Vesting Provisions.

(a)Termination of Relationship with the Company. In the event that the Participant ceases to be an Eligible Participant for any reason other than those set forth in paragraphs (b) through (f) below before the final Vesting Date (as defined in Schedule A), the RSUs that have not previously vested shall be immediately forfeited to the Company.

(b)Death or Disability. In the event that the Participant’s service with the Company (or a Subsidiary or Affiliate) is terminated by reason of death or Disability prior to the Performance Certification Date (as defined in Schedule A), 50% of the Target Award shall vest upon the date of such termination. In the event that such termination occurs on or after the Performance Certification Date but prior to the final Vesting Date, the RSUs that have not previously vested (based on the number of RSUs determined on the Performance Certification Date to be eligible to be received) shall vest 100% upon the date of such termination due to death or Disability.

(c)Discharge without Cause or for Good Reason. In the event that the Participant’s employment or service is terminated by the Company (or a Subsidiary or Affiliate) after the last

- 2 -

day of the Company’s fiscal quarter in which this Award was granted, and prior to the Performance Certification Date without “Cause” (as defined in Section 1.2 of the 2009 Restatement of Executive Severance Agreement between the Company and the Participant dated November 21, 2009, as may be amended from time to time (the “‘Severance Agreement”)) or by the Participant for Good Reason (as defined in Section 1.4 of the Severance Agreement), and such termination does not entitle the Participant to severance benefits under the Executive Change in Control Retention Agreement between the Company and the Participant dated November 21, 2009, as may be amended from time to time (the “CIC Agreement”), and provided that the performance conditions (assuming the last day of the performance period was the last day of the prior fiscal quarter) are actually achieved and the Compensation Committee has certified the achievement of the performance conditions, then 1/3 of the RSUs shall vest immediately. In the event of such termination on or after the Performance Certification Date but prior to the final Vesting Date, then the RSUs that are scheduled to vest on the next Vesting Date (based on the number of RSUs determined on the Performance Certification Date to be eligible to be received) shall vest upon the date of such termination, and the remaining RSUs shall be forfeited.

(d)Change in Control Event. In the event that the Participant’s employment or service is terminated by the Company (or a Subsidiary or Affiliate) without “Cause” (as defined in Section 1.3 of the CIC Agreement) or by the Participant for Good Reason (as defined in Section 1.4 of the CIC Agreement), within 18 months after a Change in Control Event that occurs prior to the Performance Certification Date, and such termination entitles the Participant to severance benefits under the CIC Agreement, then all unvested RSUs shall vest immediately, provided that the performance conditions (assuming the last day of the performance period was the last day of the fiscal quarter immediately prior to the Change in Control Event) are actually achieved (without regard to performance for any periods following the last day of the fiscal quarter immediately prior to the Change in Control Event) and the Compensation Committee has certified the achievement of the performance conditions. In the event of such termination on or after the Performance Certification Date but before the final Vesting Date, then all unvested RSUs (based on the number of RSUs determined on the Performance Certification Date to be eligible to be received, as adjusted pursuant to the provisions of Schedule A) shall vest upon the date of such termination.

(e)Retirement. If the Participant Retires from the Company (or a Subsidiary or Affiliate) after the later of (i) the Performance Certification Date or (ii) the second anniversary of the Award Date, then nevertheless the Participant shall become vested in the remaining RSUs to be delivered (calculated based on the units earned as of the Performance Certification Date, as adjusted pursuant to any applicable provisions of Schedule A).

(f)Discharge for Cause. In the event that the Participant is discharged by the Company (or a Subsidiary or Affiliate) for “Cause” (as defined in Section 1.2 of the Severance Agreement), all unvested RSUs and all vested RSUs that have not been delivered in accordance with Section 4 below shall terminate immediately upon the effective date of such discharge. The Participant shall be considered to have been discharged for Cause if the Company determines, within thirty (30) days after the Participant’s resignation, that discharge for Cause was warranted.

- 3 -

4.Delivery of Shares.

(a)Except as provided in (b) below, the Company shall deliver the Shares that become issuable pursuant to an RSU within the sixty (60) day period following the date the RSUs vest pursuant to Sections 2 or 3 above, but in no event later than the last day of the period specified in Treas. Reg. section 1.409A-1(b)(4)(i)(A).

(b)In the event that the Participant Retires under the conditions of Section 3(e) above, the Company shall deliver the Shares that become issuable pursuant to an RSU, to the extent not previously delivered, within the sixty (60) day period following the date such RSUs would have vested had the Participant remained employed with the Company.

(c)The Company shall not be obligated to deliver Shares to the Participant unless the issuance and delivery of such Shares shall comply with all relevant provisions of law and other legal requirements including, without limitation, any applicable federal or state securities laws and the requirements of any stock exchange upon which shares of Common Stock may then be listed.

5.Meaning and Use of Certain Terms.

For purposes of this Agreement,

(a)“Change in Control Event” has the meaning ascribed to it in the Plan.

(b)“Disability” or “Disabled.” A Participant shall be deemed to be disabled at such time as the Participant is receiving disability benefits under the Company’s (or a Subsidiary’s or Affiliate’s) long term disability coverage, as then in effect; provided however that the Participant shall not be treated as Disabled unless the disability is described under Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”).

(c)“Retire” or “Retirement.” For the purposes of this Agreement, the Participant shall be deemed to have "retired" (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company (or a Subsidiary or Affiliate), upon the Participant's resignation from employment with the Company (or a Subsidiary or Affiliate) either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake of clarity, subject to execution of a release of claims in a form acceptable to the Company, the Participant may seek to re-characterize any termination of employment initiated by the Company (or a Subsidiary or Affiliate) that is not a termination for “Cause” (as defined in Section 1.2 of the Severance Agreement) as a voluntary termination by reason of Retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company (or a Subsidiary or Affiliate) to the Participant pursuant to any agreement between the Company (or a Subsidiary or Affiliate) and the

- 4 -

Participant or any Company policy. Any such determination shall be made by the Committee in its sole discretion.

(d)“Subsidiary” or “Affiliate” has the meaning ascribed to it in the Plan, and shall for the avoidance of doubt include any such entity only so long as the Company maintains a controlling interest in such entity.

6.Restrictions on Transfer.

The Participant shall not sell, assign, transfer, pledge, hypothecate, or otherwise dispose of, by operation of law or otherwise (collectively “transfer”) any RSUs, or any interest therein, except by will or the laws of descent and distribution. Upon delivery of Shares pursuant to Section 4 above, the Participant for two years thereafter shall not transfer more than 50% of the actual net Shares delivered (after withholding for the payment of taxes); provided, however, that this restriction shall not apply to a termination of the Participant’s employment under paragraphs (b), (c), (d), or (e) of Section 3 above. The Participant acknowledges that any stock certificates or other evidence of ownership of RSUs or Shares may bear a restrictive legend evidencing any applicable transfer restrictions.

7.Provisions of the Plan.

This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.

8.Dividends; Other Corporate Transactions.

(a)If at any time during the period between the Performance Certification Date and the date that Shares are delivered after the RSU vests, the Company pays a dividend or other distribution with respect to its Common Stock, including without limitation a distribution of shares of the Company’s stock by reason of a stock dividend, stock split or otherwise, then on the date the Shares issuable upon vesting of the RSU are delivered, the Company shall pay the Participant, at the time of delivery of Shares pursuant to Section 4, the dividend or other distribution that would have been paid on such Shares if the Participant had owned such Shares during the period beginning on the Performance Certification Date and ending on the respective delivery date. No dividend or other distribution shall be paid with respect to RSUs that are forfeited.

(b)In the event of a Reorganization Event, then the rights of the Company under this Agreement and all other terms of this Agreement (including without limitation vesting provisions) shall inure to the benefit of the Company’s successor and shall apply to the cash, securities, or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to the Shares. Such cash, securities, or other property shall be delivered or paid at the time provided in Section 4, except that payments in connection with the liquidation of the Company shall be made only as permitted under Section 409A of the Code.

- 5 -

(c)Except as set forth in Section 8(a) or (b) above and in the Plan, neither the Participant nor any person claiming under or through the Participant shall be, or have any rights or privileges of, a stockholder of the Company in respect of the Shares issuable pursuant to the RSUs granted hereunder until the Shares have been delivered to the Participant.

9.Withholding Taxes; No Section 83(b) Election.

(a)The Participant expressly acknowledges that the delivery of Shares to the Participant will give rise to “wages” subject to withholding and Participant hereby authorizes the Company to hold back from the Shares to be delivered pursuant to Section 4 of this Agreement that number of Shares (which may include fractional shares) calculated to satisfy all such federal, state, local or other applicable taxes required to be withheld in connection with such delivery of Shares; provided, however, that at the Company’s discretion, a Participant who is not subject to Section 16 of the Securities Exchange Act of 1934 may provide notice to the Company prior to the delivery of the Shares that the Participant will make payment to the Company on the date of delivery to satisfy all required withholding taxes in lieu of satisfying such obligation through the withholding of Shares.

(b)The Participant acknowledges that no election under Section 83(b) of the Code may be filed with respect to this Award.

10.No Right To Employment or Other Status. The grant of an award of RSUs shall not be construed as giving the Participant the right to continued employment or any other relationship with the Company or its Subsidiaries or Affiliates. The Company and its Subsidiaries and Affiliates expressly reserve the right at any time to dismiss or otherwise terminate its relationship with the Participant free from any liability or claim under the Plan or this Agreement, except as expressly provided herein.

11.Conflicts With Other Agreements. In the event of any conflict or inconsistency between the terms of this Agreement and any employment, severance, or other agreement between the Company and the Participant, the terms of this Agreement shall govern.

12.Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to any applicable conflicts of laws and in the event of a dispute related to or arising out of this Agreement, the parties submit to the exclusive jurisdiction and venue of the Delaware federal and Chancery Courts. Notwithstanding the foregoing, for any Termination (defined below), Recapture (defined below) and/or Reimbursement (defined below) that is based, in whole or in part, on the Participant’s breach of a noncompete agreement or nonsolicitation obligation, such disputes shall be governed by and interpreted in accordance with the laws of the State of Massachusetts, and any dispute arising out of this Agreement shall be asserted exclusively in the federal or state courts located in or covering the county in which the Participant resides within the State of Massachusetts, and the parties hereby submit to the personal jurisdiction and venue of those state and federal courts.

13.Unfunded Rights. The right of the Participant to receive Common Stock pursuant to this Agreement is an unfunded and unsecured obligation of the Company. The Participant shall have

- 6 -

no rights under this Agreement other than those of an unsecured general creditor of the Company.

14.Compliance with Section 409A of the Code. This Agreement is intended to provide for deferred compensation that is exempt from or compliant with Section 409A of the Code and shall be interpreted consistently with such intent. Accordingly, the Participant shall have no right to designate the taxable year of payment. Notwithstanding any other provision of this Agreement, if and to the extent any portion of any payment under this Agreement to the Participant is payable upon the Participant’s separation from service and the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, as determined by the Company in accordance with its procedures, by which determination the Participant (through accepting the Award) agrees thatthe Participant is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six (6) months plus one (1) day after the date of “separation from service”, except as Section 409A of the Code may then permit.

The Company makes no representations or warranties and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under this Agreement are determined to constitute nonqualified deferred compensation subject to Section 409A of the Code but do not satisfy the conditions of that section.

15.Clawback. In accepting this Award, the Participant expressly agrees to be bound by, and subject to, the following clawback policy and any clawback policy that the Company has in effect (as the same may be amended from time to time) or may adopt in the future:

(a)The Award is intended to align the Participant’s long-term interests with those of the Company. Accordingly, unless otherwise expressly provided in the Plan or any other applicable agreement, plan, or policy, and to the extent permitted by applicable law, the Company may terminate any unsettled RSUs, whether vested or unvested (“Termination”), recapture any Shares acquired pursuant to the RSUs (“Recapture”), or require the Participant to reimburse the Company for any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the RSUs (“Reimbursement”), upon the occurrence of any of the following events (collectively, the “Conditions”):

(i)the Participant has engaged in misuse of the Company’s confidential information and/or conduct in breach of any (A) confidentiality obligation to the Company under any agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to, the Company’s standard form of Information and Invention Agreement applicable to such Participant, or (B) applicable noncompetition or nonsolicitation obligation to the Company under any applicable agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to the Company’s standard form of Noncompetition Agreement applicable to such Participant;

(ii)the Participant has been discharged by the Company (or a Subsidiary or Affiliate) for “Cause” (as defined in Section 1.2 of the Severance Agreement); or

- 7 -

(iii)during the Participant’s employment or other service, the Participant (A) has rendered services to or otherwise directly or indirectly engaged in or assisted, any organization or business that, in the judgment of the Company in its sole and absolute discretion, is against the interest of the Company or one of its affiliates; or (B) has engaged in activities that are materially prejudicial to or in conflict with the interests of the Company, including any breaches of fiduciary duty or the duty of loyalty.

For purposes of this Section 15, “RSU Benefits” shall mean any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the RSUs, including any sales proceeds, dividends and/or dividend equivalents.

(b)Prior to the issuance of any Shares upon settlement of vested RSUs pursuant to this Agreement, the Participant shall, if requested in writing by the Company, certify on a form acceptable to the Company that the Participant is in compliance with the terms and conditions of this Agreement and with the obligations contained in the Plan, or any other relevant agreement, plan, or contract listed in Section 15(a).

(c)Within ten (10) calendar days after receiving notice from the Company of any such activity described in Section 15(a) of this Agreement, the Participant shall either deliver to the Company the applicable Shares or make a cash payment to the Company equal to the RSU Benefits. For purposes of the Company’s exercise of its Recapture and/or Reimbursement rights hereunder, the Participant expressly and explicitly authorizes the Company to issue instructions, on the Participant’s behalf, to any brokerage firm and/or third-party administrator engaged by the Company to hold Shares and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company.

(d)Notwithstanding the foregoing provisions of this Section 15, the Company may, in its sole and absolute discretion, choose to refrain from exercising its rights of Termination, Recapture and/or Reimbursement with respect to any particular act of the Participant or with respect to any other participant in the Plan, and its determination to refrain from exercising such rights shall not in any way reduce or eliminate the Company’s authority to exercise its rights of Termination, Recapture and/or Reimbursement with respect to any other act of the Participant. Nothing in this Section 15 shall be construed to impose obligations on the Participant to refrain from engaging in lawful competition with the Company after the termination of employment that does not violate the Conditions, other than any obligations that are part of any applicable separate agreement between the Company and the Participant or that arise under applicable law.

(e)Notwithstanding anything to the contrary in the Plan or this Agreement, the Company shall not seek to exercise its rights of Termination, Recapture or Reimbursement relating to any RSUs that were vested and settled more than twelve (12) months prior to the date of the Participant’s act or omission set forth in Section 15(a); provided that, notwithstanding the foregoing, all RSUs shall be subject to the Company’s rights of Termination, Recapture and/or Reimbursement to the extent required by applicable law, including but not limited to Section 10D of the Securities Exchange Act of 1934.

- 8 -

As a condition to the grant of this Award, the Participant by signing below acknowledges receipt and affirmatively agrees to the Agreement, including without limitation the provisions of the above General Terms and Conditions.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date written below.

		THERMO FISHER SCIENTIFIC INC.
Date:
	By:
	Name:
	Title:
		Marc N. Casper

- 9 -

EX-10.6

Exhibit 10.6

THERMO FISHER SCIENTIFIC INC.

NONSTATUTORY STOCK OPTION AGREEMENT

This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below.

Notice of Grant

Name of participant (the “Participant”):	Marc N. Casper
Grant date (“Grant Date”):
Number of shares of the Company’s Common Stock subject to this Option (“Shares”):
Option exercise price per Share:
Final exercise date (“Final Exercise Date”):

Vesting Schedule:

Vesting date (“Vesting Date”):	Number of Options that vest:
Except as otherwise provided in this Agreement, all vesting is dependent on the Participant remaining an Eligible Participant (as defined in Exhibit A) through the applicable Vesting Date.

This Agreement includes this Notice of Grant and the following Exhibit, which is expressly incorporated by reference in its entirety herein:

Exhibit A – General Terms and Conditions

This agreement must be accepted on the final page below.

EXHIBIT A

GENERAL TERMS AND CONDITIONS

1.Grant of Option.

This Agreement (including the Notice of Grant) evidences the grant on the Grant Date set forth in the Notice of Grant, by the Company tothe Participant of an option (the “Option”) to purchase, in whole or in part, on the terms provided herein and in the Company’s Amended and Restated 2013 Stock Incentive Plan, as from time to time amended (the “Plan”), the number of Shares set forth in the Notice of Grant, of common stock, $1.00par value per share, of the Company (“Common Stock”), at the exercise price per Share set forth in the Notice of Grant. Unless earlier terminated pursuant to Section 3(b) through (g) below, this Option shall expire at 5:00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant.

It is intended that the Option evidenced by this Agreement shall not be an incentive stock option as defined in Section 422 of the U.S. Internal Revenue Code of 1986, as amended. Except as otherwise indicated by the context, the term “Participant”, as used in this Option, shall be deemed to include any person who acquires the right to exercise this Option validly under its terms. Capitalized terms used in this Agreement and not otherwise defined shall have the same meaning as in the Plan.

2.Vesting Schedule.

Except as otherwise provided in paragraphs (c) through (g) of Section 3 below and the Plan, this Option will become exercisable (“vest”) in accordance with the Vesting Schedule set forth in the Notice of Grant, provided that on each such Vesting Date set forth in the Notice of Grant the Participant is, and has been at all times since the Grant Date, an employee, officer or director of, or consultant or advisor to, the Company (or a Subsidiary or Affiliate) (an “Eligible Participant”). Unless otherwise determined by the Committee, the Participant shall continue to be an Eligible Participant upon a change in the employment or service relationship (e.g. a change from employee to a director). The right of exercise shall be cumulative so that to the extent the Option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this Option under Section 3 hereof or the Plan.

3.Exercise of Option.

(a)Form of Exercise. Each election to exercise this Option shall be in accordance with the instructions provided from time to time by the Company. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this Option may be for any fractional share.

(b)Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (c)-(g) below, the right to exercise this Option shall terminatethree months after such cessation (but in no event after the

- 2 -

Final Exercise Date), providedthat this Option shall be exercisable only to the extent that the Participant was entitled to exercise this Option on the date of such cessation.

(c)Death or Disability. If the Participant’s service with the Company (or a Subsidiary or Affiliate) is terminated by reason of death or “disability” (as defined below) prior to the Final Exercise Date while the Participant is an Eligible Participant, this Option shall vest and become 100% exercisable upon the date of such termination due to death or disability and the right to exercise this Option shall terminate one year following such date (but in no event after the Final Exercise Date). For the purposes of this Agreement, the Participant shall be deemed to be “disabled” at such time as the Participant is receiving disability benefits under the Company’s (or a Subsidiary’s or Affiliate’s) long term disability coverage, as then in effect.

(d)Discharge Without Cause or for Good Reason. If the Participant’s employment or service is terminated by the Company (or a Subsidiary or Affiliate) without “Cause” (as defined in Section 1.2 of the 2009 Restatement of Executive Severance Agreement between the Company and the Participant dated November 21, 2009, as may be amended from time to time (the “Severance Agreement”)) or by the Participant for Good Reason (as defined in Section 1.4 of the Severance Agreement), and such termination does not entitle the Participant to severance benefits under the Executive Change in Control Retention Agreement between the Company and the Participant dated November 21, 2009, as may be amended from time to time (the “CIC Agreement”) prior to the Final Exercise Date, the unvested portion of this Option shall vest as to the 25% tranche of this Option next scheduled to vest under this Agreement (the “Accelerated Option Shares”), and the Accelerated Option Shares shall become exercisable upon the date of such termination of employment or service, and the right to exercise this Option (including the Accelerated Option Shares) shall terminate two years following such date (but in no event after the Final Exercise Date).

(e)Discharge for Cause. If the Participant, prior to the Final Exercise Date, is discharged by the Company (or a Subsidiary or Affiliate) for “Cause” (as defined in Section 1.2 of the Severance Agreement), the right to exercise this Option shall terminate immediately upon the effective date of such discharge. The Participant shall be considered to have been discharged for Cause if the Company determines, within thirty (30) days after the Participant’s resignation, that discharge for Cause was warranted.

(f)Retirement. If the Participant “retires” from the Company (or a Subsidiary or Affiliate) prior to the Final Exercise Date then, subject to Section 3(e) above, the right to exercise this Option shall terminate on the Final Exercise Date, and, provided that the retirement date occurs at least two years after the Grant Date, this Option shall vest and become 100% exercisable upon the date of such retirement. For the purposes of this Agreement, the Participant shall be deemed to have “retired” (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company (or a Subsidiary or Affiliate), upon the Participant’s resignation from employment with the Company, Subsidiary or Affiliate either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake

- 3 -

of clarity, subject to execution of a release of claims in a form acceptable to the Company, the Participant may seek to re-characterize any termination of employment initiated by the Company (or a Subsidiary or Affiliate), that is not a termination for “Cause” (as defined in Section 1.2 of the Severance Agreement) as a voluntary termination by reason of retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company (or a Subsidiary or Affiliate) to the Participant pursuant to any agreement between the Company (or a Subsidiary or Affiliate) and the Participant or any Company policy. Any such determination shall be made by the Committee in its sole discretion.

(g)Change in Control Event. If the Participant’s employment or service is terminated by the Company or any Subsidiary or Affiliate without “Cause” (as defined in Section 1.3 of the CIC Agreement) or by the Participant for Good Reason (as defined in Section 1.4 of the CIC Agreement) and such termination entitles the Participant to severance benefits under the CIC Agreement, this Option shall vest and become 100% exercisable upon the date of such termination of employment or service and the right to exercise this Option shall terminate two years following such date (but in no event after the Final Exercise Date).

4.Withholding. No Shares will be issued pursuant to the exercise of this Option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of any federal, state, local, or other applicable taxes required to be withheld in respect of this Option in accordance with the instructions provided from time to time by the Company; provided, however, where Shares are being used to satisfy such tax obligations for a Participant who is not subject to Section 16 of the Securities Exchange Act of 1934, the Participant hereby authorizes the Company to hold back from the Shares to be delivered pursuant to this Agreement that number of Shares (which may include fractional shares) calculated to satisfy all such federal, state, local or other applicable taxes required to be withheld in connection with the issuance of such Shares.

5.Meaning and Use of Certain Terms. “Subsidiary” or “Affiliate” has the meaning ascribed to it in the Plan, and shall for the avoidance of doubt include any such entity only so long as the Company maintains a controlling interest in such entity.

6.Nontransferability of Option. This Option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this Option shall be exercisable only by the Participant. Notwithstanding the foregoing, the Company consents to the gratuitous transfer of this Option by the Participant to or for the benefit of any immediate family member, family trust or family partnership established solely for the benefit of the Participant and/or an immediate family member thereof; provided that with respect to such proposed transferee the Company would be eligible to use a Form S-8 for the registration of the sale of the Common Stock subject to such Option under the Securities Act of 1933, as amended; and provided further that the Company shall not be required to recognize any such transfer until such time as the Participant and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of this Agreement.

- 4 -

7.Provisions of the Plan. This Option is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.

8.No Right To Employment or Other Status. The grant of this Option shall not be construed as giving the Participant the right to continued employment or any other relationship with the Company or its Subsidiaries or Affiliates. The Company and its Subsidiaries and Affiliates expressly reserve the right at any time to dismiss or otherwise terminate its relationship with the Participant free from any liability or claim under the Plan or this Agreement, except as expressly provided herein.

9.Clawback. In accepting this Option, the Participant expressly agrees to be bound by, and subject to, the following clawback policy and any clawback policy that the Company has in effect (as the same may be amended from time to time), or may adopt in the future:

(a)The Option is intended to align the Participant’s long-term interests with those of the Company. Accordingly, unless otherwise expressly provided in the Plan or any other applicable agreement, plan, or policy, and to the extent permitted by applicable law, the Company may terminate any unsettled portion of the Option, whether vested, unvested or unexercised (“Termination”), recapture any Shares acquired pursuant to the Option (“Recapture”), or require the Participant to reimburse the Company for any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the Option (“Reimbursement”), upon the occurrence of any of the following events (collectively, the “Conditions”):

(i)the Participant has engaged in misuse of the Company’s confidential information and/or conduct in breach of any (A) confidentiality obligation to the Company under any agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to, the Company’s standard form of Information and Invention Agreement applicable to such Participant, or (B) applicable noncompetition or nonsolicitation obligation to the Company under any applicable agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to the Company’s standard form of Noncompetition Agreement applicable to such Participant;

(ii)the Participant has been discharged by the Company (or a Subsidiary or Affiliate) for “Cause” (as defined in Section 1.2 of the Severance Agreement); or

(iii)during the Participant’s employment or other service, the Participant (A) has rendered services to or otherwise directly or indirectly engaged in or assisted, any organization or business that, in the judgment of the Company in its sole and absolute discretion, is against the interest of the Company or one of its affiliates; or (B) has engaged in activities that are materially prejudicial to or in conflict with the interests of the Company, including any breaches of fiduciary duty or the duty of loyalty.

For purposes of this Section 9, “Option Benefits” shall mean any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the Option, including any sales proceeds and/or dividends.

(b)Prior to the issuance of any Shares upon settlement of the Option pursuant to this Agreement, the Participant shall, if requested in writing by the Company, certify on a form

- 5 -

acceptable to the Company that the Participant is in compliance with the terms and conditions of this Agreement and with the obligations contained in the Plan, or any other relevant agreement, plan, or contract listed in Section 9(a).

(c)Within ten (10) calendar days after receiving notice from the Company of any such activity described in Section 9(a) of this Agreement, the Participant shall either deliver to the Company the applicable Shares or make a cash payment to the Company equal to the Option Benefits. For purposes of the Company’s exercise of its Recapture and/or Reimbursement rights hereunder, the Participant expressly and explicitly authorizes the Company to issue instructions, on the Participant’s behalf, to any brokerage firm and/or third-party administrator engaged by the Company to hold Shares and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company.

(d)Notwithstanding the foregoing provisions of this Section 9, the Company may, in its sole and absolute discretion, choose to refrain from exercising its rights of Termination, Recapture and/or Reimbursement with respect to any particular act of the Participant or with respect to any other participant in the Plan, and its determination to refrain from exercising such rights shall not in any way reduce or eliminate the Company’s authority to exercise its rights of Termination, Recapture and/or Reimbursement with respect to any other act of the Participant. Nothing in this Section 9 shall be construed to impose obligations on the Participant to refrain from engaging in lawful competition with the Company after the termination of employment that does not violate the Conditions, other than any obligations that are part of any applicable separate agreement between the Company and the Participant or that arise under applicable law.

(e)Notwithstanding anything to the contrary in the Plan or this Agreement, the Company shall not seek to exercise its rights of Termination, Recapture or Reimbursement relating to any Options that were settled more than twelve (12) months prior to the date of the Participant’s act or omission set forth in Section 9(a); provided that, notwithstanding the foregoing, all Options shall be subject to the Company’s rights of Termination, Recapture and/or Reimbursement to the extent required by applicable law, including but not limited to Section 10D of the Securities Exchange Act of 1934.

10.Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to any applicable conflicts of laws and in the event of a dispute related to or arising out of this Agreement, the parties submit to the exclusive jurisdiction and venue of the Delaware federal and Chancery Courts. Notwithstanding the foregoing, for any Termination, Recapture, and/or Reimbursement that is based, in whole or in part, on the Participant’s breach of a noncompete agreement or nonsolicitation obligation, such disputes shall be governed by and interpreted in accordance with the laws of the State of Massachusetts, and any dispute arising out of the Agreement shall be asserted exclusively in the federal or state courts located in or covering the county in which the Participant resides within the State of Massachusetts, and the Parties hereby submit to the personal jurisdiction and venue of those state and federal courts.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

- 6 -

As a condition to the grant of this Award, the Participant by signing below acknowledges receipt and affirmatively agrees to the Agreement, including without limitation the provisions of the above General Terms and Conditions.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date written below.

		THERMO FISHER SCIENTIFIC INC.
Date:
	By:
	Name:
	Title:
		Marc N. Casper

- 7 -

EX-10.7

Exhibit 10.7

THERMO FISHER SCIENTIFIC INC.

NONSTATUTORY STOCK OPTION AGREEMENT

This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below.

Notice of Grant

Name of participant (the “Participant”):	Marc N. Casper
Grant date (“Grant Date”):
Number of shares of the Company’s Common Stock subject to this Option upon full satisfaction of vesting conditions, including performance at target (“Shares”):
Option exercise price per Share:
Final exercise date (“Final Exercise Date”):

Vesting Schedule:

Vesting date (“Vesting Date”):	Number of Options that vest:
See Schedule A	See Schedule A
Except as otherwise provided in this Agreement, all vesting is dependent on the Participant remaining an Eligible Participant (as defined in Exhibit A) through the applicable Vesting Date.

This Agreement includes this Notice of Grant and the following Exhibits, which are expressly incorporated by reference in their entirety herein:

Exhibit A – General Terms and Conditions

    This agreement must be accepted on the final page below.

EXHIBIT A

GENERAL TERMS AND CONDITIONS

1.Grant of Option. This Agreement (including the Notice of Grant) evidences the grant on the Grant Date set forth in the Notice of Grant, by the Company tothe Participant of an option (the “Option”) to purchase, in whole or in part, subject to the terms, conditions and restrictions provided herein and in the Company’s Amended and Restated 2013 Stock Incentive Plan, as from time to time amended (the “Plan”), the number of Shares set forth in the Notice of Grant, of common stock, $1.00par value per share, of the Company (“Common Stock”), at the exercise price per Share set forth in the Notice of Grant. The number of shares subject to the Option as set forth in the Notice of Award is referred to as the “Target Award.” Unless earlier terminated pursuant to Section 3(b) through (f) below, this Option shall expire at 5:00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant.

It is intended that the Option evidenced by this Agreement shall not be an incentive stock option as defined in Section 422 of the U.S. Internal Revenue Code of 1986, as amended. Except as otherwise indicated by the context, the term “Participant”, as used in this Agreement, shall be deemed to include any person who acquires the right to exercise this Option validly under its terms. Capitalized terms used in this Agreement and not otherwise defined shall have the same meaning as in the Plan.

2.Vesting Schedule. Except as otherwise provided in paragraphs (c) through (f) of Section 3 below and the Plan, this Option will become exercisable (“vest”) as described on Schedule A hereto, provided that on the Vesting Date (as defined in Schedule A) the Participant is, and has been at all times since the Grant Date, an employee, officer or director of, or consultant or advisor to, the Company (or a Subsidiary or Affiliate) (an “Eligible Participant”). Unless otherwise determined by the Committee, the Participant shall continue to be an Eligible Participant upon a change in the employment or service relationship (e.g. a change from employee to a director).

3.Exercise of Option.

(a)Form of Exercise. Each election to exercise this Option shall be in accordance with the instructions provided from time to time by the Company. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this Option may be for any fractional share.

(b)Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (c)-(f) below, the right to exercise this Option shall terminatethree months after such cessation (but in no event after the Final Exercise Date), providedthat this Option shall be exercisable only to the extent that the Participant was entitled to exercise this Option on the date of such cessation; and, provided further that, if the Participant’s service with the Company (or a Subsidiary or Affiliate) is terminated by the Company without “Cause” (as defined in Section 1.2 of the 2009 Restatement of Executive Severance Agreement between the Company and the Participant dated November

- 2 -

21, 2009, as may be amended from time to time (the “Severance Agreement”)) and if the date on which such Participant’s Option would terminate pursuant to this Section 3(b) occurs at a time when trading in the shares of Common Stock by the Participant is prohibited by the Company’s insider trading policy (or during a Company-imposed “blackout period”), then the termination date (or the Final Exercise Date, if earlier) shall be automatically extended until the 30th day following the expiration of such prohibition, but not beyond the day before the tenth anniversary of the Grant Date.

(c)Death or Disability. If the Participant's service with the Company (or a Subsidiary or Affiliate) is terminated by reason of death or "disability" (as defined below) prior to the Vesting Date (as defined in Schedule A) while the Participant is an Eligible Participant, this Option shall vest and become exercisable to the extent that and upon the date that such Option would have vested had the Participant remained employed with the Company on the Vesting Date and the right to exercise this Option shall terminate one year following such Vesting Date (but in no event after the Final Exercise Date). For the purposes of this Agreement, the Participant shall be deemed to be "disabled" at such time as the Participant is receiving disability benefits under the Company's (or a Subsidiary’s or Affiliate’s) long term disability coverage, as then in effect.

(d)Discharge for Cause. If the Participant, prior to the Final Exercise Date, is discharged by the Company (or a Subsidiary or Affiliate) for “Cause” (as defined in Section 1.2 of the Severance Agreement), the right to exercise this Option shall terminate immediately upon the effective date of such discharge. The Participant shall be considered to have been discharged for Cause if the Company determines, within thirty (30) days after the Participant's resignation, that discharge for Cause was warranted.

(e)Retirement. If the Participant “retires” from the Company (or a Subsidiary or Affiliate) prior to the Vesting Date then, subject to Section 3(d) above, this Option shall vest and become exercisable to the extent that and upon the date that such Option would have vested had the Participant remained employed with the Company on the Vesting Date, subject to further adjustment under the “Retirement” provisions of Schedule A),and the right to exercise this Option shall terminate on the Final Exercise Date. For the purposes of this Agreement, the Participant shall be deemed to have “retired” (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company (or a Subsidiary or Affiliate), upon the Participant’s resignation from employment with the Company, Subsidiary or Affiliate either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company (or a Subsidiary or Affiliate) comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake of clarity, subject to execution of a release of claims in a form acceptable to the Company, the Participant may seek to re-characterize any termination of employment initiated by the Company (or a Subsidiary or Affiliate) that is not a “termination for Cause” as a voluntary termination by reason of retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company (or a Subsidiary or

- 3 -

Affiliate) to the Participant pursuant to any agreement between the Company (or a Subsidiary or Affiliate) and the Participant or any Company policy. Any such determination shall be made by the Committee in its sole discretion.

(f)Change in Control Event. If the Participant’s employment or service is terminated by the Company or any Subsidiary or Affiliate without “Cause” (as defined in Section 1.3 of the Executive Change in Control Retention Agreement between the Company and the Participant dated November 21, 2009, as may be amended from time to time (the “CIC Agreement”)) or by the Participant for Good Reason (as defined in Section 1.4 of the CIC Agreement) and such termination entitles the Participant to severance benefits under the CIC Agreement, this Option shall vest and become 100% exercisable upon the date of such termination of employment or service and the right to exercise this Option shall terminate one year following such date (but in no event after the Final Exercise Date).

4.Withholding. No Shares will be issued pursuant to the exercise of this Option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of any federal, state, local, or other applicable taxes required to be withheld in respect of this Option in accordance with the instructions provided from time to time by the Company; provided, however, where Shares are being used to satisfy such tax obligations for a Participant who is not subject to Section 16 of the Securities Exchange Act of 1934, the Participant hereby authorizes the Company to hold back from the Shares to be delivered pursuant to this Agreement that number of Shares (which may include fractional shares) calculated to satisfy all such federal, state, local or other applicable taxes required to be withheld in connection with the issuance of such Shares.

5.Meaning and Use of Certain Terms. “Subsidiary” or “Affiliate” has the meaning ascribed to it in the Plan, and shall for the avoidance of doubt include any such entity only so long as the Company maintains a controlling interest in such entity.

6.Nontransferability of Option. This Option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this Option shall be exercisable only by the Participant. Notwithstanding the foregoing, the Company consents to the gratuitous transfer of this Option by the Participant to or for the benefit of any immediate family member, family trust or family partnership established solely for the benefit of the Participant and/or an immediate family member thereof; provided that with respect to such proposed transferee the Company would be eligible to use a Form S-8 for the registration of the sale of the Common Stock subject to such Option under the Securities Act of 1933, as amended; and providedfurther that the Company shall not be required to recognize any such transfer until such time as the Participant and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of this Agreement.

7.Provisions of the Plan. This Option is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.

- 4 -

8.No Right To Employment or Other Status. The grant of this Option shall not be construed as giving the Participant the right to continued employment or any other relationship with the Company or its Subsidiaries or Affiliates. The Company and its Subsidiaries and Affiliates expressly reserve the right at any time to dismiss or otherwise terminate its relationship with the Participant free from any liability or claim under the Plan or this Agreement, except as expressly provided herein.

9.Clawback. In accepting this Option, the Participant expressly agrees to be bound by, and subject to, the following clawback policy and any clawback policy that the Company has in effect (as the same may be amended from time to time), or may adopt in the future.

(a)The Option is intended to align the Participant’s long-term interests with those of the Company. Accordingly, unless otherwise expressly provided in the Plan or any other applicable agreement, plan, or policy, and to the extent permitted by applicable law, the Company may terminate any unsettled portion of the Option, whether vested, unvested or unexercised (“Termination”), recapture any Shares acquired pursuant to the Option (“Recapture”), or require the Participant to reimburse the Company for any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the Option (“Reimbursement”), upon the occurrence of any of the following events (collectively, the “Conditions”):

(i)the Participant has engaged in misuse of the Company’s confidential information and/or conduct in breach of any (A) confidentiality obligation to the Company under any agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to, the Company’s standard form of Information and Invention Agreement applicable to such Participant, or (B) applicable noncompetition or nonsolicitation obligation to the Company under any applicable agreement between the Company and the Participant, or any policy or plan of the Company, including but not limited to the Company’s standard form of Noncompetition Agreement applicable to such Participant;

(ii)the Participant has been discharged by the Company or a Subsidiary for “Cause” (as defined in Section 1.2 of the Severance Agreement); or

(iii)during the Participant’s employment or other service, the Participant (A) has rendered services to or otherwise directly or indirectly engaged in or assisted, any organization or business that, in the judgment of the Company in its sole and absolute discretion, is against the interest of the Company or one of its Affiliates; or (B) has engaged in activities that are materially prejudicial to or in conflict with the interests of the Company, including any breaches of fiduciary duty or the duty of loyalty.

For purposes of this Section 9, “Option Benefits” shall mean any and all amounts realized from the acquisition or disposition of Shares acquired pursuant to the Option, including any sales proceeds and/or dividends.

(b)Prior to the issuance of any Shares upon settlement of the Option pursuant to this Agreement, the Participant shall, if requested in writing by the Company, certify on a form

- 5 -

acceptable to the Company that the Participant is in compliance with the terms and conditions of this Agreement and with the obligations contained in the Plan, or any other relevant agreement, plan, or contract listed in Section 9(a).

(c)Within ten (10) calendar days after receiving notice from the Company of any such activity described in Section 9(a) of this Agreement, the Participant shall either deliver to the Company the applicable Shares or make a cash payment to the Company equal to the Option Benefits. For purposes of the Company's exercise of its Recapture and/or Reimbursement rights hereunder, the Participant expressly and explicitly authorizes the Company to issue instructions, on the Participant's behalf, to any brokerage firm and/or third-party administrator engaged by the Company to hold Shares and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company.

(d)Notwithstanding the foregoing provisions of this Section 9, the Company may, in its sole and absolute discretion, choose to refrain from exercising its rights of Termination, Recapture and/or Reimbursement with respect to any particular act of the Participant or with respect to any other participant in the Plan, and its determination to refrain from exercising such rights shall not in any way reduce or eliminate the Company’s authority to exercise its rights of Termination, Recapture and/or Reimbursement with respect to any other act of the Participant. Nothing in this Section 9 shall be construed to impose obligations on the Participant to refrain from engaging in lawful competition with the Company after the termination of employment that does not violate the Conditions, other than any obligations that are part of any applicable separate agreement between the Company and the Participant or that arise under applicable law.

(e)Notwithstanding anything to the contrary in the Plan or this Agreement, the Company shall not seek to exercise its rights of Termination, Recapture or Reimbursement relating to any Options that were settled more than twelve (12) months prior to the date of the Participant's act or omission set forth in Section 9(a); provided that, notwithstanding the foregoing, all Options shall be subject to the Company's rights of Termination, Recapture and/or Reimbursement to the extent required by applicable law, including but not limited to Section 10D of the Securities Exchange Act of 1934.

10.Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to any applicable conflicts of laws and in the event of a dispute related to or arising out of this Agreement, the parties submit to the exclusive jurisdiction and venue of the Delaware federal and Chancery Courts. Notwithstanding the foregoing, for any Termination, Recapture, and/or Reimbursement that is based, in whole or in part, on the Participant’s breach of a noncompete agreement or nonsolicitation obligation, such disputes shall be governed by and interpreted in accordance with the laws of the State of Massachusetts, and any dispute arising out of this Agreement shall be asserted exclusively in the federal or state courts located in or covering the county in which the Participant resides within the State of Massachusetts, and the parties hereby submit to the personal jurisdiction and venue of those state and federal courts.

- 6 -

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date written below.

		THERMO FISHER SCIENTIFIC INC.
Date:
	By:
	Name:
	Title:
		Marc N. Casper

- 7 -

EX-31.1

Exhibit 31.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc N. Casper, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 3, 2024

/s/ Marc N. Casper

Marc N. Casper
Chairman, President and Chief Executive Officer

EX-31.2

Exhibit 31.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen Williamson, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 3, 2024

/s/ Stephen Williamson

Stephen Williamson
Senior Vice President and Chief Financial Officer

EX-32.1

Exhibit 32.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended March 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, Chairman, President and Chief Executive Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  May 3, 2024

/s/ Marc N. Casper

Marc N. Casper
Chairman, President and Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended March 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Williamson, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  May 3, 2024

/s/ Stephen Williamson

Stephen Williamson

Senior Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Cover	3 Months Ended
	Mar. 30, 2024 shares
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 30, 2024
Document Transition Report	false
Entity File Number	1-8002
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2209186
Entity Address, Address Line One	168 Third Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	622-1000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	381,716,323
Entity Central Index Key	0000097745
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Common Stock, $1.00 par value
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	TMO
Security Exchange Name	NYSE
0.750% Notes due 2024
Entity Listings [Line Items]
Title of 12(b) Security	0.750% Notes due 2024
Trading Symbol	TMO 24A
Security Exchange Name	NYSE
0.125% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	0.125% Notes due 2025
Trading Symbol	TMO 25B
Security Exchange Name	NYSE
2.000% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	2.000% Notes due 2025
Trading Symbol	TMO 25
Security Exchange Name	NYSE
3.200% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	3.200% Notes due 2026
Trading Symbol	TMO 26B
Security Exchange Name	NYSE
1.400% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	1.400% Notes due 2026
Trading Symbol	TMO 26A
Security Exchange Name	NYSE
1.450% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.450% Notes due 2027
Trading Symbol	TMO 27
Security Exchange Name	NYSE
1.750% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2027
Trading Symbol	TMO 27B
Security Exchange Name	NYSE
0.500% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	0.500% Notes due 2028
Trading Symbol	TMO 28A
Security Exchange Name	NYSE
1.375% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	1.375% Notes due 2028
Trading Symbol	TMO 28
Security Exchange Name	NYSE
1.950% Notes due 2029
Entity Listings [Line Items]
Title of 12(b) Security	1.950% Notes due 2029
Trading Symbol	TMO 29
Security Exchange Name	NYSE
0.875% Notes due 2031
Entity Listings [Line Items]
Title of 12(b) Security	0.875% Notes due 2031
Trading Symbol	TMO 31
Security Exchange Name	NYSE
2.375% Notes due 2032
Entity Listings [Line Items]
Title of 12(b) Security	2.375% Notes due 2032
Trading Symbol	TMO 32
Security Exchange Name	NYSE
3.650% Notes due 2034
Entity Listings [Line Items]
Title of 12(b) Security	3.650% Notes due 2034
Trading Symbol	TMO 34
Security Exchange Name	NYSE
2.875% Notes due 2037
Entity Listings [Line Items]
Title of 12(b) Security	2.875% Notes due 2037
Trading Symbol	TMO 37
Security Exchange Name	NYSE
1.500% Notes due 2039
Entity Listings [Line Items]
Title of 12(b) Security	1.500% Notes due 2039
Trading Symbol	TMO 39
Security Exchange Name	NYSE
1.875% Notes due 2049
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2049
Trading Symbol	TMO 49
Security Exchange Name	NYSE

XML

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 5,499	$ 8,077
Short-term investments	1,751	3
Accounts receivable, less allowances of $197 and $193	7,931	8,221
Inventories	5,133	5,088
Contract assets, net	1,422	1,443
Other current assets	1,904	1,757
Total current assets	23,640	24,589
Property, plant and equipment, net	9,324	9,448
Acquisition-related intangible assets, net	16,048	16,670
Other assets	4,241	3,999
Goodwill	43,843	44,020
Total assets	97,095	98,726
Current liabilities:
Short-term obligations and current maturities of long-term obligations	4,451	3,609
Accounts payable	2,555	2,872
Accrued payroll and employee benefits	1,314	1,596
Contract liabilities	2,632	2,689
Other accrued expenses	2,985	3,246
Total current liabilities	13,937	14,012
Deferred income taxes	1,811	1,922
Other long-term liabilities	4,567	4,642
Long-term obligations	31,157	31,308
Redeemable noncontrolling interest	119	118
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued	0	0
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,822,699 and 442,188,634 shares issued	443	442
Capital in excess of par value	17,482	17,286
Retained earnings	48,542	47,364
Treasury stock at cost, 61,106,376 and 55,541,290 shares	(18,186)	(15,133)
Accumulated other comprehensive income/(loss)	(2,764)	(3,224)
Total Thermo Fisher Scientific Inc. shareholders’ equity	45,516	46,735
Noncontrolling interests	(12)	(11)
Total equity	45,504	46,724
Total liabilities, redeemable noncontrolling interest and equity	$ 97,095	$ 98,726

XML

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance	$ 197	$ 193
Preferred stock, $100 par value - par value (in dollars per share)	$ 100	$ 100
Preferred stock, $100 par value - shares authorized (in shares)	50,000	50,000
Preferred stock, $100 par value - shares issued (in shares)	0	0
Common stock, $1 par value - par value (in dollars per share)	$ 1	$ 1
Common stock, $1 par value - shares authorized (in shares)	1,200,000,000	1,200,000,000
Common stock, $1 par value - shares issued (in shares)	442,822,699	442,188,634
Treasury stock at cost (in shares)	61,106,376	55,541,290

XML

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Revenues
Revenues	$ 10,345	$ 10,710
Costs and operating expenses:
Selling, general and administrative expenses	2,183	2,119
Research and development expenses	331	346
Restructuring and other costs	29	112
Total costs and operating expenses	8,682	9,147
Operating income	1,663	1,563
Interest income	279	146
Interest expense	(363)	(300)
Other income/(expense)	10	(46)
Income before income taxes	1,589	1,363
Provision for income taxes	(281)	(46)
Equity in earnings/(losses) of unconsolidated entities	23	(25)
Net income	1,331	1,292
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest	4	3
Net income attributable to Thermo Fisher Scientific Inc.	$ 1,328	$ 1,289
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic (in dollars per share)	$ 3.47	$ 3.34
Diluted (in dollars per share)	$ 3.46	$ 3.32
Weighted average shares
Basic (in shares)	382	386
Diluted (in shares)	384	388
Product revenues
Revenues
Revenues	$ 5,955	$ 6,404
Costs and operating expenses:
Cost of revenues	2,939	3,337
Service revenues
Revenues
Revenues	4,390	4,306
Costs and operating expenses:
Cost of revenues	$ 3,201	$ 3,233

XML

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Comprehensive income
Net income	$ 1,331	$ 1,292
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $166 and $(36))	456	44
Unrealized gains/(losses) on available-for-sale debt securities
Unrealized holding losses arising during the period (net of tax (provision) benefit of $0 and $0)	(1)	0
Unrealized gains/(losses) on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax (provision) benefit of $0 and $1)	1	3
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax (provision) benefit of $0 and $(1))	1	1
Total other comprehensive income/(loss)	457	48
Comprehensive income	1,788	1,340
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest	1	6
Comprehensive income attributable to Thermo Fisher Scientific Inc.	$ 1,787	$ 1,334

XML

Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ 166	$ (36)
Tax (provision) benefit on unrealized holding losses arising during the period	0	0
Tax provision (benefit) on reclassification adjustment for losses on hedging instruments recognized in net income	0	(1)
Tax benefit (provision) on pension and other postretirement benefit liability adjustments arising during the period	$ 0	$ (1)

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Operating activities
Net income	$ 1,331	$ 1,292
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	285	253
Amortization of acquisition-related intangible assets	551	606
Change in deferred income taxes	(253)	(146)
Stock-based compensation	70	76
Other non-cash expenses, net	53	181
Changes in assets and liabilities, excluding the effects of acquisitions	(787)	(1,533)
Net cash provided by operating activities	1,251	729
Investing activities
Purchases of property, plant and equipment	(347)	(458)
Proceeds from sale of property, plant and equipment	4	6
Proceeds from cross-currency interest rate swap interest settlements	64	2
Acquisitions, net of cash acquired	0	(2,704)
Purchases of investments	(1,758)	(2)
Other investing activities, net	7	14
Net cash used in investing activities	(2,030)	(3,142)
Financing activities
Net proceeds from issuance of debt	1,205	0
Proceeds from issuance of commercial paper	0	1,027
Repayments of commercial paper	0	(523)
Purchases of company common stock	(3,000)	(3,000)
Dividends paid	(135)	(117)
Other financing activities, net	110	20
Net cash used in financing activities	(1,821)	(2,593)
Exchange rate effect on cash	22	(31)
Decrease in cash, cash equivalents and restricted cash	(2,578)	(5,037)
Cash, cash equivalents and restricted cash at beginning of period	8,097	8,537
Cash, cash equivalents and restricted cash at end of period	$ 5,519	$ 3,500

XML

Condensed Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Unaudited) - USD ($) $ in Millions	Total	Total Thermo Fisher Scientific Inc. Shareholders’ Equity	Common Stock, $1.00 par value	Capital in Excess of Par Value	Retained Earnings	Treasury Stock	Accumulated Other Comprehensive Items	Noncontrolling Interests
Beginning Balance at Dec. 31, 2022	$ 116
Redeemable Noncontrolling Interest [Roll Forward]
Net income/(loss)	4
Other comprehensive income/(loss)	3
Ending Balance at Apr. 01, 2023	123
Balance (in shares) at Dec. 31, 2022			441,000,000
Beginning Balance at Dec. 31, 2022	44,032	$ 43,978	$ 441	$ 16,743	$ 41,910	$ (12,017)	$ (3,099)	$ 54
Treasury stock beginning balance (in shares) at Dec. 31, 2022						50,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under stock plans	34	34		70		$ (36)
Stock-based compensation	76	76		76
Purchases of company common stock (in shares)						5,000,000
Purchases of company common stock	(3,000)	(3,000)				$ (3,000)
Dividends declared	(135)	(135)			(135)
Net income/(loss)	1,288	1,289			1,289			(1)
Other comprehensive items	45	45					45
Excise tax from stock repurchases	(30)	(30)				$ (30)
Balance (in shares) at Apr. 01, 2023			441,000,000
Treasury stock ending balance (in shares) at Apr. 01, 2023						55,000,000
Ending Balance at Apr. 01, 2023	42,310	42,257	$ 441	16,889	43,064	$ (15,083)	(3,054)	53
Beginning Balance at Dec. 31, 2023	118
Redeemable Noncontrolling Interest [Roll Forward]
Net income/(loss)	4
Other comprehensive income/(loss)	(3)
Ending Balance at Mar. 30, 2024	119
Balance (in shares) at Dec. 31, 2023			442,000,000
Beginning Balance at Dec. 31, 2023	$ 46,724	46,735	$ 442	17,286	47,364	$ (15,133)	(3,224)	(11)
Treasury stock beginning balance (in shares) at Dec. 31, 2023	55,541,290					56,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under stock plans (in shares)			1,000,000
Issuance of shares under stock plans	$ 103	103	$ 1	126		$ (24)
Stock-based compensation	70	70		70
Purchases of company common stock (in shares)						6,000,000
Purchases of company common stock	(3,000)	(3,000)				$ (3,000)
Dividends declared	(149)	(149)			(149)
Net income/(loss)	1,328	1,328			1,328
Other comprehensive items	460	460					460
Contributions from (distributions to) noncontrolling interests	(1)							(1)
Excise tax from stock repurchases	$ (29)	(29)				$ (29)
Balance (in shares) at Mar. 30, 2024			443,000,000
Treasury stock ending balance (in shares) at Mar. 30, 2024	61,106,376					61,000,000
Ending Balance at Mar. 30, 2024	$ 45,504	$ 45,516	$ 443	$ 17,482	$ 48,542	$ (18,186)	$ (2,764)	$ (12)

XML

Condensed Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Statement of Stockholders' Equity [Abstract]
Dividends declared (in dollars per share)	$ 0.39	$ 0.35

XML

Nature of Operations and Summary of Significant Accounting Policies

3 Months Ended

Mar. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.

Interim Financial Statements

The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at March 30, 2024, the results of operations for the three-month periods ended March 30, 2024 and April 1, 2023, and the cash flows for the three-month periods ended March 30, 2024 and April 1, 2023. Interim results are not necessarily indicative of results for a full year.

The condensed consolidated balance sheet presented as of December 31, 2023 has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the 2023 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Certain reclassifications of prior year amounts have been made to conform to the current year presentation.

Note 1 to the consolidated financial statements for 2023 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the three months ended March 30, 2024.

Amounts and percentages reported within these condensed consolidated financial statements are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

Inventories

The components of inventories are as follows:

(In millions)	March 30, 2024		December 31, 2023
Raw materials	$	2,038	$	2,057
Work in process	787		705
Finished goods	2,308		2,326
Inventories	$	5,133	$	5,088

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.

Recent Accounting Pronouncements

The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.

Standard	Description	Required adoption timing and approach	Impact of adoption or other significant matters
Standards recently adopted
ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations	New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented.	Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 annual report using a prospective method	Not material
Standards not yet adopted
ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures	Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.	2024 annual report and interim periods thereafter using a retrospective method	Will increase disclosures in Note 4
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures	Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.	2025 annual report and interim periods thereafter using a prospective or retrospective method	Will increase disclosures in Note 5

XML

Acquisitions

3 Months Ended

Mar. 30, 2024

Business Combination and Asset Acquisition [Abstract]

Acquisitions

Acquisitions

The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.

Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

Proposed Acquisition

On October 17, 2023, the company entered into a purchase agreement to acquire all of the issued and outstanding shares of Olink Holding AB (publ) at a price of $26.00 per share, or approximately $3.1 billion. Olink is a leading provider of next-generation proteomics solutions that will expand the company’s capabilities in this field. The company has commenced a tender offer to acquire all of the American Depositary Shares and common shares of Olink. The transaction is expected to close by mid-year 2024, subject to the satisfaction of customary closing conditions including receipt of applicable regulatory approvals, and completion of the tender offer. Upon completion, Olink will become part of the Life Sciences Solutions segment. The company intends to finance the purchase price with cash on hand and the net proceeds from issuances of debt.

2023

On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not tax deductible.

On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a result of this business combination is not tax deductible.

The components of the purchase price and net assets acquired are as follows:

(In millions)	The Binding Site		CorEvitas
Purchase price
Cash paid	$	2,412	$	730
Debt settled	307		184
Cash acquired	(20)		(4)
	$	2,699	$	910
Net assets acquired
Definite-lived intangible assets:
Customer relationships	$	868	$	260
Product technology	162		47
Tradenames	42		—
Backlog	—		46
Goodwill	1,741		627
Net tangible assets	174		(2)
Deferred tax assets (liabilities)	(288)		(68)
	$	2,699	$	910

In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-line measurement.

The weighted-average amortization periods for definite-lived intangible assets acquired in 2023 are 18 years for customer relationships, 14 years for product technology, 15 years for tradenames, and 13 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2023 is 17 years.

XML

Revenue and Contract-related Balances

3 Months Ended

Mar. 30, 2024

Revenue from Contract with Customer [Abstract]

Revenue and Contract-related Balances

Revenues and Contract-related Balances

Disaggregated Revenues

Revenues by type are as follows:

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Revenues
Consumables	$	4,328	$	4,506
Instruments	1,627		1,898
Services	4,390		4,306
Consolidated revenues	$	10,345	$	10,710

Revenues by geographic region based on customer location are as follows:

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Revenues
North America	$	5,519	$	5,778
Europe	2,619		2,601
Asia-Pacific	1,861		1,986
Other regions	346		345
Consolidated revenues	$	10,345	$	10,710

Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data.

Remaining Performance Obligations

The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of March 30, 2024 was $26.37 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 51% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.

Contract-related Balances

Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows:

(In millions)	March 30, 2024		December 31, 2023
Current contract assets, net	$	1,422	$	1,443
Noncurrent contract assets, net	9		4
Current contract liabilities	2,632		2,689
Noncurrent contract liabilities	1,427		1,499

In the three months ended March 30, 2024, the company recognized revenues of $1.32 billion that were included in the contract liabilities balance at December 31, 2023. In the three months ended April 1, 2023, the company recognized revenues of $1.30 billion that were included in the contract liabilities balance at December 31, 2022.

XML

Business Segment and Geographical Information

3 Months Ended

Mar. 30, 2024

Segment Reporting [Abstract]

Business Segment and Geographical Information

Business Segment and Geographical Information

Business Segment Information

	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Revenues
Life Sciences Solutions	$	2,285	$	2,612
Analytical Instruments	1,687		1,723
Specialty Diagnostics	1,109		1,108
Laboratory Products and Biopharma Services	5,723		5,763
Eliminations	(460)		(496)
Consolidated revenues	10,345		10,710
Segment Income
Life Sciences Solutions	840		836
Analytical Instruments	400		421
Specialty Diagnostics	294		280
Laboratory Products and Biopharma Services	744		793
Subtotal reportable segments	2,278		2,330
Cost of revenues adjustments	(15)		(41)
Selling, general and administrative expenses adjustments	(19)		(8)
Restructuring and other costs	(29)		(112)
Amortization of acquisition-related intangible assets	(551)		(606)
Consolidated operating income	1,663		1,563
Interest income	279		146
Interest expense	(363)		(300)
Other income/(expense)	10		(46)
Consolidated income before taxes	$	1,589	$	1,363

Cost of revenues adjustments included in the above table consist of charges for the sale of inventories revalued at the date of acquisition and inventory write-downs associated with large-scale abandonment of product lines. Selling, general and administrative expenses adjustments included in the above table consist of third-party transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration.

Geographical Information

Revenues by country based on customer location are as follows:

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Revenues
United States	$	5,322	$	5,587
Other	5,023		5,123
Consolidated revenues	$	10,345	$	10,710

XML

Income Taxes

3 Months Ended

Mar. 30, 2024

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following:

	Three months ended
(In millions)	March 30, 2024			April 1, 2023
Statutory federal income tax rate	21		%	21		%
Provision for income taxes at statutory rate	$	334		$	286
Increases (decreases) resulting from:
Foreign rate differential	(38)			(52)
Income tax credits	(89)			(83)
Global intangible low-taxed income	12			12
Foreign-derived intangible income	(22)			(23)
Excess tax benefits from stock options and restricted stock units	(33)			(27)
Provision for (reversal of) tax reserves, net	185			9
Intra-entity transfers	(102)			(144)
Provision for (reversal of) valuation allowances, net	47			67
Withholding taxes	4			5
Tax return reassessments and settlements	(29)			(3)
State income taxes, net of federal tax	19			24
Other, net	(6)			(25)
Provision for income taxes	$	281		$	46

During the first quarter of 2024, the company recorded a tax reserve and associated interest of $240 million related to the potential settlement of international tax audits for tax years 2009 through 2016.

The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate.

Unrecognized Tax Benefits

As of March 30, 2024 the company had $0.69 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:

(In millions)	2024
Balance at beginning of year	$	540
Additions for tax positions of prior years	195
Reductions for tax positions of prior years	(42)
Balance at end of period	$	693

XML

Earnings Per Share

3 Months Ended

Mar. 30, 2024

Earnings Per Share [Abstract]

Earnings Per Share

Earnings per Share

	Three months ended
	March 30,		April 1,
(In millions except per share amounts)	2024		2023
Net income attributable to Thermo Fisher Scientific Inc.	$	1,328	$	1,289
Basic weighted average shares	382		386
Plus effect of: stock options and restricted stock units	2		2
Diluted weighted average shares	384		388
Basic earnings per share	$	3.47	$	3.34
Diluted earnings per share	$	3.46	$	3.32
Antidilutive stock options excluded from diluted weighted average shares	2		2

XML

Debt and Other Financing Arrangements

3 Months Ended

Mar. 30, 2024

Debt Disclosure [Abstract]

Debt and Other Financing Arrangements

Debt and Other Financing Arrangements

	Effective interest rate at March 30,		March 30,	December 31,
(Dollars in millions)	2024		2024	2023
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)	0.93	%	1,079	1,104
1.215% 3-Year Senior Notes, Due 10/18/2024	1.42	%	2,500	2,500
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)	0.40	%	863	883
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)	2.10	%	691	706
0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated)	1.05	%	147	158
0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated)	0.15	%	593	607
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)	3.38	%	540	552
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)	1.52	%	755	773
4.953% 3-Year Senior Notes, Due 8/10/2026	5.19	%	600	600
5.000% 3-Year Senior Notes, Due 12/5/2026	5.25	%	1,000	1,000
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)	1.65	%	540	552
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)	1.96	%	647	662
1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated)	1.18	%	191	205
4.80% 5-Year Senior Notes, Due 11/21/2027	5.00	%	600	600
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)	0.77	%	863	883
1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated)	1.77	%	366	—
0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated)	0.90	%	192	206
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)	1.46	%	647	662
1.75% 7-Year Senior Notes, Due 10/15/2028	1.89	%	700	700
5.000% 5-Year Senior Notes, Due 1/31/2029	5.24	%	1,000	1,000
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)	2.07	%	755	773
2.60% 10-Year Senior Notes, Due 10/1/2029	2.74	%	900	900
1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated)	1.44	%	31	33
4.977% 7-Year Senior Notes, Due 8/10/2030	5.12	%	750	750
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)	0.88	%	1,888	1,932
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)	1.13	%	971	993
2.00% 10-Year Senior Notes, Due 10/15/2031	2.23	%	1,200	1,200
1.840% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated)	1.91	%	460	—
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)	2.54	%	647	662
1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated)	1.60	%	42	45

	Effective interest rate at March 30,		March 30,		December 31,
(Dollars in millions)	2024		2024		2023
4.95% 10-Year Senior Notes, Due 11/21/2032	5.09	%	600		600
5.086% 10-Year Senior Notes, Due 8/10/2033	5.20	%	1,000		1,000
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)	1.20	%	1,619		1,656
5.200% 10-Year Senior Notes, Due 1/31/2034	5.34	%	500		500
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)	3.76	%	809		828
1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated)	1.58	%	142		152
2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated)	2.09	%	361		—
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)	2.94	%	755		773
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)	1.73	%	971		993
2.80% 20-Year Senior Notes, Due 10/15/2041	2.90	%	1,200		1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)	1.77	%	1,349		1,380
2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated)	2.13	%	97		104
5.404% 20-Year Senior Notes, Due 8/10/2043	5.50	%	600		600
2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated)	2.06	%	192		206
5.30% 30-Year Senior Notes, Due 2/1/2044	5.37	%	400		400
4.10% 30-Year Senior Notes, Due 8/15/2047	4.23	%	750		750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)	1.98	%	1,079		1,104
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)	2.07	%	809		828
2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated)	2.43	%	220		236
Other			75		77
Total borrowings at par value			35,687		35,028
Unamortized discount			(108)		(113)
Unamortized debt issuance costs			(186)		(188)
Total borrowings at carrying value			35,393		34,727
Finance lease liabilities			215		190
Less: Short-term obligations and current maturities			4,451		3,609
Long-term obligations			$	31,157	$	31,308

The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs.

See Note 10 for fair value information pertaining to the company’s long-term borrowings.

Credit Facilities

The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), a Euro Interbank Offered Rate (EURIBOR)-based rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of March 30, 2024, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.

Commercial Paper Programs

The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis.

Senior Notes

Interest is payable annually on the euro and Swiss franc-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S. dollar and euro-denominated fixed rate senior notes and Japanese yen-denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of Japanese yen-denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants related to its senior notes at March 30, 2024.

Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes outstanding as of March 30, 2024, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.

XML

Commitments and Contingencies

3 Months Ended

Mar. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Environmental Matters

The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. At March 30, 2024, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2023 financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.

Litigation and Related Contingencies

The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in the company’s 2023 financial statements and notes included in the company’s Annual Report on Form 10-K, nor are material losses deemed probable for such matters. It is reasonably possible, however, that

an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more such matters could have a material adverse effect on the company’s results of operations, financial position and cash flows.

Product Liability, Workers Compensation and Other Personal Injury Matters

The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. At March 30, 2024, there have been no material changes to the accruals for pending product liability, workers compensation, and other personal injury matters disclosed in the company’s 2023 financial statements and notes included in the company’s Annual Report on Form 10-K. Although the company believes that the amounts accrued and estimated insurance recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.

XML

Comprehensive Income/(Loss) and Shareholders' Equity

3 Months Ended

Mar. 30, 2024

Stockholders' Equity Note [Abstract]

Comprehensive Income/(Loss) and Shareholders' Equity

Comprehensive Income/(Loss) and Shareholders' Equity

Comprehensive Income/(Loss)

Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows:

(In millions)	Currency translation adjustment		Unrealized gains/(losses) on available-for-sale debt securities		Unrealized gains/(losses) on hedging instruments		Pension and other postretirement benefit liability adjustment		Total
Balance at December 31, 2023	$	(2,941)	$	—	$	(28)	$	(255)	$	(3,224)
Other comprehensive income/(loss) before reclassifications	456		(1)		—		1		456
Amounts reclassified from accumulated other comprehensive income/(loss)	3		—		1		—		4
Net other comprehensive income/(loss)	459		(1)		1		1		460
Balance at March 30, 2024	$	(2,482)	$	(1)	$	(27)	$	(254)	$	(2,764)

XML

Fair Value Measurements and Fair Value of Financial Instruments

3 Months Ended

Mar. 30, 2024

Fair Value Disclosures [Abstract]

Fair Value Measurements and Fair Value of Financial Instruments

Fair Value Measurements and Fair Value of Financial Instruments

Fair Value Measurements

The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:

	March 30,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
(In millions)	2024		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	2,692	$	2,692	$	—	$	—
Bank time deposits	1,751		1,751		—		—
Investments	21		21		—		—
Insurance contracts	221		—		221		—
Derivative contracts	220		—		220		—
Total assets	$	4,904	$	4,464	$	440	$	—
Liabilities
Derivative contracts	$	57	$	—	$	57	$	—
Contingent consideration	83		—		—		83
Total liabilities	$	141	$	—	$	57	$	83

	December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
(In millions)	2023		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	5,021	$	5,021	$	—	$	—
Bank time deposits	3		3		—		—
Investments	20		20		—		—
Insurance contracts	210		—		210		—
Derivative contracts	8		—		8		—
Total assets	$	5,262	$	5,044	$	218	$	—
Liabilities
Derivative contracts	$	290	$	—	$	290	$	—
Contingent consideration	87		—		—		87
Total liabilities	$	377	$	—	$	290	$	87

The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense.

In the three months ended March 30, 2024 and April 1, 2023, the company recorded $10 million and $(44) million, respectively, of net gains/(losses) on investments, which are included in other income/(expense) in the accompanying statements of income.

The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.

	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Contingent consideration
Beginning balance	$	87	$	174
Payments	(2)		(15)
Changes in fair value included in earnings	(2)		(23)
Ending balance	$	83	$	136

Derivative Contracts

The following table provides the aggregate notional value of outstanding derivative contracts.

(In millions)	March 30, 2024		December 31, 2023
Cross-currency interest rate swaps designated as net investment hedge - euro	$	1,000	$	1,000
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen	4,650		4,650
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc	2,500		2,500
Currency exchange contracts	1,381		1,567

While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.

	Fair value – assets				Fair value – liabilities
	March 30,		December 31,		March 30,		December 31,
(In millions)	2024		2023		2024		2023
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a)	$	219	$	5	$	56	$	287
Derivatives not designated as hedging instruments
Currency exchange contracts (b)	1		3		1		3
Total derivatives	$	220	$	8	$	57	$	290

(a)    The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.

(b)    The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.

	Gain (loss) recognized
	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to interest expense	$	(1)	$	—
Amount reclassified from accumulated other comprehensive items to other income/(expense)	—		(4)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items	275		(144)
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items	444		(9)
Included in interest expense	66		17
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues	3		(3)
Included in other income/(expense)	(6)		23

Gains and losses recognized on currency exchange contracts are included in the accompanying statements of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.

The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.

See Note 1 to the consolidated financial statements for 2023 included in the company’s Annual Report on Form 10-K for additional information on the company’s risk management objectives and strategies.

Fair Value of Other Financial Instruments

The carrying value and fair value of the company’s debt instruments are as follows:

	March 30, 2024				December 31, 2023
	Carrying		Fair		Carrying		Fair
(In millions)	value		value		value		value
Senior notes	$	35,318	$	32,587	$	34,650	$	32,191
Other	75		75		77		77
	$	35,393	$	32,662	$	34,727	$	32,268

The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.

XML

Supplemental Cash Flow Information

3 Months Ended

Mar. 30, 2024

Supplemental Cash Flow Information [Abstract]

Supplemental Cash Flow Information

Supplemental Cash Flow Information

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment	$	165	$	242
Declared but unpaid dividends	150		137
Issuance of stock upon vesting of restricted stock units	63		91
Excise tax from stock repurchases	29		30

Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:

(In millions)	March 30, 2024		December 31, 2023
Cash and cash equivalents	$	5,499	$	8,077
Restricted cash included in other current assets	7		6
Restricted cash included in other assets	14		14
Cash, cash equivalents and restricted cash	$	5,519	$	8,097

Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

XML

Restructuring and Other Costs

3 Months Ended

Mar. 30, 2024

Restructuring and Related Activities [Abstract]

Restructuring and Other Costs

Restructuring and Other Costs

In the first three months of 2024, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2024, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.

As of May 3, 2024, the company has identified restructuring actions that will result in additional charges of approximately $75 million, primarily in 2024, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred.

Restructuring and other costs by segment are as follows:

	Three months ended
(In millions)	March 30, 2024
Life Sciences Solutions	$	2
Analytical Instruments	7
Specialty Diagnostics	5
Laboratory Products and Biopharma Services	14
Corporate	1
	$	29

The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheet. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.

(In millions)	Total (a)
Balance at December 31, 2023	$	60
Net restructuring charges incurred in 2024 (b)	25
Payments	(32)
Currency translation	(2)
Balance at March 30, 2024	$	51

(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.

(b)Excludes $4 million of net non-cash charges.

The company expects to pay accrued restructuring costs primarily through 2024.

XML

Insider Trading Arrangements

3 Months Ended

Mar. 30, 2024

shares

Trading Arrangements, by Individual

Non-Rule 10b5-1 Arrangement Adopted

false

Rule 10b5-1 Arrangement Terminated

false

Non-Rule 10b5-1 Arrangement Terminated

false

Stephen Williamson [Member]

Trading Arrangements, by Individual

Material Terms of Trading Arrangement

On February 12, 2024, Stephen Williamson, our senior vice president and chief financial officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Williamson’s plan is for the exercise of vested stock options and the associated sale of up to 21,925 shares of company common stock through February 26, 2025. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and February 27, 2025.

Name

Stephen Williamson

Title

senior vice president and chief financial officer

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

February 12, 2024

Arrangement Duration

380 days

Aggregate Available

21,925

Gianluca Pettiti [Member]

Trading Arrangements, by Individual

Material Terms of Trading Arrangement

On March 14, 2024, Gianluca Pettiti, our executive vice president, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Pettiti’s plan is for the sale of up to 1,200 shares of company common stock through April 28, 2025. The foregoing sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and April 30, 2025.

Name

Gianluca Pettiti

Title

executive vice president

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

March 14, 2024

Arrangement Duration

410 days

Aggregate Available

1,200

XML

Nature of Operations and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.

Standard	Description	Required adoption timing and approach	Impact of adoption or other significant matters
Standards recently adopted
ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations	New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented.	Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 annual report using a prospective method	Not material
Standards not yet adopted
ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures	Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.	2024 annual report and interim periods thereafter using a retrospective method	Will increase disclosures in Note 4
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures	Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.	2025 annual report and interim periods thereafter using a prospective or retrospective method	Will increase disclosures in Note 5

Acquisitions

The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.

Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

XML

Nature of Operations and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Components of Inventories

Inventories

The components of inventories are as follows:

(In millions)	March 30, 2024		December 31, 2023
Raw materials	$	2,038	$	2,057
Work in process	787		705
Finished goods	2,308		2,326
Inventories	$	5,133	$	5,088

XML

Acquisitions (Tables)

3 Months Ended

Mar. 30, 2024

Business Combination and Asset Acquisition [Abstract]

Components of Purchase Price and Net Assets Acquired

The components of the purchase price and net assets acquired are as follows:

(In millions)	The Binding Site		CorEvitas
Purchase price
Cash paid	$	2,412	$	730
Debt settled	307		184
Cash acquired	(20)		(4)
	$	2,699	$	910
Net assets acquired
Definite-lived intangible assets:
Customer relationships	$	868	$	260
Product technology	162		47
Tradenames	42		—
Backlog	—		46
Goodwill	1,741		627
Net tangible assets	174		(2)
Deferred tax assets (liabilities)	(288)		(68)
	$	2,699	$	910

XML

Revenue and Contract-related Balances (Tables)

3 Months Ended

Mar. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregated Revenues

Disaggregated Revenues

Revenues by type are as follows:

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Revenues
Consumables	$	4,328	$	4,506
Instruments	1,627		1,898
Services	4,390		4,306
Consolidated revenues	$	10,345	$	10,710

Revenues by geographic region based on customer location are as follows:

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Revenues
North America	$	5,519	$	5,778
Europe	2,619		2,601
Asia-Pacific	1,861		1,986
Other regions	346		345
Consolidated revenues	$	10,345	$	10,710

Schedule of Contract Asset and Liability Balances

Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows:

(In millions)	March 30, 2024		December 31, 2023
Current contract assets, net	$	1,422	$	1,443
Noncurrent contract assets, net	9		4
Current contract liabilities	2,632		2,689
Noncurrent contract liabilities	1,427		1,499

XML

Business Segment and Geographical Information (Tables)

3 Months Ended

Mar. 30, 2024

Segment Reporting [Abstract]

Schedule of Business Segment Information

Business Segment Information

	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Revenues
Life Sciences Solutions	$	2,285	$	2,612
Analytical Instruments	1,687		1,723
Specialty Diagnostics	1,109		1,108
Laboratory Products and Biopharma Services	5,723		5,763
Eliminations	(460)		(496)
Consolidated revenues	10,345		10,710
Segment Income
Life Sciences Solutions	840		836
Analytical Instruments	400		421
Specialty Diagnostics	294		280
Laboratory Products and Biopharma Services	744		793
Subtotal reportable segments	2,278		2,330
Cost of revenues adjustments	(15)		(41)
Selling, general and administrative expenses adjustments	(19)		(8)
Restructuring and other costs	(29)		(112)
Amortization of acquisition-related intangible assets	(551)		(606)
Consolidated operating income	1,663		1,563
Interest income	279		146
Interest expense	(363)		(300)
Other income/(expense)	10		(46)
Consolidated income before taxes	$	1,589	$	1,363

Schedule of Revenue by Country Based on Customer Location

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Revenues
United States	$	5,322	$	5,587
Other	5,023		5,123
Consolidated revenues	$	10,345	$	10,710

XML

Income Taxes (Tables)

3 Months Ended

Mar. 30, 2024

Income Tax Disclosure [Abstract]

Schedule of the Provision for Income Taxes

The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following:

	Three months ended
(In millions)	March 30, 2024			April 1, 2023
Statutory federal income tax rate	21		%	21		%
Provision for income taxes at statutory rate	$	334		$	286
Increases (decreases) resulting from:
Foreign rate differential	(38)			(52)
Income tax credits	(89)			(83)
Global intangible low-taxed income	12			12
Foreign-derived intangible income	(22)			(23)
Excess tax benefits from stock options and restricted stock units	(33)			(27)
Provision for (reversal of) tax reserves, net	185			9
Intra-entity transfers	(102)			(144)
Provision for (reversal of) valuation allowances, net	47			67
Withholding taxes	4			5
Tax return reassessments and settlements	(29)			(3)
State income taxes, net of federal tax	19			24
Other, net	(6)			(25)
Provision for income taxes	$	281		$	46

Schedule of Unrecognized Tax Benefits

(In millions)	2024
Balance at beginning of year	$	540
Additions for tax positions of prior years	195
Reductions for tax positions of prior years	(42)
Balance at end of period	$	693

XML

Earnings per Share (Tables)

3 Months Ended

Mar. 30, 2024

Earnings Per Share [Abstract]

Schedule of Earnings Per Share

	Three months ended
	March 30,		April 1,
(In millions except per share amounts)	2024		2023
Net income attributable to Thermo Fisher Scientific Inc.	$	1,328	$	1,289
Basic weighted average shares	382		386
Plus effect of: stock options and restricted stock units	2		2
Diluted weighted average shares	384		388
Basic earnings per share	$	3.47	$	3.34
Diluted earnings per share	$	3.46	$	3.32
Antidilutive stock options excluded from diluted weighted average shares	2		2

XML

Debt and Other Financing Arrangements (Tables)

3 Months Ended

Mar. 30, 2024

Debt Disclosure [Abstract]

Schedule of Outstanding Debt

	Effective interest rate at March 30,		March 30,	December 31,
(Dollars in millions)	2024		2024	2023
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)	0.93	%	1,079	1,104
1.215% 3-Year Senior Notes, Due 10/18/2024	1.42	%	2,500	2,500
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)	0.40	%	863	883
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)	2.10	%	691	706
0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated)	1.05	%	147	158
0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated)	0.15	%	593	607
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)	3.38	%	540	552
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)	1.52	%	755	773
4.953% 3-Year Senior Notes, Due 8/10/2026	5.19	%	600	600
5.000% 3-Year Senior Notes, Due 12/5/2026	5.25	%	1,000	1,000
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)	1.65	%	540	552
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)	1.96	%	647	662
1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated)	1.18	%	191	205
4.80% 5-Year Senior Notes, Due 11/21/2027	5.00	%	600	600
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)	0.77	%	863	883
1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated)	1.77	%	366	—
0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated)	0.90	%	192	206
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)	1.46	%	647	662
1.75% 7-Year Senior Notes, Due 10/15/2028	1.89	%	700	700
5.000% 5-Year Senior Notes, Due 1/31/2029	5.24	%	1,000	1,000
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)	2.07	%	755	773
2.60% 10-Year Senior Notes, Due 10/1/2029	2.74	%	900	900
1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated)	1.44	%	31	33
4.977% 7-Year Senior Notes, Due 8/10/2030	5.12	%	750	750
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)	0.88	%	1,888	1,932
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)	1.13	%	971	993
2.00% 10-Year Senior Notes, Due 10/15/2031	2.23	%	1,200	1,200
1.840% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated)	1.91	%	460	—
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)	2.54	%	647	662
1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated)	1.60	%	42	45

	Effective interest rate at March 30,		March 30,		December 31,
(Dollars in millions)	2024		2024		2023
4.95% 10-Year Senior Notes, Due 11/21/2032	5.09	%	600		600
5.086% 10-Year Senior Notes, Due 8/10/2033	5.20	%	1,000		1,000
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)	1.20	%	1,619		1,656
5.200% 10-Year Senior Notes, Due 1/31/2034	5.34	%	500		500
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)	3.76	%	809		828
1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated)	1.58	%	142		152
2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated)	2.09	%	361		—
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)	2.94	%	755		773
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)	1.73	%	971		993
2.80% 20-Year Senior Notes, Due 10/15/2041	2.90	%	1,200		1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)	1.77	%	1,349		1,380
2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated)	2.13	%	97		104
5.404% 20-Year Senior Notes, Due 8/10/2043	5.50	%	600		600
2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated)	2.06	%	192		206
5.30% 30-Year Senior Notes, Due 2/1/2044	5.37	%	400		400
4.10% 30-Year Senior Notes, Due 8/15/2047	4.23	%	750		750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)	1.98	%	1,079		1,104
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)	2.07	%	809		828
2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated)	2.43	%	220		236
Other			75		77
Total borrowings at par value			35,687		35,028
Unamortized discount			(108)		(113)
Unamortized debt issuance costs			(186)		(188)
Total borrowings at carrying value			35,393		34,727
Finance lease liabilities			215		190
Less: Short-term obligations and current maturities			4,451		3,609
Long-term obligations			$	31,157	$	31,308

XML

Comprehensive Income/(Loss) and Shareholders' Equity (Tables)

3 Months Ended

Mar. 30, 2024

Stockholders' Equity Note [Abstract]

Schedule of Changes in Each Component of Accumulated Other Comprehensive Items

Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows:

(In millions)	Currency translation adjustment		Unrealized gains/(losses) on available-for-sale debt securities		Unrealized gains/(losses) on hedging instruments		Pension and other postretirement benefit liability adjustment		Total
Balance at December 31, 2023	$	(2,941)	$	—	$	(28)	$	(255)	$	(3,224)
Other comprehensive income/(loss) before reclassifications	456		(1)		—		1		456
Amounts reclassified from accumulated other comprehensive income/(loss)	3		—		1		—		4
Net other comprehensive income/(loss)	459		(1)		1		1		460
Balance at March 30, 2024	$	(2,482)	$	(1)	$	(27)	$	(254)	$	(2,764)

XML

Fair Value Measurements and Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 30, 2024

Fair Value Disclosures [Abstract]

Schedule of Information About the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:

	March 30,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
(In millions)	2024		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	2,692	$	2,692	$	—	$	—
Bank time deposits	1,751		1,751		—		—
Investments	21		21		—		—
Insurance contracts	221		—		221		—
Derivative contracts	220		—		220		—
Total assets	$	4,904	$	4,464	$	440	$	—
Liabilities
Derivative contracts	$	57	$	—	$	57	$	—
Contingent consideration	83		—		—		83
Total liabilities	$	141	$	—	$	57	$	83

	December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
(In millions)	2023		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	5,021	$	5,021	$	—	$	—
Bank time deposits	3		3		—		—
Investments	20		20		—		—
Insurance contracts	210		—		210		—
Derivative contracts	8		—		8		—
Total assets	$	5,262	$	5,044	$	218	$	—
Liabilities
Derivative contracts	$	290	$	—	$	290	$	—
Contingent consideration	87		—		—		87
Total liabilities	$	377	$	—	$	290	$	87

Rollforward of the Fair Value of Investments

The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.

	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Contingent consideration
Beginning balance	$	87	$	174
Payments	(2)		(15)
Changes in fair value included in earnings	(2)		(23)
Ending balance	$	83	$	136

Schedule of the Aggregate Notional Value of Outstanding Derivative Contracts

The following table provides the aggregate notional value of outstanding derivative contracts.

(In millions)	March 30, 2024		December 31, 2023
Cross-currency interest rate swaps designated as net investment hedge - euro	$	1,000	$	1,000
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen	4,650		4,650
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc	2,500		2,500
Currency exchange contracts	1,381		1,567

Schedule of the Fair Value of Derivative Instruments

While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.

	Fair value – assets				Fair value – liabilities
	March 30,		December 31,		March 30,		December 31,
(In millions)	2024		2023		2024		2023
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a)	$	219	$	5	$	56	$	287
Derivatives not designated as hedging instruments
Currency exchange contracts (b)	1		3		1		3
Total derivatives	$	220	$	8	$	57	$	290

(a)    The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.

(b)    The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.

Schedule of Derivative Instruments Gains and Losses

	Gain (loss) recognized
	Three months ended
	March 30,		April 1,
(In millions)	2024		2023
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to interest expense	$	(1)	$	—
Amount reclassified from accumulated other comprehensive items to other income/(expense)	—		(4)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items	275		(144)
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items	444		(9)
Included in interest expense	66		17
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues	3		(3)
Included in other income/(expense)	(6)		23

Schedule of the Fair Value of the Company's Debt Instruments

The carrying value and fair value of the company’s debt instruments are as follows:

	March 30, 2024				December 31, 2023
	Carrying		Fair		Carrying		Fair
(In millions)	value		value		value		value
Senior notes	$	35,318	$	32,587	$	34,650	$	32,191
Other	75		75		77		77
	$	35,393	$	32,662	$	34,727	$	32,268

The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.

Schedule of the Carrying Value of the Company's Debt Instruments

The carrying value and fair value of the company’s debt instruments are as follows:

	March 30, 2024				December 31, 2023
	Carrying		Fair		Carrying		Fair
(In millions)	value		value		value		value
Senior notes	$	35,318	$	32,587	$	34,650	$	32,191
Other	75		75		77		77
	$	35,393	$	32,662	$	34,727	$	32,268

The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.

XML

Supplemental Cash Flow Information (Tables)

3 Months Ended

Mar. 30, 2024

Supplemental Cash Flow Information [Abstract]

Schedule of Supplemental Cash Flow Information

	Three months ended
(In millions)	March 30, 2024		April 1, 2023
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment	$	165	$	242
Declared but unpaid dividends	150		137
Issuance of stock upon vesting of restricted stock units	63		91
Excise tax from stock repurchases	29		30

Schedule of Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:

(In millions)	March 30, 2024		December 31, 2023
Cash and cash equivalents	$	5,499	$	8,077
Restricted cash included in other current assets	7		6
Restricted cash included in other assets	14		14
Cash, cash equivalents and restricted cash	$	5,519	$	8,097

XML

Restructuring and Other Costs (Tables)

3 Months Ended

Mar. 30, 2024

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Other Costs by Segment

Restructuring and other costs by segment are as follows:

	Three months ended
(In millions)	March 30, 2024
Life Sciences Solutions	$	2
Analytical Instruments	7
Specialty Diagnostics	5
Laboratory Products and Biopharma Services	14
Corporate	1
	$	29

Summary of Changes in the Company's Accrued Restructuring Balance

The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheet. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.

(In millions)	Total (a)
Balance at December 31, 2023	$	60
Net restructuring charges incurred in 2024 (b)	25
Payments	(32)
Currency translation	(2)
Balance at March 30, 2024	$	51

(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.

(b)Excludes $4 million of net non-cash charges.

XML

Nature of Operations and Summary of Significant Accounting Policies - Schedule of Components of Inventories (Details) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 2,038	$ 2,057
Work in process	787	705
Finished goods	2,308	2,326
Inventories	$ 5,133	$ 5,088

XML

Acquisitions - Components of Purchase Price and Net Assets Acquired (Details) - USD ($) $ in Millions			12 Months Ended
	Aug. 14, 2023	Jan. 03, 2023	Dec. 31, 2023
Business Acquisition [Line Items]
Weighted-average amortization period			17 years
Customer relationships
Business Acquisition [Line Items]
Weighted-average amortization period			18 years
Product technology
Business Acquisition [Line Items]
Weighted-average amortization period			14 years
Tradenames
Business Acquisition [Line Items]
Weighted-average amortization period			15 years
Backlog
Business Acquisition [Line Items]
Weighted-average amortization period			13 years
The Binding Site Group
Business Acquisition [Line Items]
Cash paid		$ 2,412
Debt settled		307
Cash acquired		(20)
Purchase price		2,699
Goodwill		1,741
Net tangible assets		174
Deferred tax assets (liabilities)		(288)
Net assets acquired		2,699
The Binding Site Group | Customer relationships
Business Acquisition [Line Items]
Definite-lived intangible assets:		868
The Binding Site Group | Product technology
Business Acquisition [Line Items]
Definite-lived intangible assets:		162
The Binding Site Group | Tradenames
Business Acquisition [Line Items]
Definite-lived intangible assets:		42
The Binding Site Group | Backlog
Business Acquisition [Line Items]
Definite-lived intangible assets:		$ 0
CorEvitas, LLC
Business Acquisition [Line Items]
Cash paid	$ 730
Debt settled	184
Cash acquired	(4)
Purchase price	910
Goodwill	627
Net tangible assets	(2)
Deferred tax assets (liabilities)	(68)
Net assets acquired	910
CorEvitas, LLC | Customer relationships
Business Acquisition [Line Items]
Definite-lived intangible assets:	260
CorEvitas, LLC | Product technology
Business Acquisition [Line Items]
Definite-lived intangible assets:	47
CorEvitas, LLC | Tradenames
Business Acquisition [Line Items]
Definite-lived intangible assets:	0
CorEvitas, LLC | Backlog
Business Acquisition [Line Items]
Definite-lived intangible assets:	$ 46

XML

Acquisitions (Details) - USD ($) $ / shares in Units, $ in Billions		12 Months Ended
	Oct. 17, 2023	Dec. 31, 2023
Business Acquisition [Line Items]
Weighted-average amortization period		17 years
Olink Holding AB
Business Acquisition [Line Items]
Expected price per share of acquisition (dollars per share)	$ 26.00
Expected purchase price of acquisition	$ 3.1
Customer relationships
Business Acquisition [Line Items]
Weighted-average amortization period		18 years
Product technology
Business Acquisition [Line Items]
Weighted-average amortization period		14 years
Tradenames
Business Acquisition [Line Items]
Weighted-average amortization period		15 years
Backlog
Business Acquisition [Line Items]
Weighted-average amortization period		13 years

XML

Revenue and Contract-related Balances - Schedule of Disaggregated Revenues (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 10,345	$ 10,710
North America
Disaggregation of Revenue [Line Items]
Revenues	5,519	5,778
Europe
Disaggregation of Revenue [Line Items]
Revenues	2,619	2,601
Asia-Pacific
Disaggregation of Revenue [Line Items]
Revenues	1,861	1,986
Other regions
Disaggregation of Revenue [Line Items]
Revenues	346	345
Consumables
Disaggregation of Revenue [Line Items]
Revenues	4,328	4,506
Instruments
Disaggregation of Revenue [Line Items]
Revenues	1,627	1,898
Service revenues
Disaggregation of Revenue [Line Items]
Revenues	$ 4,390	$ 4,306

XML

Revenue and Contract-related Balances - Revenue Performance Obligations (Details) $ in Millions	Mar. 30, 2024 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation amount	$ 26,370
Minimum [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Warranty agreement	3 years
Maximum [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Warranty agreement	5 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-31
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation percentage	51.00%
Remaining performance obligation, expected timing	12 months

XML

Revenue and Contract-related Balances - Schedule of Contract Asset and Liability Balances (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Current contract assets, net	$ 1,422		$ 1,443
Noncurrent contract assets, net	9		4
Current contract liabilities	2,632		2,689
Noncurrent contract liabilities	1,427		$ 1,499
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 1,320	$ 1,300

XML

Business Segment and Geographical Information - Schedule of Business Segment Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Segment Reporting Information [Line Items]
Revenues	$ 10,345	$ 10,710
Segment Income	1,663	1,563
Restructuring and other costs	(29)	(112)
Amortization of acquisition-related intangible assets	(551)	(606)
Interest income	279	146
Interest expense	(363)	(300)
Other income/(expense)	10	(46)
Income before income taxes	1,589	1,363
Total Reportable Segments
Segment Reporting Information [Line Items]
Segment Income	2,278	2,330
Total Reportable Segments | Life Sciences Solutions
Segment Reporting Information [Line Items]
Revenues	2,285	2,612
Segment Income	840	836
Restructuring and other costs	(2)
Total Reportable Segments | Analytical Instruments
Segment Reporting Information [Line Items]
Revenues	1,687	1,723
Segment Income	400	421
Restructuring and other costs	(7)
Total Reportable Segments | Specialty Diagnostics
Segment Reporting Information [Line Items]
Revenues	1,109	1,108
Segment Income	294	280
Restructuring and other costs	(5)
Total Reportable Segments | Laboratory Products and Biopharma Services
Segment Reporting Information [Line Items]
Revenues	5,723	5,763
Segment Income	744	793
Restructuring and other costs	(14)
Eliminations
Segment Reporting Information [Line Items]
Revenues	(460)	(496)
Segment Reconciling Items
Segment Reporting Information [Line Items]
Cost of revenues adjustments	(15)	(41)
Selling, general and administrative expenses adjustments	(19)	(8)
Restructuring and other costs	(29)	(112)
Amortization of acquisition-related intangible assets	$ (551)	$ (606)

XML

Business Segment and Geographical Information - Schedule of Revenue by Country Based on Customer Location (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 10,345	$ 10,710
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	5,322	5,587
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 5,023	$ 5,123

XML

Income Taxes - Schedule of the Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory federal income tax rate	21.00%	21.00%
Provision for income taxes at statutory rate	$ 334	$ 286
Foreign rate differential	(38)	(52)
Income tax credits	(89)	(83)
Global intangible low-taxed income	12	12
Foreign-derived intangible income	(22)	(23)
Excess tax benefits from stock options and restricted stock units	(33)	(27)
Provision for (reversal of) tax reserves, net	185	9
Intra-entity transfers	(102)	(144)
Provision for (reversal of) valuation allowances, net	47	67
Withholding taxes	4	5
Tax return reassessments and settlements	(29)	(3)
State income taxes, net of federal tax	19	24
Other, net	(6)	(25)
Provision for income taxes	$ 281	$ 46

XML

Income Taxes - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 30, 2024 USD ($) country	Dec. 31, 2023 USD ($)
Income Tax Disclosure [Abstract]
Increase related to potential settlement of international tax audits	$ 240
Countries with taxable presence | country	70
Unrecognized tax benefits	$ 693	$ 540

XML

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) $ in Millions	3 Months Ended
	Mar. 30, 2024 USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of year	$ 540
Additions for tax positions of prior years	195
Reductions for tax positions of prior years	(42)
Balance at end of period	$ 693

XML

Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Earnings Per Share [Abstract]
Net income	$ 1,328	$ 1,289
Basic weighted average shares (in shares)	382	386
Plus effect of: stock options and restricted stock units (in shares)	2	2
Diluted weighted average shares (in shares)	384	388
Basic (in dollars per share)	$ 3.47	$ 3.34
Diluted (in dollars per share)	$ 3.46	$ 3.32
Antidilutive stock options excluded from diluted weighted average shares (in shares)	2	2

XML

Debt and Other Financing Arrangements - Schedule of Outstanding Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total borrowings at par value	$ 35,687	$ 35,028
Unamortized discount	(108)	(113)
Unamortized debt issuance costs	(186)	(188)
Total borrowings at carrying value	35,393	34,727
Finance lease liabilities	215	190
Less: Short-term obligations and current maturities	4,451	3,609
Long-term obligations	31,157	31,308
Senior Notes
Debt Instrument [Line Items]
Total borrowings at carrying value	$ 35,318	34,650
Senior Notes | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.75%
Term	8 years
Effective interest rate	0.93%
Total borrowings at par value	$ 1,079	1,104
Senior Notes | 1.215% 3-Year Senior Notes, Due 10/18/2024
Debt Instrument [Line Items]
Interest rate	1.215%
Term	3 years
Effective interest rate	1.42%
Total borrowings at par value	$ 2,500	2,500
Senior Notes | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.125%
Term	5 years 6 months
Effective interest rate	0.40%
Total borrowings at par value	$ 863	883
Senior Notes | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2.00%
Term	10 years
Effective interest rate	2.10%
Total borrowings at par value	$ 691	706
Senior Notes | 0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	0.853%
Term	3 years
Effective interest rate	1.05%
Total borrowings at par value	$ 147	158
Senior Notes | 0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.00%
Term	4 years
Effective interest rate	0.15%
Total borrowings at par value	$ 593	607
Senior Notes | 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	3.20%
Term	3 years
Effective interest rate	3.38%
Total borrowings at par value	$ 540	552
Senior Notes | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.40%
Term	8 years 6 months
Effective interest rate	1.52%
Total borrowings at par value	$ 755	773
Senior Notes | 4.953% 3-Year Senior Notes, Due 8/10/2026
Debt Instrument [Line Items]
Interest rate	4.953%
Term	3 years
Effective interest rate	5.19%
Total borrowings at par value	$ 600	600
Senior Notes | 5.000% 3-Year Senior Notes, Due 12/5/2026
Debt Instrument [Line Items]
Interest rate	5.00%
Term	3 years
Effective interest rate	5.25%
Total borrowings at par value	$ 1,000	1,000
Senior Notes | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.45%
Term	10 years
Effective interest rate	1.65%
Total borrowings at par value	$ 540	552
Senior Notes | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.75%
Term	7 years
Effective interest rate	1.96%
Total borrowings at par value	$ 647	662
Senior Notes | 1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.054%
Term	5 years
Effective interest rate	1.18%
Total borrowings at par value	$ 191	205
Senior Notes | 4.80% 5-Year Senior Notes, Due 11/21/2027
Debt Instrument [Line Items]
Interest rate	4.80%
Term	5 years
Effective interest rate	5.00%
Total borrowings at par value	$ 600	600
Senior Notes | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.50%
Term	8 years 6 months
Effective interest rate	0.77%
Total borrowings at par value	$ 863	883
Senior Notes | $1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.6525%
Term	4 years
Effective interest rate	1.77%
Total borrowings at par value	$ 366
Senior Notes | 0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	0.77%
Term	5 years
Effective interest rate	0.90%
Total borrowings at par value	$ 192	206
Senior Notes | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.375%
Term	12 years
Effective interest rate	1.46%
Total borrowings at par value	$ 647	662
Senior Notes | 1.75% 7-Year Senior Notes, Due 10/15/2028
Debt Instrument [Line Items]
Interest rate	1.75%
Term	7 years
Effective interest rate	1.89%
Total borrowings at par value	$ 700	700
Senior Notes | 5.000% 5-Year Senior Notes, Due 1/31/2029
Debt Instrument [Line Items]
Interest rate	5.00%
Term	5 years
Effective interest rate	5.24%
Total borrowings at par value	$ 1,000	1,000
Senior Notes | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.95%
Term	12 years
Effective interest rate	2.07%
Total borrowings at par value	$ 755	773
Senior Notes | 2.60% 10-Year Senior Notes, Due 10/1/2029
Debt Instrument [Line Items]
Interest rate	2.60%
Term	10 years
Effective interest rate	2.74%
Total borrowings at par value	$ 900	900
Senior Notes | 1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.279%
Term	7 years
Effective interest rate	1.44%
Total borrowings at par value	$ 31	33
Senior Notes | 4.977% 7-Year Senior Notes, Due 8/10/2030
Debt Instrument [Line Items]
Interest rate	4.977%
Term	7 years
Effective interest rate	5.12%
Total borrowings at par value	$ 750	750
Senior Notes | 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.80%
Term	9 years
Effective interest rate	0.88%
Total borrowings at par value	$ 1,888	1,932
Senior Notes | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.875%
Term	12 years
Effective interest rate	1.13%
Total borrowings at par value	$ 971	993
Senior Notes | 2.00% 10-Year Senior Notes, Due 10/15/2031
Debt Instrument [Line Items]
Interest rate	2.00%
Term	10 years
Effective interest rate	2.23%
Total borrowings at par value	$ 1,200	1,200
Senior Notes | $1.840% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.84%
Term	8 years
Effective interest rate	1.91%
Total borrowings at par value	$ 460
Senior Notes | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2.375%
Term	12 years
Effective interest rate	2.54%
Total borrowings at par value	$ 647	662
Senior Notes | 1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.49%
Term	10 years
Effective interest rate	1.60%
Total borrowings at par value	$ 42	45
Senior Notes | 4.95% 10-Year Senior Notes, Due 11/21/2032
Debt Instrument [Line Items]
Interest rate	4.95%
Term	10 years
Effective interest rate	5.09%
Total borrowings at par value	$ 600	600
Senior Notes | 5.086% 10-Year Senior Notes, Due 8/10/2033
Debt Instrument [Line Items]
Interest rate	5.086%
Term	10 years
Effective interest rate	5.20%
Total borrowings at par value	$ 1,000	1,000
Senior Notes | 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.125%
Term	12 years
Effective interest rate	1.20%
Total borrowings at par value	$ 1,619	1,656
Senior Notes | 5.200% 10-Year Senior Notes, Due 1/31/2034
Debt Instrument [Line Items]
Interest rate	5.20%
Term	10 years
Effective interest rate	5.34%
Total borrowings at par value	$ 500	500
Senior Notes | 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	3.65%
Term	12 years
Effective interest rate	3.76%
Total borrowings at par value	$ 809	828
Senior Notes | 1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.50%
Term	12 years
Effective interest rate	1.58%
Total borrowings at par value	$ 142	152
Senior Notes | $2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	2.0375%
Term	12 years
Effective interest rate	2.09%
Total borrowings at par value	$ 361	0
Senior Notes | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2.875%
Term	20 years
Effective interest rate	2.94%
Total borrowings at par value	$ 755	773
Senior Notes | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.50%
Term	20 years
Effective interest rate	1.73%
Total borrowings at par value	$ 971	993
Senior Notes | 2.80% 20-Year Senior Notes, Due 10/15/2041
Debt Instrument [Line Items]
Interest rate	2.80%
Term	20 years
Effective interest rate	2.90%
Total borrowings at par value	$ 1,200	1,200
Senior Notes | 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.625%
Term	20 years
Effective interest rate	1.77%
Total borrowings at par value	$ 1,349	1,380
Senior Notes | 2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	2.069%
Term	20 years
Effective interest rate	2.13%
Total borrowings at par value	$ 97	104
Senior Notes | 5.404% 20-Year Senior Notes, Due 8/10/2043
Debt Instrument [Line Items]
Interest rate	5.404%
Term	20 years
Effective interest rate	5.50%
Total borrowings at par value	$ 600	600
Senior Notes | 2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	2.02%
Term	20 years
Effective interest rate	2.06%
Total borrowings at par value	$ 192	206
Senior Notes | 5.30% 30-Year Senior Notes, Due 2/1/2044
Debt Instrument [Line Items]
Interest rate	5.30%
Term	30 years
Effective interest rate	5.37%
Total borrowings at par value	$ 400	400
Senior Notes | 4.10% 30-Year Senior Notes, Due 8/15/2047
Debt Instrument [Line Items]
Interest rate	4.10%
Term	30 years
Effective interest rate	4.23%
Total borrowings at par value	$ 750	750
Senior Notes | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.875%
Term	30 years
Effective interest rate	1.98%
Total borrowings at par value	$ 1,079	1,104
Senior Notes | 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2.00%
Term	30 years
Effective interest rate	2.07%
Total borrowings at par value	$ 809	828
Senior Notes | 2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	2.382%
Term	30 years
Effective interest rate	2.43%
Total borrowings at par value	$ 220	236
Other
Debt Instrument [Line Items]
Total borrowings at par value	75	77
Total borrowings at carrying value	$ 75	$ 77

XML

Debt and Other Financing Arrangements (Details)	3 Months Ended
	Mar. 30, 2024 USD ($)
Senior Notes
Short-term Financing [Line Items]
Redemption price	100.00%
Revolving Credit Facility
Short-term Financing [Line Items]
Borrowing capacity	$ 5,000,000,000
Minimum consolidated interest coverage ratio	3.5
Borrowings outstanding	$ 0
0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	0.00%
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	0.80%
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	1.125%
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	1.625%
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	2.00%
Commercial Paper | U.S. Commercial Paper Program
Short-term Financing [Line Items]
Maximum maturity period	397 days
Commercial Paper | Euro Commercial Paper Program
Short-term Financing [Line Items]
Maximum maturity period	183 days

XML

Comprehensive Income/(Loss) and Shareholders' Equity - Schedule of Changes in Each Component of Accumulated Other Comprehensive Items (Details) $ in Millions	3 Months Ended
	Mar. 30, 2024 USD ($)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 46,724
Ending Balance	45,504
Currency translation adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(2,941)
Other comprehensive income/(loss) before reclassifications	456
Amounts reclassified from accumulated other comprehensive income/(loss)	3
Net other comprehensive income/(loss)	459
Ending Balance	(2,482)
Unrealized gains/(losses) on available-for-sale debt securities
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	0
Other comprehensive income/(loss) before reclassifications	(1)
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Net other comprehensive income/(loss)	(1)
Ending Balance	(1)
Unrealized gains/(losses) on hedging instruments
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(28)
Other comprehensive income/(loss) before reclassifications	0
Amounts reclassified from accumulated other comprehensive income/(loss)	1
Net other comprehensive income/(loss)	1
Ending Balance	(27)
Pension and other postretirement benefit liability adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(255)
Other comprehensive income/(loss) before reclassifications	1
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Net other comprehensive income/(loss)	1
Ending Balance	(254)
Accumulated Other Comprehensive Items
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(3,224)
Other comprehensive income/(loss) before reclassifications	456
Amounts reclassified from accumulated other comprehensive income/(loss)	4
Net other comprehensive income/(loss)	460
Ending Balance	$ (2,764)

XML

Fair Value Measurements and Fair Value of Financial Instruments - Assets and Liabilities on a Recurring Basis (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 31, 2023
Liabilities [Abstract]
Gain (loss) on sale of investments	$ 10	$ (44)
Fair Value, Recurring
Assets [Abstract]
Cash equivalents	2,692		$ 5,021
Bank time deposits	1,751		3
Investments	21		20
Insurance contracts	221		210
Derivative contracts	220		8
Total Assets	4,904		5,262
Liabilities [Abstract]
Derivative contracts	57		290
Contingent consideration	83		87
Total Liabilities	141		377
Fair Value, Recurring | Quoted Prices in Active Markets (Level I)
Assets [Abstract]
Cash equivalents	2,692		5,021
Bank time deposits	1,751		3
Investments	21		20
Insurance contracts	0		0
Derivative contracts	0		0
Total Assets	4,464		5,044
Liabilities [Abstract]
Derivative contracts	0		0
Contingent consideration	0		0
Total Liabilities	0		0
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)
Assets [Abstract]
Cash equivalents	0		0
Bank time deposits	0		0
Investments	0		0
Insurance contracts	221		210
Derivative contracts	220		8
Total Assets	440		218
Liabilities [Abstract]
Derivative contracts	57		290
Contingent consideration	0		0
Total Liabilities	57		290
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)
Assets [Abstract]
Cash equivalents	0		0
Bank time deposits	0		0
Investments	0		0
Insurance contracts	0		0
Derivative contracts	0		0
Total Assets	0		0
Liabilities [Abstract]
Derivative contracts	0		0
Contingent consideration	83		87
Total Liabilities	$ 83		$ 87

XML

Fair Value Measurements and Fair Value of Financial Instruments - Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent consideration - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 87	$ 174
Payments	(2)	(15)
Changes in fair value included in earnings	(2)	(23)
Ending balance	$ 83	$ 136
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses

XML

Fair Value Measurements and Fair Value of Financial Instruments - Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 31, 2023
Cross-currency interest rate swaps | Derivatives Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Fair value – assets	$ 219	$ 5
Fair value – liabilities	56	287
Cross-currency interest rate swaps | Financial instruments designated as net investment hedges | Cross-currency interest rate swaps designated as net investment hedge - euro
Derivatives, Fair Value [Line Items]
Notional amount	1,000	1,000
Cross-currency interest rate swaps | Financial instruments designated as net investment hedges | Cross-currency interest rate swaps designated as net investment hedge - Japanese yen
Derivatives, Fair Value [Line Items]
Notional amount	4,650	4,650
Cross-currency interest rate swaps | Financial instruments designated as net investment hedges | Cross-currency interest rate swaps designated as net investment hedge - Swiss franc
Derivatives, Fair Value [Line Items]
Notional amount	2,500	2,500
Currency exchange contracts
Derivatives, Fair Value [Line Items]
Notional amount	1,381	1,567
Currency exchange contracts | Derivatives Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Fair value – assets	1	3
Fair value – liabilities	1	3
Fair Value, Recurring
Derivatives, Fair Value [Line Items]
Fair value – assets	220	8
Fair value – liabilities	$ 57	$ 290

XML

Fair Value Measurements and Fair Value of Financial Instruments - Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Currency exchange contracts | Included in other income/(expense) | Derivatives Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative	$ (6)	$ 23
Currency exchange contracts | Included in cost of product revenues | Derivatives Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative	3	(3)
Derivatives designated as cash flow hedges | Interest rate swaps | Amount reclassified from accumulated other comprehensive items to interest expense | Derivatives Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on cash flow hedge reclassified from AOCI	(1)	0
Derivatives designated as cash flow hedges | Interest rate swaps | Included in other income/(expense) | Derivatives Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on cash flow hedge reclassified from AOCI	0	(4)
Financial instruments designated as net investment hedges | Foreign currency-denominated debt and other payables | Derivatives Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on currency translation adjustment	275	(144)
Financial instruments designated as net investment hedges | Cross-currency interest rate swaps | Derivatives Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on currency translation adjustment	444	(9)
Gain (loss) on derivative	$ 66	$ 17

XML

Fair Value Measurements and Fair Value of Financial Instruments - Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value	$ 35,393	$ 34,727
Fair value	32,662	32,268
Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value	35,318	34,650
Fair value	32,587	32,191
Other
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value	75	77
Fair value	$ 75	$ 77

XML

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 31, 2023	Dec. 31, 2022
Non-cash Investing and Financing Activities [Abstract]
Acquired but unpaid property, plant and equipment	$ 165	$ 242
Declared but unpaid dividends	150	137
Issuance of stock upon vesting of restricted stock units	63	91
Excise tax from stock repurchases	29	30
Cash and cash equivalents	5,499		$ 8,077
Restricted cash included in other current assets	7		6
Restricted cash included in other assets	14		14
Cash, cash equivalents and restricted cash	$ 5,519	$ 3,500	$ 8,097	$ 8,537
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets		Other current assets
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible Enumeration]	Other assets		Other assets

XML

Restructuring and Other Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	May 03, 2024
Restructuring Cost and Reserve [Line Items]
Workforce reduction (less than)	1.00%
Restructuring and other costs	$ 29	$ 112
Corporate, Non-Segment
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	1
Life Sciences Solutions | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	2
Analytical Instruments | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	7
Specialty Diagnostics | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	5
Laboratory Products and Biopharma Services | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	$ 14
Forecast
Restructuring Cost and Reserve [Line Items]
Additional restructuring charges			$ 75

XML

Restructuring and Other Costs - Reserves (Details) $ in Millions	3 Months Ended
	Mar. 30, 2024 USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 60
Net restructuring charges incurred in 2024	25
Payments	(32)
Currency translation	(2)
Ending balance	51
Non-cash charges	$ 4